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General introduction
Glycosylation and glycosylation disorders
Protein glycosylation is a common post-translational modification that is 
required for a variety of biological functions, including mediation of cell-
cell and cell-matrix interactions, modulation of protein function and protein 
folding and stability (Varki, 1993; Lis & Sharon, 1993; Wyss & Wagner, 1996). 
Diverse glycosylation types exist: protein N-linked, O-linked and C-linked glycans 
(Varki, 1993; Vliegenthart & Casset, 1998). N-glycans and O-glycans, linked to 
respectively a nitrogen atom of an asparagine or a hydroxyl oxygen atom of a 
serine or threonine residue, are the most common types. Three different types 
of N-glycans that share a common core consisting of three mannose and two 
N-acetylglucosaminyl (GlcNAc) residues are known (Kornfeld & Kornfeld, 1985). 
The most common O-linked glycans are mucin O-glycans, that are linked via 
N-acetylgalactosamine (GalNAc) to proteins. Additional types of O-glycans are 
known, such as O-mannose, O-GlcNAc, O-fucose and O-xylose linked glycans 
(Hansen et al, 1996). Proteins are glycosylated in the endoplasmic reticulum (ER) 
and Golgi apparatus using sugar substrates produced in the cytoplasm (Freeze 
& Elbein, 2009). 
Defects in glycosylation pathways cause congenital disorders of glycosylation 
(CDG). N-linked glycosylation disorders are the most prevalent and can be divided 
into two groups: CDG type I, caused by ER-assembly defects and CDG type II, 
caused by defects during Golgi processing. Patients present with a variable and 
multisystem phenotype, such as neurological aberrations, dysmorphism, liver 
disease, skeletal abnormalities and hypoglycemia. Diagnostic prescreening 
is performed by isoelectric focusing of serum transferrin, that can be used to 
distinguish between CDG type I and type II (Jaeken, 2010). 
O-glycosylation disorders can be characterized by a multisystem phenotype as 
well. Hypotonia, skin aberrations, skeletal dysplasia and neurologic abnormalities 
are some of the characteristic symptoms (Wopereis et al, 2006). To prescreen for 
mucin type O-glycosylation disorders, isoelectric focusing of serum apolipoprotein 
C-III is performed (Wopereis et al, 2003), however this method is not suitable 
to detect specific O-mannosylation defects. In contrast to other glycosylation 
disorders, O-mannosylation defects result in a more restricted phenotype with 
muscle, brain and in the most severe cases also eye abnormalities. In addition 
to isolated O-mannosylation defects, patients can present with a combined 
O-mannosylation and N-glycosylation phenotype, originating from a defect in 
the production of the common precursor dolichol-phosphate-mannose (Jaeken, 
2010; Wells, 2013). No prescreening methods are available for O-mannosylation 
disorders and therefore the initial diagnosis can only be given on basis of the 
clinical phenotype. Nowadays, most of the glycosylation pathways are well known 
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and in a majority of all cases genetic analysis can confirm the initial diagnosis. 
However, the complex O-mannosylation pathway is only partly understood and 
often the initial, clinical-based diagnosis of an O-mannosylation disorder cannot 
be confirmed. 
Protein O-mannosylation
O-mannose glycans are a rare type of O-linked glycans that were originally 
identified on a number of yeast cell wall proteins (Strahl-Bolsinger et al, 
1999). While about half of all proteins in human contains one or more glycan 
structures (Apweiler et al, 1999), only a small minority of the proteins contains 
an O-mannose glycan (Endo, 1999; Praissman & Wells, 2014). These glycan 
structures are synthesized in the ER and Golgi by several glycosyltransferases 
(Praissman & Wells, 2014). The substrates for these glycosyltransferases are 
activated nucleotide sugars that are produced in the cytoplasm (Bulter & Elling, 
1999) and transported to the ER and Golgi by nucleotide sugar specific transporter 
proteins (Kawakita et al, 1998). About 50 different proteins are O-mannosylated 
and over 23 O-mannose structures have been described (Vester-Christensen 
et al, 2013). α-Dystroglycan (α-DG) is by far the most studied O-mannosylated 
protein in mammals. This extracellular protein has a crucial role in linking the 
cytoskeleton with the extracellular matrix. α-DG is connected to the cytoskeleton 
via transmembrane protein β-dystroglycan (β-DG) and can bind to extracellular 
matrix ligands using a very specific O-mannose linked glycan epitope (Ervasti & 
Campbell, 1993; Ibraghimov-Beskrovnaya et al, 1992).
Muscular dystrophy-dystroglycanopathy syndromes
Defects in O-mannnosyl glycosyltransferases or proteins that are involved 
in producing or transporting activated nucleotide sugars required for α-DG 
O-mannosylation can give rise to muscular dystrophy-dystroglycanopathy 
(MDDG) syndromes. These disorders have a broad clinical spectrum and are 
characterized by muscular dystrophy, and at the severe end of the spectrum by 
brain and eye abnormalities (Muntoni et al, 2007). Reduced O-mannosylation 
of α-DG because of a genetic defect in O-mannose synthesis, results in deficient 
binding of α-DG to its ligands (Michele et al, 2002). The initial diagnosis is usually 
based on the clinical presentation of the patient. However, genetic testing, 
immunohistochemical analyses in skeletal muscle tissue or biochemical analyses 
of α-DG-ligand binding capacity are important to support the clinical diagnosis. 
In about 50% of all cases the diagnosis can be confirmed by genetic analysis 
(van Reeuwijk et al, 2005). Functional confirmation of novel gene defects is 
hard. Expression levels of O-mannosylated α-DG in human fibroblasts are low 
11
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and therefore these cells are not suitable as a functional model for confirmation 
of novel gene defects. Other model systems are limited, as O-mannosylated 
α-DG is predominantly expressed in muscle, brain and eye tissue and genetic 
engineering of such cell lines is challenging. Therapies are not yet available, but 
promising possibilities, based on restoration of α-DG O-mannosylation by gene-
transfer, are currently developed in mouse models (Muntoni et al, 2011).
Purpose of this study and outline of this thesis
The exact structure of the α-DG O-mannose glycan that is required for ligand 
binding is unknown. Several proteins playing a role in the O-mannosylation 
pathway either by producing or transporting activated nucleotide sugars or 
by functioning as glycosyltransferase remain to be identified. Not all disease-
causative genes are known, and at the start of this project only in about 
half of all MDDG syndrome patients a genetic defect could be detected. 
Identification of novel gene defects by genetic analysis can help elucidation of 
the O-mannosylation pathway and vice versa, novel insights in the O-mannose 
glycan structure acquired by biochemical approaches might be useful to identify 
novel disease causative genes. 
The purpose of my PhD-research was to come to a better understanding of the 
ligand-binding O-mannose glycan on α-DG using two complementary approaches. 
In Part	I:	Novel	gene	defects	in	muscular	dystrophy-dystroglycanopathy	syndrome	
patients, I describe the use of innovative genetic tools towards identification 
of new gene defects underlying defective α-DG O-mannosylation. In addition, 
I have used new methodologies to functionally confirm the identified gene 
defects. Part	II:	Dissecting	the	O-mannosylation	pathway describes biochemical 
research aiming at the functional characterization of proteins involved in the 
O-mannosylation process. The results of this research project will contribute to 
improvement of patient diagnostics and future therapy development. 
Chapter 2 introduces the current knowledge about MDDG syndromes. Clinical 
features, diagnosis, genetic defects and the molecular pathogenesis are 
described, with the focus on the most severe MDDG syndrome variant, Walker-
Warburg syndrome (WWS). In Part	I:	Novel	gene	defects	in	muscular	dystrophy-
dystroglycanopathy	 syndrome	 patients four different gene defects identified 
in MDDG syndrome patients ranging from a very severe to only a mild clinical 
phenotype are described. Chapter 3 describes the identification of a single base 
pair deletion in the DAG1 gene, encoding α-DG and β-DG, in five severe WWS 
patients. I show that the deletion leads to a premature stop codon, resulting in 
complete absence of both α-DG and β-DG expression. In Chapter 4, I describe 
the identification of novel mutations in ISPD in severely affected WWS patients. 
12
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Chapter 5 describes two patients with an atypical mild phenotype, characterized 
by developmental delay, but without muscular dystrophy. Mutations in 
B3GALNT2 were found to be the underlying genetic defect. Chapter 6 describes 
the identification of B3GNT1 as a novel MDDG syndrome causative gene. In	vitro 
and in	vivo analysis was performed to confirm that the mutations in this newly 
identified gene lead to a disrupted α-DG-ligand binding. In Part	II:	Dissecting	the	
O-mannosylation	pathway two studies aiming to identify the exact function of 
proteins known to be involved in the O-mannosylation of α-DG are described. In 
Chapter 7, ISPD is shown to produce a novel nucleotide sugar that is required for 
α-DG O-mannosylation. In Chapter 8, I show that the CMP-sialic acid transporter 
SLC35A1 is required in the O-mannosylation pathway, but not by transporting 
CMP-sialic acid. I hypothesize that this protein might have additional transporter 
activity and possibly transports the novel identified nucleotide sugar produced 
by ISPD.
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Abstract
Impaired post-translation modification of α-dystroglycan is the hallmark of Walker-
Warburg syndrome, a rare recessive disorder characterized by severe congenital 
muscular dystrophy, structural brain anomalies and eye abnormalities. Walker-
Warburg syndrome shows an unexpectedly high level of genetic heterogeneity 
and mutations in twelve different genes, all engaged in the O-glycosylation 
of α-dystroglycan, have been connected to Walker-Warburg syndrome so far. 
Strikingly, there is large clinical variability and mutations in these genes have also 
been identified for other muscular dystrophy-dystroglycanopathy syndromes, 
which are typically milder in their phenotypic presentation. 
Chapter summary
Walker-Warburg syndrome is the most severe variant of a group of congenital 
muscular dystrophy-dystroglycanopathy syndromes. Besides muscular 
dystrophy, brain and eye abnormalities are the most important characteristics. 
Muscular dystrophy-dystroglycanopathy syndromes are caused by a deficient 
glycosylation of α-dystroglycan. This heavily glycosylated protein has a main 
function in the dystrophin-glycoprotein complex in the cell membrane, 
which forms the link between the cytoskeleton and the extracellular matrix. 
Within this protein complex, the glycans of α-dystroglycan bind with various 
extracellular ligands, such as laminin-α2 in muscle and neurexin in brain. The 
muscular dystrophy-dystroglycanopathy syndromes are caused by mutations in 
genes encoding proteins that play a role in the glycosylation of α-dystroglycan. 
Diagnosis can be given based on DNA sequence analysis or biochemical assays. 
Promising therapies are in development for the milder end of the MDDG 
syndrome phenotype spectrum, but not yet available for patients.
Gene description
Recessive mutations in a growing number of genes have been associated with 
Walker-Warburg syndrome and other muscular dystrophy-dystroglycanopathy 
syndromes. Mutations in POMT1, POMT2, POMGNT1, FKTN, FKRP, LARGE, 
ISPD, TMEM5, GTDC2, B3GNT1, B3GALNT2, SGK196 and DAG1 lead to muscular 
dystrophy-dystroglycanopathy syndromes that primarily involve impaired 
O-glycosylation of α-dystroglycan. Mutations in DOLK, DPM1, DPM2 and 
DPM3 result in a phenotype with characteristics of both MDDG syndrome and 
congenital disorders of glycosylation, which typically comprise N-glycosylation 
defects.
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Clinical summary
Walker-Warburg syndrome (WWS) is the most severe variant of the congenital 
muscular dystrophy-dystroglycanopathy (MDDG) syndromes and was first 
reported by Walker (Walker, 1942) and Warburg (Warburg, 1976; Warburg, 1978). 
The main characteristics of WWS are severe congenital muscular dystrophy, type 
II cobblestone lissencephaly, cerebellar abnormalities and eye malformations 
(Figure 1). Ventricular dilatation with or without hydrocephalus are often, but 
not in all cases, reported. Less frequent observed brain abnormalities, which are 
sometimes already prenatally diagnosed with MRI, are: congenital macrocephaly 
or microcephaly, Dandy-Walker malformation, slit-like ventricles, white matter 
abnormalities, fused hemispheres, absence of septum and corpus callosum, 
abnormal tectum, flat pons, hypoplastic or absent vermis and encephalocele. Eye 
abnormalities might include microphthalmia, anterior chamber malformation, 
ocular colobomas, congenital cataracts and retinal dysplasia. WWS is presented 
at birth. Typical symptoms are: hypotonia, muscle weakness, high serum creatine 
kinase levels (above 1000 U/L), developmental delay, mental retardation and in 
some cases seizures, cleft lip/palate and genital abnormalities in males (Cormand 
et al, 2001; Dobyns et al, 1989). The life expectancy is less than three years, with 
an average of 0.8 years (Vajsar & Schachter, 2006; van Reeuwijk et al, 2005a).
WWS is the most severe variant of the MDDG syndromes, which have overlapping 
phenotypic features and which carry mutations in a shared set of genes. Because 
of the rapidly expanding number of MDDG syndromes and associated genes, 
a new classification was recently proposed (Godfrey et al, 2011; Mercuri & 
Muntoni, 2012) and adopted by Online Mendelian Inheritance in Man (OMIM; 
www.ncbi.nlm.nih.gov/omim). In this classification there are three main MDDG 
syndrome types (A, B, and C), which reflect the severity of the phenotype. 
In addition, there are already 10 subclasses and more to be annotated soon, 
each of them connected to a single gene (Table 1). WWS, muscle-eye-brain 
disease (MEB), and Fukuyama congenital muscular dystrophy (FCMD), which 
were previously known as the cobblestone lissencephaly syndromes, constitute 
the type A MDDG syndromes. In this classification WWS is subclassified into 
MDDGA1-8 and MDDGA10 and this number is still increasing. However, also 
MEB and FCMD are similarly annotated and classified under the same identifier 
in OMIM, and therefore the clinical utility of this MDDG-classification is not 
apparent. For a complete overview, we have provided both the new and the old 
classification in Table 1. 
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MEB patients have a similar, but less severe clinical phenotype as compared to 
WWS patients. FCMD is the mildest MDDG syndrome type A variant and is most 
prevalent in Japan. In FCMD patients the brain abnormalities are milder compared 
to WWS and MEB patients and only in some cases the eyes are affected (Muntoni 
et al, 2007; van Reeuwijk et al, 2005a). The MDDG syndrome spectrum is even 
broader, characterized by different subtypes that can be divided in variants B 
and C. Variant B MDDG syndromes contain three types of congenital muscular 
dystrophies (CMD). The most severe variant is CMD with brain abnormalities 
and mental retardation. However, there are also patients reported with mental 
retardation, but without structural brain abnormalities. The mildest group of 
CMD patients in the type B MDDG syndrome group has a normal IQ and no brain 
abnormalities (Godfrey et al, 2007; Godfrey et al, 2011). Based on the muscle 
phenotype, type C MDDG syndrome types represent the mildest group of the 
MDDG syndrome spectrum. These syndromes are called limb-girdle-muscular 
dystrophies (LGMD) and have a later onset, sometimes even in late adulthood. 
LGMD can occur with or without mental retardation (Godfrey et al, 2007) and 
recently also an LGMD patient with structural brain abnormalities was reported 
(Cirak et al, 2013).
In addition to the classical muscle, eye and brain abnormalities reported in MDDG 
syndrome patients, cardiac problems are associated with MDDG syndromes. In 
about 6% of all MDDG syndrome patients, dilated cardiomyopathy (DCM) or 
other cardiac problems were observed (Brockington et al, 2001; Muller et al, 
2005; Murakami et al, 2006; Pane et al, 2012). Recently, DCM was also reported 
in patients with a combined congenital disorders of glycosylation (CDG) and 
MDDG syndrome (Lefeber et al, 2011; Lefeber et al, 2009). This phenotype has 
not yet been included into the MDDG syndrome nomenclature.
Molecular genetics
MDDG syndromes are genetically heterogeneous and have an autosomal 
recessive inheritance. Mutations in most of the identified genes can give rise 
to severe WWS, but also to the milder phenotypes of CMD and LGMD (Table 
1). The broad clinical spectrum can only be partly explained by the severity 
of the mutations. In general, homozygous or compound heterozygous loss of 
function alleles are associated with severe phenotypes, whereas mild-end 
phenotypes are more often associated with missense mutations. However, there 
is a considerable number of exceptions, suggesting that the specific disrupted 
function of the affected protein function and the presence of complementing 
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Table 1: Overview gene mutations and phenotypes according to OMIM classification. 
 Type A B C
WWS MEB/
FCMD
CMD
CBR
CMD
MR
CMD LGMD
CBR
LGMD
MR
LGMD CDG CDG/DCM
POMT1 1 X X X X X X X
236670 613155 609308
POMT2 2 X X X X X X
613150 613156 613158
POMGNT1 3 X X X X
253280 613151 613157
FKTN 4 X X X X
253800 613152 611588
FKRP 5 X X X X X
613153 606612 607155
LARGE 6 X X X
613154 608840
ISPD 7 X X X X X X
614643 * *
GTDC2 8 X
614830
DAG1 9 X
613818
TMEM5 10 X X
615041
B3GNT1 X
*
B3GALNT2 X X
*
SGK196 X
*
DPM2  X
 615042
DPM3 X
612937
DOLK X
610768
CBR: with cerebellar involvement. MR: with mental retardation. *= not yet in OMIM database. The 
genes most frequently mutated in different MDDG syndrome types are highlighted in dark grey.
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proteins might contribute to the unclear genotype-phenotype relationship of 
the MDDG syndromes (van Reeuwijk et al, 2005b).
The first MDDG syndrome gene to be identified was the fukutin gene (FKTN), 
which was found to carry a founder mutation – a retrotransposon insertion 
in the 3’-UTR of the gene – underlying FCMD (Kobayashi et al, 1998). This 
prevalent Japanese mutant is a hypomorph and indeed later studies showed 
that more severe mutations in FKTN are associated with a more severe a WWS/
MEB phenotype (Beltrán-Valero de Bernabé et al, 2003; Silan et al, 2003; van 
Reeuwijk et al, 2005b). On basis of homology with FKTN the gene for fukutin-
related protein (FKRP) was identified and mutations were associated with 
CMD/LGMD phenotypes with or without brain involvement (MDDGB and 
MDDGC) (Brockington et al, 2001) and subsequently also with WWS (Beltrán-
Valero de Bernabé et al, 2004). The first evidence that glycosylation defects 
of α-dystroglycan (α-DG) were associated with a cobblestone lissencephaly 
syndrome was provided by the seminal work of groups of Dr. Toda and Dr. 
Endo, who linked mutations in the gene for protein O-mannose β-1,2-N-
acetylglucosaminyltransferase (POMGNT1) to MEB (Yoshida et al, 2001). Later, 
also WWS patients with mutations in POMGNT1 were described (Taniguchi et 
al, 2003). The work of Yoshida et al. (2001) initiated the analysis of proteins that 
were predicted to be engaged in the synthesis of the same O-glycan modification 
of α-DG, resulting in the identification of the protein O-mannosyltransferase 
gene (POMT1) as the first causative gene in WWS (Beltrán-Valero de Bernabé 
et al, 2002). Since it was shown that the protein product of POMT1 forms a 
complex with the protein product of POMT2 and that this complex is required 
for O-mannosylation, POMT2 was considered as a MDDG syndrome candidate 
gene. Indeed, two years later, homozygosity mapping combined with a 
candidate gene approach led to the identification of POMT2 as a WWS gene 
(van Reeuwijk et al, 2005a; van Reeuwijk et al, 2005b). Later on, other studies 
showed that mutations in POMT2 are associated with MEB (Mercuri et al, 
2006), CMD (Yanagisawa et al, 2007) and LGMD (Biancheri et al, 2007). LARGE 
became another MDDG syndrome candidate gene when it was shown that in a 
spontaneous mutated myodystrophy mouse, an intragenic deletion of exon 4-7 
of the mouse LARGE homolog causes the muscular dystrophy phenotype. Two 
years later, mutations in the human LARGE gene were described in patients with 
LGMD, mental retardation and mild brain abnormalities (Longman et al, 2003) 
and later on, LARGE mutations were associated with WWS (van Reeuwijk et al, 
2007) too. 
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For several years, the mentioned six genes were the only known MDDG syndrome 
genes, yet collectively these genes only explained about 30-50% of all WWS 
patients. However, with the fast development of next generation sequencing 
methods, the number of MDDG syndrome associated genes increased very 
rapidly. The first new gene that was unravelled using next generation sequencing 
was ISPD (Roscioli et al, 2012; Willer et al, 2012). Mutations in this gene are 
the second most common cause of the WWS after POMT1. Later on, mutations 
in ISPD were also associated with MEB, less severe CMD and LGMD (Cirak 
et al, 2013). Next generation sequencing of a cohort of WWS patients led to 
the identification of mutations in GTDC2 (Manzini et al, 2012). In addition, 
TMEM5 was found as another WWS/MEB causative gene using next generation 
sequencing (Vuillaumier-Barrot et al, 2012). Furthermore, again using whole-
exome sequencing, B3GALNT2 was shown to be a WWS causative gene (Stevens 
et al, 2013). Seven patients with a mutation in B3GALNT2 were identified with 
phenotypes ranging from severe WWS to FCMD.
Another recently identified WWS associated gene is B3GNT1 (Buysse et al, 2013), 
encoding an N-glucosaminyltransferase (Bao et al, 2009). Mutations in B3GNT1 
are a rare cause of WWS, possibly because severe mutations in this gene cause 
embryonic lethality (Buysse et al, 2013). The same may be true for mutations in 
DAG1, encoding α-DG and β-dystroglycan (β-DG), as only one mild LGMD patient 
with a mutation in this gene has been reported thus far (Hara et al, 2011).
The newest identified WWS associated gene is SGK196 (Jae et al, 2013). This 
gene was identified by taking advantage of the notion that glycosylated α-DG is 
used as a receptor for Lassa virus infection. A haploid screen using Lassa virus 
(LASV) was performed. LASV infects and kills wild type human fibroblasts, while 
fibroblasts from a patient with an ISPD mutation survive. Mutagenized haploid 
(HAP1) cells were exposed to LASV entry and subsequently genes significantly 
enriched for gene-trap insertion sites were determined in virus-resistant cells. 
This method revealed all known WWS genes as well as several new candidate 
genes, including SGK196. Mutations in this gene were shown to be the underlying 
cause of WWS in one patient.
Besides the described gene defects that cause MDDG syndromes, there are 
four genes described that are associated with a phenotype characterized 
by a combination of N-glycosylation defects typical for CDG and impaired 
O-glycosylation of α-DG. Such a combined phenotype may result from mutations 
in DOLK, DPM2, DPM3, and most likely also DPM1, all encoding proteins required 
for synthesis of precursor sugars of both O-mannosylation and N-glycosylation 
(Barone et al, 2012; Lefeber et al, 2011; Lefeber et al, 2009). Remarkably, dilated 
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cardiomyopathy (DCM) is the most prominent symptom in patients with a 
mutation in DOLK (Lefeber et al, 2011). DCM was previously found also in LGMD 
patients with mutations in DPM3 (Lefeber et al., 2009), FKTN (Murakami et 
al, 2006) and FKRP (Mercuri et al, 2003). Besides, cardiac involvement is also 
observed in patients with mutations in POMT1 (Bello et al, 2012; D’Amico et al, 
2006), POMT2	(Yanagisawa et al, 2007) and ISPD (Cirak et al, 2013).
Diagnosis
The diagnosis of WWS and the other MDDG syndromes is based on the detection 
of hypoglycosylated α-DG in patient skeletal muscle. Immunohistochemistry is 
performed on muscle sections obtained from a muscle biopsy using the IIH6 and/
or VIA4 antibody, that both recognize O-glycosylated α-DG (Figure 1). In addition, 
skeletal muscle homogenates can be used for Western blotting. Hypoglycosylated 
α-DG can be detected by direct staining with IIH6 or VIA4 antibodies or with a 
ligand-overlay assay, in which the ability to bind laminin, agrin or neurexin, can 
be tested (Michele et al, 2002). Biochemical analysis is difficult, but it is feasible 
to study enzymatic activities of POMT1/2 and POMGnT1 in lymphoblasts (Manya 
et al, 2008). Dolichol kinase activity and dolichol-phosphate-mannose synthase 
activity can be measured in patient fibroblasts (Lefeber et al., 2009; Lefeber et 
al., 2011). In addition, for patients with a combined MDDG syndrome – CDG 
phenotype, it is useful to study protein N-glycosylation by iso-electric focusing of 
serum-isolated transferrin protein (de Jong et al, 1994). Besides, DNA sequence 
analysis of the ten known MDDG syndrome genes and the four genes giving a 
combined MDDG syndrome – CDG phenotype is used as diagnostic tool. Before 
sequencing of all known genes is started, homozygosity mapping might be 
performed to exclude genes in regions where no homozygosity is found. 
Until now, in only about 50% of all WWS patients a mutation in one of the ten 
known genes can be identified (Roscioli et al., 2012). Consequently, as a muscle 
biopsy is not always available, a lot of patients have remained undiagnosed at the 
molecular level. The use of next generation sequencing will likely improve WWS 
diagnostics. This technique, that already facilitated the discovery of new genetic 
defects, will hopefully contribute to the identification of more MDDG syndrome 
genes. In the near future, next generation sequencing will also become available 
as a diagnostic tool for WWS. Until then, sequence analysis can be made easier 
by the use of microchips (Yershov et al, 1996). Using these methods sequencing 
analysis of multiple disease genes can be performed in a single assay (Mandal 
et al, 2005).
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To summarize, nowadays the diagnostic work flow includes three steps:
Diagnosis. The initial diagnosis is based on the clinical phenotype. The presence 
and severity of muscle, eye, brain and occasionally cardiac abnormalities have 
to be determined. 
Biochemical analysis. The O-mannosylation in patient skeletal muscle have to be 
analyzed using an immunohistochemistry staining and/or laminin overlay assay 
and immunodetection on western blot. In case of a combined MDDG syndrome 
– CDG phenotype, transferrin iso-electric focusing have to be performed. 
Genetic analysis. To identify the MDDG syndrome causative mutations, sequence 
analysis of the known genes have to be performed. Until new generation 
sequencing methods are available as routine diagnostic tools, an efficient genetic 
workflow has to be followed. Sequencing of the most frequently mutated genes 
corresponding to the specific phenotype of the patient (Table 1) might be 
performed first. Besides, homozygosity mapping is useful to select homozygous 
regions to prioritize the sequencing of known MDDG syndrome causative genes.
Therapies for WWS and the other MDDG syndromes are not available. 
Administration of steroids seemed to slightly improve the muscular symptoms in 
LGMD (MDDGC4) (Godfrey et al, 2006), but the mechanism of action is unknown. 
One promising therapy is based on restoring α-DG glycosylation by LARGE 
overexpression (Barresi et al, 2004). Transgenic FKTN- and POMGNT1-deficient 
mouse models that were subjected to adenoviral LARGE gene transfer in skeletal 
muscle, show a restoration of α-DG glycosylation and laminin binding (Kanagawa 
et al, 2009). LARGE overexpression in healthy wild type mice did not lead to 
pathological effects and therefore it was concluded that LARGE overexpression 
can safely be applied in	vivo (Mercuri & Muntoni, 2012). A recent report shows 
that LARGE gene therapy helps to restore α-DG glycosylation and rescues the 
muscular dystrophy phenotype in LARGE- and POMGNT1-deficient mice (Yu et 
al, 2013). Moreover, LARGE	overexpression in the LARGE myd mouse is shown 
to restore the neuromuscular structure (Gumerson et al, 2013). In conclusion, 
LARGE gene therapy is a promising therapy for MDDG syndromes at the mild end 
of the phenotype spectrum. However, we do not yet understand the mechanism 
by which LARGE restores α-DG glycosylation. To fully understand this possible 
therapy, the molecular pathogenesis of the MDDG syndromes has to be clarified.
Molecular pathogenesis
MDDG syndromes are caused by an aberrant glycosylation of α-DG (Michele et 
al, 2002; Moore et al, 2002). Together with β-DG, α-DG is the central part of 
the dystrophin-glycoprotein complex (DGC), that bridges the cytoskeleton with 
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the extracellular matrix. The membrane bound β-DG protein is connected to 
intracellular actin. Via the peripheral part, β-DG binds non-covalently to α-DG. 
The glycans of the extracellular α-DG protein bind to several extracellular ligands, 
including laminin, agrin, perlecan, neurexin, pikachurin and slit (Campanelli et al, 
1994; Ervasti & Campbell, 1993; Gee et al, 1994; Henry & Campbell, 1996; Peng 
et al, 1998; Sato et al, 2008; Sugita et al, 2001; Wright et al, 2012). Functional 
glycosylation of α-DG in skeletal muscle tissue can be tested by a laminin overlay 
assay and a histochemical staining with IIH6, an antibody that recognizes the 
laminin-binding epitope.
α-DG contains three types of glycans: N-glycans, O-mucin glycans and O-mannose 
glycans (Chiba et al, 1997; Holt et al, 2000; Sasaki et al, 1998). Ligand binding 
requires specific O-mannose glycans that are attached via oxygen atoms of 
serine or threonine residues (Ervasti & Campbell, 1993). There seem to exist 
two variants of O-mannose glycans on α-DG. The first identified structure is a 
tetrasaccharide: Neu5Acα2-3Galβ1-4GlcNAcβ1-2Man-Ser/Thr (Chiba et al., 
1997). A few years ago, a trisaccharide (GalNAcβ1-3GlcNAcβ1-4Man-Ser/Thr) 
that is 6-O-phosphorylated on the mannose residue, was identified (Yoshida-
Moriguchi et al, 2010). The phosphate group has a diester linkage and is probably 
bound to other, LARGE-dependent glycan residues. This part of the O-mannose 
glycan might have a substantial contribution to the ligand-binding function. 
The protein products of all MDDG syndrome causative genes might play a role in 
the synthesis of the O-mannose glycans. However the function of most of these 
proteins is not yet clear, for several proteins a role related to the O-mannose 
synthesis has been demonstrated. Dolichol kinase, encoded by DOLK, 
phosphorylates membrane-bound dolichol (Schenk et al, 2001). Subsequently 
the dolichol-phosphate mannose complex, encoded by DPM1, DPM2 and DPM3, 
adds mannose from GDP-mannose to dolichol-phosphate (Maeda et al, 2000). 
Protein O-mannosyl transferase 1 and 2, encoded by POMT1	and POMT2, use 
dolichol-phosphate-mannose to add the mannose residue to α-DG (Manya et al, 
2004). The β1,2-linked N-acetylglucosamine (GlcNAc) residue is incorporated by 
protein O-linked-mannose β-1,2-N-acetylglucosaminyltransferase 1 (Yoshida et 
al, 2001). The β1,3-linked N-acetylgalactosamine (GalNAc) of the trisaccharide 
might be transferred by β-1,3-N-acetylgalactosaminyltransferase 2, however this 
hypothesis is not yet proven (Stevens et al, 2013). It is still unknown by which 
enzyme the β1,4-linked GlcNAc residue, and all other building blocks of the 
described O-mannose glycans, including the phosphate group, are incorporated. 
The protein products of FKTN, FKRP, ISPD, TMEM5, GTDC2 and SGK196 might all 
play a role in the incorporation of sugar building blocks. Although the function 
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of the protein products of LARGE and B3GNT1 are partly understood (Inamori 
et al, 2012; Sasaki et al, 1997), their exact position in the O-mannosylation 
pathway is still unknown. LARGE acts as a bifunctional glycosyltransferase 
that transfers both xylose and glucuronic acid (Inamori et al., 2012) and 
β-1,3-N-acetylglucosaminyltransferase 1 is able to add GlcNAc residues to 
N-acetyllactosamines attached to N-glycans in a β1,3-linkage. However, the 
presence of β1,3-linked GlcNAc as well as xylose and glucuronic acid have not 
yet been confirmed as part of the O-mannose ligand-binding glyco-epitope. 
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Abstract
Objective: To identify the underlying genetic defect in five patients from a 
consanguineous family with a Walker-Warburg phenotype, together with 
intracranial calcifications. 
Methods: Homozygosity mapping and exome sequencing, followed by Sanger 
sequencing of the obtained candidate gene was performed. Expression of 
the candidate gene was tested by RT-PCR. Patient fibroblasts were converted 
to myotubes and the expression and function of dystroglycan was tested by 
western blotting.
Results: We detected a homozygous loss-of-function frameshift mutation in the 
DAG1 gene and showed that this mutation results in a complete absence of both 
α- and β-dystroglycan.
Conclusions: A loss-of-function mutation in DAG1 can result in Walker-Warburg 
syndrome and is not embryonic lethal.
Introduction
Walker-Warburg syndrome (WWS) is the most severe variant of the muscular 
dystrophy-dystroglycanopathy (MDDG) syndromes and is characterized by 
congenital muscular dystrophy, ocular malformations and brain abnormalities, 
including cobblestone lissencephaly, pontocerebellar abnormalities and 
hydrocephalus (Dobyns et al, 1989). MDDG syndromes are caused by 
α-dystroglycan (α-DG) dysfunction (Michele et al, 2002; Moore et al, 2002), 
which may either be primary or secondary, resulting from mutations in DAG1 
or defects in α-DG O-mannosylation, respectively (Muntoni et al, 2011). DAG1 
encodes both α-DG and β-DG. α-DG requires extensive O-mannosylation to 
form a link between extracellular matrix ligands and the cytoskeleton via the 
transmembrane protein β-dystroglycan (β-DG) (Ibraghimov-Beskrovnaya et al, 
1992; Ervasti & Campbell, 1993). Only three cases with primary MDDG syndrome 
have been reported to date, all carrying homozygous missense mutations that 
directly affect either α-DG or β-DG (Hara et al, 2011; Geis et al, 2013). Here, we 
report a family with WWS caused by a homozygous DAG1 mutation that leads to 
the absence of both α-DG and β-DG. 
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Materials and Methods
Patients
A consanguineous Israeli-Arab kindred was consented for inclusion in this study 
after approval by the Institutional Ethics Review Committee and by the National 
Committee for Genetic Studies of the Israeli Ministry of Health. Laboratory 
screening studies included routine measurements in plasma and metabolic 
testing (serum lactate, pyruvate, amino acids, very-long-chain fatty acids, 
transferrin isoforms, urinary amino acids, organic acids and cerebrospinal fluid 
lactate). 
Homozygosity mapping
CNV analysis and homozygosity mapping was carried out as described previously 
(McMullan et al, 2009; Roscioli et al, 2012). Regions of excess homozygosity were 
identified using an algorithm adapted from a previous study using the Affymetrix 
GeneChip Human Mapping 250K array (Woods et al, 2006).
Exome sequencing
Exome sequencing for individuals V-3 and V-13 was performed as described 
previously (Roscioli et al, 2012). Read mapping and variant calling was performed 
with SOLiD bioscope software v1.3 using hg19 as the human reference genome. 
Annotated DNA variants were subsequently integrated with familial homozygosity 
data in a variant prioritization scheme. Exclusion of known variants was based on 
dbSNPv132 and an in-house database including 1142 in-house analyzed exomes. 
Primers surrounding the candidate disease-causing mutation were designed: 
5’-CCAGCAGGCATTCTGAATTA and 5’-AGCCAAGCTGAGCAGACATT and Sanger 
sequencing was performed.
Cell culture and MyoD overexpression
Patient fibroblasts were converted to myoblasts by transduction with an 
adenoviral vector containing the MyoD gene (Ad50MyoD; Crucell B.V., Leiden, 
the Netherlands) (Aartsma-Rus et al, 2003; Roest et al, 1996). Immortalized 
human myoblast cells were used as a control (Zhu et al, 2007). Both cell lines were 
induced to form myotubes via serum deprivation using medium supplemented 
with 2% fetal bovine serum and incubated for 8 days. For western blot analysis, 
cells were harvested by scraping in 0.35 M sucrose, 3 mM EDTA and 30 mM Tris 
buffer.
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RT-PCR
RNA was purified from fibroblasts using a Nucleospin RNA kit (Macherey-
Nagel). cDNA synthesis was performed using the iSCRIPT cDNA synthesis kit 
(Biorad) and used for PCR and Sanger sequencing using the following primers: 
5’-CAACAGATTTGATTGCCTCCAG and 5’ GGTAGCCAAGCTGAGCAGAC.
Western blotting
SDS-PAGE and western blotting were performed according to standard 
procedures. Primary antibody incubation was performed overnight at 4 °C, 
including polyclonal rabbit anti-human DAG1 (Genetex, GTX105038, 1:1000 
dilution), monoclonal IgG mouse anti-human β-dystroglycan (Novacastra 
Laboratories, 1:250 dilution), monoclonal IgG mouse anti-rat myogenin (BD 
Pharmingen, 1:500 dilution) and monoclonal IgG rabbit anti-human HSP90 
(Thermo Scientific, MA5-14866, 1:1000 dilution). Secondary antibody incubation 
was performed for 1 h using horse radish peroxidase-conjugated polyclonal goat 
anti-mouse or goat anti-rabbit immunoglobulins (DAKO, 1:5000 dilution). A 
laminin overlay was performed as described (Michele et al, 2002; Lefeber et al, 
2011).
Results
Clinical findings
Couple IV-1+2 had three affected daughters and three spontaneous miscarriages 
(Figure 1A and Table 1). Patient V-1 was born at 36 weeks of gestation, and 
presented with severe hydrocephalus, microphthalmia of the left eye and 
right corneal opacity. A brain computed tomography (CT) scan identified 
hydrocephalus and scattered calcifications, raising the possibility of intrauterine 
infection. Toxoplasmosis, rubella, cytomegalovirus and herpes virus (TORCH) 
serology screening in the baby and her mother were negative. Patient V-1 died 
at age 2 days from respiratory failure. Patient V-2 was born at 41 weeks of 
gestation. Her head circumference was 39 cm (>97th percentile) and she had a 
large open fontanel and widely patent sutures. Severe hypotonia was present 
with absence of spontaneous movements and tendon reflexes. Brain ultrasound 
detected severe hydrocephalus of all ventricles and cerebral calcifications. 
Laboratory studies showed elevated creatine kinase (CK) (840 U/L) and lactate 
dehydrogenase (LDH) (2000 U/L) and mild elevation of aspartate aminotransferse 
(AST) and alanine aminotransferase (ALT). She died of respiratory failure at 18 
hours of age. TORCH serology was negative. Patient V-3 was born at 40 weeks of 
gestation, and presented with severe hypotonia, absence of primary reflexes and 
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Figure 1: Clinical characteristics. A) Pedigree of the family indicating the mutation status (+: 
present; -: absent; NA: not available). B-F) CT scan of patient V-13 showing severe hydrocephalus, 
apparently absent cavum septum pellucidum, and absent cerebral gyration. Two dense deposits 
are visualized along the right ventricular wall (D, arrows) which represent calcifications. A posterior 
midline encephalocele is noted (B, asterix). The posterior fossa is small with hypoplastic cerebellar 
hemispheres and almost complete absence of the cerebellar vermis (E,F).
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bilateral buphthalmus. Her head circumference was 39.5 cm (>97th percentile) 
and she had a large open fontanel and widely patent sutures. Death occurred 
at 3 days of age secondary to respiratory failure. Brain ultrasound detected 
severe hydrocephalus. Couple IV-3+4, had two affected female patients. (Figure 
1A and Table 1). Patient V-12 had severe hydrocephalus, bilateral buphthalmus 
and severe hypotonia. She died a few hours after birth. Prenatal ultrasound in 
V-13 at 15 weeks gestation detected severe brain malformations, interpreted as 
holoprosencephaly. The baby was born at 36 weeks of gestation and required 
ventilator support for 3 hours before being extubated and breathing without 
assistance. Hypertonia was present and no primary reflexes were elicitable. She 
was fed by nasogastric tube. Ophthalmological examination detected bilateral 
corneal opacities and glaucoma. Cerebral ultrasounds detected progressive 
increase in size of the lateral and 3rd ventricles with multiple periventricular 
punctate calcifications. Cerebral CT scan identified severe hydrocephalus, a 
small posterior fossa, a small midline encephalocele, a hypoplastic vermis and 
calcifications along the lateral ventricular walls (Figure 1B-F). Elevated levels of 
CK (1944-2000 U/L) and LDH (1820-5063 U/L) and to a lesser extent AST and ALT 
were present. Muscle biopsy performed at 3 months of age detected marked 
variation in muscle fiber size without inflammation or fibrosis. There was 
complete lack of psychomotor development. The baby died at age 3.5 months 
following aspiration pneumonia and respiratory failure.
Molecular genetics
Whole exome sequencing on DNA from patients V-3 and V-13 detected a protein 
truncating homozygous single base pair deletion (c.743C>del, p.Ala248Glufs*19) 
in DAG1 (NM004393.4) (Supplementary Table 1), which was located within the 
largest interval of common homozygosity identified by SNP-microarray analysis 
(Supplementary Table 2). Sanger sequencing confirmed the presence of this 
mutation in homozygous form in the probands and in heterozygous form in both 
parents (Figure 1A). 
The frameshift mutation is located in exon 3 of DAG1 and results in a frameshift 
with a stop codon after 19 mismatched amino acids. To investigate the effect of this 
mutation on splicing and stability of DAG1 mRNA, we analyzed DAG1 expression 
in patient fibroblasts. A single RT-PCR product of the expected size of about 630-
bp was seen for patient as well as control cells (Figure 2A), indicating that the 
mutation does not give rise to alternative splicing. Sequence analysis of the RT-
PCR product showed the presence of the DAG1 transcript harboring the identified 
c.743C>del mutation in patient cells (Figure 2B), indicating that the mutant 
DAG1 transcript is not completely degraded by nonsense-mediated RNA decay.
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Biochemical analysis
Western blot was performed to analyze the effect of the mutation on both α-DG 
and β-DG protein in patient tissue. Fibroblasts obtained from patient V-13 were 
transformed to myoblasts by MyoD overexpression and converted to myotubes 
by serum starvation. On a laminin overlay blot, a control myotube sample showed 
a band at approximately 120 kDa of the properly glycosylated α-DG, whereas no 
detectable signal was seen in patient myotubes (Figure 2C), showing a complete 
absence of laminin binding. Moreover, immunostaining with antibodies against 
the α-DG and β-DG core proteins revealed signals at ~120 kDa and 43 kDa, 
respectively in control myotubes, whereas these bands were undetectable in 
patient myotubes. In contrast, control proteins myogenin and HSP90 could be 
clearly detected in patient cells (Figure 2C). These results indicate the complete 
absence of both α-DG and β-DG in the patient as a result of the homozygous 
deletion in DAG1 (Figure 2D).
Discussion
This report describes the first patients with a complete absence of α-DG and 
β-DG. Affected individuals show a WWS phenotype, together with intracranial 
calcifications. A novel homozygous frameshift mutation in DAG1 was identified 
which results in a premature stop codon.
Intracranial calcification is a non-specific finding with a wide differential diagnosis. 
An intrauterine TORCH infection was considered as a possible diagnosis in the 
patients reported here, however this diagnosis was not confirmed by serology. 
A wide range of genetic disorders that present intracranial calcifications, 
including the pseudo-TORCH syndrome (O’Driscoll et al, 2010; Livingston et al, 
2014), could be excluded based on the clinical findings and lack of support by 
the results of exome sequencing. To our knowledge, there is only one previous 
report of the occurrence of periventricular brain calcifications in a patient with a 
WWS-phenotype, however, in this case the causative mutation was not reported 
(Asano et al, 2000). 
The calcifications identified in the families reported in this study are non-specific 
and could result from cell damage, prior hemorrhage, hamartomas, etc. Further 
studies are required to clarify their etiology. However, our findings confirm that 
cerebral calcifications may be identified in WWS and their presence does not 
necessarily suggest an alternative diagnosis. 
Only two other primary MDDG syndromes due to mutations in DAG1 have been 
described previously. The first report describes a patient with a mild limb-girdle 
muscular dystrophy phenotype caused by a missense mutation (Thr192Met) in 
the N-terminal domain of α-DG, that precludes binding of LARGE for subsequent 
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modification of phosphorylated O-mannosyl glycans on α-DG (Hara et al, 2011). 
The other report describes a missense mutation (Cys669Phe) in two siblings with 
a severe muscle-eye-brain disease phenotype. This mutation is located in the 
β-DG encoding-part of DAG1 and is predicted to disrupt the tertiary structure of 
β-DG (Geis et al, 2013). Neither missense mutation leads to a complete absence 
of α-DG and β-DG, which might explain the less severe phenotype in comparison 
with the patients described here. 
A total of eight patients with DAG1 mutations have been diagnosed to date and 
remarkably these are all female patients. This observation could be coincidental, 
but might also reflect a gender-specific effect by which mutations in DAG1 lead 
to embryonic lethality in males and neonatal lethality in females (Gershoni et al, 
2014). Further studies are needed to prove this hypothesis.
This report expands the mutation spectrum in the MDDG syndromes and 
confirms that protein-truncating mutations in DAG1 may result in WWS and are 
not embryonic lethal.
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Supplementary Tables
Supplementary Table 1: Overview results exome sequencing.
Patient Chr. Genomic 
DNA
Ref. Abberation Reads Variation 
reads
Gene mRNA Protein PhyloP
V-3 3 49568687 C Deletion 6 4 (67%) DAG1 c.743del p.Ala248Glufs*19 6,026
V-13 3 49568687 C Deletion 5 5 (100%) DAG1 c.743del p.Ala248Glufs*19 6,026
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Abstract
Walker-Warburg syndrome is the most severe variant of the muscular dystrophy-
dystroglycanopathy syndromes. Walker-Warburg syndrome is characterized by 
muscular dystrophy, severe structural brain malformations and ophthalmologic 
abnormalities. Muscular dystrophy-dystroglycanopathy syndromes are caused 
by α-dystroglycan dysfunction, leading to a disrupted link between the cell 
membrane and extracellular matrix. Mutations in ISPD are the second most 
common cause of Walker-Warburg syndrome. Here, we report four patients with 
a Walker-Warburg syndrome phenotype. Affected individuals showed patients 
presented with muscular dystrophy, eye abnormalities and severe structural 
brain abnormalities, including cobblestone lissencephaly, hydrocephalus, and 
pontocerebellar atrophy. We describe two novel ISPD gene defects as the 
underlying cause of the disease and therewith further expand the genetic 
spectrum of Walker-Warburg syndrome.
Introduction
Walker-Warburg syndrome (WWS) is the most severe variant of the muscular 
dystrophy-dystroglycanopathy (MDDG) syndromes and is characterized by early 
infantile death, muscular dystrophy, severe structural brain malformations and 
eye abnormalities (van Reeuwijk et al, 2005). MDDG syndromes are caused by 
disruptions of α-dystroglycan (α-DG) O-mannosylation (Michele et al, 2002; 
Moore et al, 2002). α-DG is a heavily glycosylated extracellular protein that links 
the cytoskeleton and the basal lamina by binding to different extracellular matrix 
proteins, such as laminin in muscle and agrin and neurexin in brain. (Ervasti & 
Campbell, 1993; Campanelli et al, 1994; Gee et al, 1994; Sugita et al, 2001). 
The ligand-binding moiety contains a rare phosphorylated O-mannosyl glycan 
(Yoshida-Moriguchi et al, 2010), however, the exact binding-epitope is unknown. 
Mutations in DAG1, encoding α-DG and β-dystroglycan (β-DG) or, in the majority 
of cases, in genes encoding proteins involved in the O-mannosylation pathway, 
give rise to MDDG syndrome (Muntoni et al, 2011). Previous research showed 
that in about 10% of all WWS patients the ISPD gene is mutated (Roscioli et al, 
2012; Willer et al, 2012; Vuillaumier-Barrot et al, 2012) and that ISPD mutations 
can give rise to mild limb-girdle muscular dystrophy (LGMD) as well (Tasca et al, 
2013; Cirak et al, 2013). Here, we report novel ISPD gene defects in four patients 
that present with a characteristic WWS phenotype.
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Materials and Methods
Patients
Two patients (A and B) were diagnosed at the Radboud university medical center 
Nijmegen, the Netherlands and two (C and D) at the VU university medical center 
Amsterdam, the Netherlands between 2009 and 2012. Descriptions of medical 
history, physical, neurological and ophthalmic examination, results of laboratory 
tests, imaging, muscle biopsy and electroencephalography were obtained.
Genetic analysis
Informed consent was received from the parents. Whole exome sequencing, 
Sanger sequencing and copy-number variant (CNV) analysis of ISPD 
(NM_001101426.3) were performed as described (Roscioli et al, 2012). The 
cohorts of the 1000 Genomes project (approximately 2500 individuals) and 
the University of Washington (Exome Variant Server, approximately 6500 
individuals) were analyzed for the presence of the identified mutations. RT-PCR 
was performed using cDNA obtained from patient fibroblasts using standard 
procedures. Primer sequences are available upon request. 
Biochemical analysis
Immunohistochemistry staining using the IIH6 antibody and western blotting 
followed by a laminin overlay assay and desmin staining were performed as 
described previously (Michele et al, 2002; Lefeber et al, 2011). 
Results
Clinical findings
The clinical findings of the four patients are summarized in Table 1. 
Patients A and B are cousins. Patient C is from a consanguineous marriage and 
patient D is an isolated case born to healthy unrelated parents. None of the 
patients had a relevant clinical family history. Prenatal ultrasound was performed 
and showed hydrocephalus in all four cases and eye abnormalities in patient 
A. MRI of patient C during pregnancy additionally showed a ‘kinked’ brainstem 
and a hypoplastic cerebellar vermis. Relevant findings at physical examination 
after birth were macrocephaly, hypotonia, pupil defects (in patients A and D) and 
sunset sign. Ophthalmologic examination showed various symptoms, including 
cataract, proptosis, microphthalmus, buphthalmus and glaucoma.
MRI was performed in all cases and showed extensive abnormalities compatible 
with WWS, namely hydrocephalus, cobblestone lissencephaly and abnormal 
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anatomy of the brainstem and cerebellum (Figure 1 A-B). Serum creatine kinase 
levels varied between 9120 and 86390 U/L (normal <170 U/L). Muscle biopsy was 
performed for patient A, revealing clear muscular dystrophy. A laminin overlay 
assay showed a clear reduction of the laminin-binding capacity compared to 
the control (Figure 1C). Moreover, immunohistochemical staining using the IIH6 
antibody showed a strong reduction of O-mannosylated α-DG in muscle tissue 
of the patient (Figure 1D). In all four patients the diagnosis WWS was highly 
suspected by the combination of clinical findings and the typical abnormalities 
at imaging on MRI. 
All patients received a ventriculoperitoneal shunt; patients B and D within several 
days after delivery, and patients A and C after a month. All developed epileptic 
seizures. Patients A, C and D hardly showed any psychomotor development. Patient 
B died within a month after birth. All patients died due to complications during the 
course of disease, namely infection, status epilepticus or respiratory insufficiency. 
Genetic analysis
Exome sequencing performed to search for the underlying genetic defect in 
patient A, revealed a homozygous missense mutation, c. 614G>A (p.Arg205His) 
in the ISPD gene (NM_001101426.3). The mutation was confirmed by Sanger 
Table 1: Clinical characteristics of the patients.
Patient A B C D
Male/Female Female Female Male Male
Classical MRI 
abnormalities*
+ + + +
Ophthalmologic 
abnormalities
+ + Not available +
Muscle biopsy Dystrophy, reduced 
laminin and IIH6 
staining (Figure 1C-D)
Not available Not available  Not available
Creatine kinase (CK) (U/L) 10754 9120 86390 Not available
Epileptic seizures + + + +
Age of death 4 years 1 month 1 year Loss of follow-up
Cause of death Respiratory 
insufficiency
Meningits, status 
epilepticus
Pneumonia Unknown
*Lissencephaly, hydrocephalus, pontocerebellar atrophy and kinking of the brainstem 
(Figure 1A-B).
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sequencing. The same mutation was also found in patient B. This missense 
mutation is positioned in exon 3, encoding part of the strongly conserved 
N-terminal region containing the 4-diphosphocytidyl-2C-methyl-D-erythritol 
synthase (ISPD) domain (Figure 2A-B). SIFT (Ng & Henikoff, 2001), Polyphen 
(Adzhubei et al, 2010) and Mutation Taster (Schwarz et al, 2010) predicted that 
the mutation is probably damaging. In addition, Sanger sequencing revealed 
a homozygous splice site mutation in intron 7 of the ISPD gene (c.1027-3T>G) 
in patient C. RT-PCR analysis showed that this mutation affects splicing, as two 
different aberrant ISPD transcripts were identified in patient cells. A minority 
Figure 1: Clinical and biochemical findings. A-B) MRI at 3 weeks of age. Sagittal T2W image showing 
severe hydrocephalus, pontocerebellar atrophy and kinked brainstem (A). Axial T2W FLAIR image 
showing lissencephaly (B). C) A laminin overlay (LO) using patient (P) and control (C) skeletal 
muscle homogenates. Desmin staining was used as loading control. D) Immunohistochemistry of 
patient skeletal muscle was performed using the IIH6 antibody directed against the ligand-binding 
moiety on α-DG. A control staining was performed using spectrin antibody.
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Figure 2: Overview of ISPD mutations. A) Schematic representation of the ISPD gene and the 
identified mutations and deletion. B) Conservation at nucleotide and amino acid level of the 
missense mutation (c.614G>A, p.Arg215His, red box) detected in patient A and B. C) RT-PCR 
analysis of patient C, harboring the c.1027-3T>G splice site mutation, that leads to skipping of 
exon 8 (upper two panels) and to skipping of both exon 7 and 8 (lower two panels) P = patient, C 
= control.
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of all transcripts lacks exon 8 (r.1027_1119del, p.Thr344_Ser373del), while the 
majority of the transcripts lacks both exon 7 and 8 (r.934_1119del, p.His312_
Ser373del) (Figure 2C). Finally, CNV analysis revealed a 84-kb deletion in patient 
D (g.16247621-g.16331281), causing absence of exons 6 to 9.
Discussion
About 30 deletions, missense, nonsense and splice site mutations in the ISPD 
gene were previously identified in patients ranging from severe WWS to mild 
LGMD (Vuillaumier-Barrot et al, 2012; Cirak et al, 2013; Tasca et al, 2013; 
Willer et al, 2012; Roscioli et al, 2012). Here, we describe four WWS patients 
with mutations in ISPD. Patients presented with a typical WWS phenotype, 
characterized by severe ophthalmological and structural brain abnormalities, 
including hydrocephalus and cobblestone lissencephaly. In addition, muscular 
dystrophy was observed and staining of patient muscle tissue clearly showed 
absence of IIH6- and laminin-binding.
The p.Arg205His mutation we identified homozygously in patients A and B, was 
previously identified as a compound heterozygous allele in combination with 
a heterozygous 160-kb deletion in a WWS patient (Czeschik et al, 2013). The 
homozygous splice site mutation detected in patient C resulted in the expression 
of two aberrant ISPD transcripts, indicating that the mutation disrupts the 
acceptor site required for proper intron splicing. The deletion of exon 6 to 9 
identified in patient D causes absence of almost the complete C-terminal domain 
of ISPD. Previously, substantial deletions of the C-terminus were observed in 
WWS patients as well (Roscioli et al, 2012), suggesting that this domain might 
be required for proper ISPD activity. However, in contrast to the N-terminal ISPD 
domain, the C-terminal domain is not conserved and the exact function of the 
ISPD protein still remains unknown. 
In conclusion, we presented four WWS patient with novel genetic defects and 
therewith we expand the genetic spectrum of WWS.
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Abstract
Objective: To identify the underlying genetic defect in two brothers of 14 and 8 
years of age with speech and psychomotor developmental delay and behavioral 
problems.
Methods: Whole exome sequencing, followed by Sanger sequencing of the 
obtained candidate genes was performed. The binding of α-dystroglycan to 
laminin in patient muscle tissue was tested using immunohistochemistry. A 
complementation assay was performed by overexpressing different B3GALNT2 
mutants in a B3GALNT2-deficient cell line. To analyze the effect on α-DG 
O-mannosylation, the laminin-binding epitope was stained with the IIH6 
antibody and signal was measured using flow cytometry.
Results: A compound heterozygous mutation in B3GALNT2 was identified as the 
underlying genetic defect. The associated phenotype of mild intellectual disability 
was remarkably in comparison with previously reported patients with a muscular 
dystrophy-dystroglycanopathy syndrome phenotype. Immunohistochemical 
analysis of muscle biopsy revealed no significant aberrations, in line with the 
absence of a muscular phenotype. Remarkably, the complementation assays 
indicated that the identified mutations had comparable effects as those that 
were previously associated with severe muscular phenotypes.
Conclusions: Mutations in B3GALNT2 can give rise to a mild intellectual disability 
phenotype with no apparent muscular features. B3GALNT2 activity as assessed 
by the complementation assay does not correlate with the severity of the 
phenotype.
Introduction
Congenital muscular dystrophy-dystroglycanopathy (MDDG) syndromes are a 
group of inherited disorders with a broad clinical phenotype. The most severe 
variant is the Walker-Warburg syndrome (WWS), which has an onset at birth and 
is characterized by severe muscular dystrophy, type II lissencephaly, cerebellar 
abnormalities, hydrocephalus and eye malformations. Patients with muscle-eye-
brain disease (MEB) and Fukuyama congenital muscular dystrophy (FCMD) have 
a similar, but less severe phenotype. The mildest MDDG syndrome variants are 
limb-girdle muscular dystrophies (LGMD), which have a later age of onset and 
present only in a few patients with mild structural brain abnormalities (Muntoni 
& Voit, 2004; Godfrey et al, 2007). 
MDDG syndromes are caused by defective O-mannosylation of α-dystroglycan 
(α-DG), leading to reduced α-DG-laminin binding in the extracellular matrix 
(Michele et al, 2002; Moore et al, 2002). Mutations in DAG1 (Hara et al, 2011; 
Geis et al, 2013), encoding α-DG, and in seventeen other genes, including POMT1	
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(Beltrán-Valero de Bernabé et al, 2002), POMT2	 (van Reeuwijk et al, 2005), 
POMGNT1	(Yoshida et al, 2001), FKTN (Kobayashi	et	al,	1998), FKRP	(Brockington 
et al, 2001), LARGE	(Longman et al, 2003), ISPD (Roscioli et al, 2012; Willer et al, 
2012), POMGNT2	(GTDC2) (Manzini et al, 2012), TMEM5	(Vuillaumier-Barrot et 
al, 2012), B3GNT1	(Buysse et al, 2013), B3GALNT2 (Stevens et al, 2013), SGK196	
(Jae et al, 2013), GMPPB	(Carss et al, 2013), DOLK	(Lefeber et al, 2011), DPM1	
(Yang et al, 2013), DPM2	(Barone et al, 2012) and DPM3	(Lefeber et al, 2009), 
encoding proteins involved in the O-mannosylation pathway, cause different 
variants of MDDG syndrome. 
So far, eight patients with mutations in the B3GALNT2 gene (Stevens et al, 
2013; Hedberg et al, 2014) have been described. These patients have various 
combinations of missense mutations and mutations causing premature stop 
codons associated with variable but consistently severe phenotypes with 
congenital muscular dystrophy in all cases. In this work, we describe a family 
with two affected siblings that present with a novel and atypical, very mild MDDG 
syndrome variant caused by a compound heterozygous mutation in B3GALNT2. 
In addition, we performed complementation assays to analyze the effect of the 
various mutations on the O-mannosylation of α-DG.
Materials and Methods
Patients
The patients were ascertained in a large cohort study comprising individuals with 
unexplained intellectual disability at the Department of Human Genetics of the 
Radboud university medical center in Nijmegen, the Netherlands, where they 
had a thorough genetic diagnostic evaluation (Willemsen and Kleefstra, clinical 
genetics 2013). The parents consented to this study and the study was approved 
by the local ethical committee. 
Exome sequencing
DNA was extracted from peripheral blood using standard procedures. Exome 
sequencing was performed as described previously (Roscioli et al, 2012) and in 
Supplementary Materials and Methods.
Biochemical analysis
IIH6 staining on patient skeletal muscle section was performed as described 
(Lefeber et al, 2011).
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Cell culture
Human haploid HAP1 cells (Carette et al, 2011) were cultured in Iscove’s modified 
Dulbecco’s medium (IMDM, Gibco) supplemented with 10% fetal bovine serum 
and 1% penicillin/streptomycin/L-glutamine (Gibco) at 37 °C under 5% CO
2
 
atmosphere.
Complementation of B3GALNT2-deficient HAP1 cells
B3GALNT2 cDNA was cloned into a retrovirus expression vector pBabe-puro using 
EcoRI and SalI restriction sites as previously described (Jae et al, 2013). Mutant 
constructs were obtained by site-mutagenesis using Phusion® High Fidelity DNA 
Polymerase (New England Biolabs) and Q-solution (Qiagen). Primer sequences 
are described in Supplementary Materials and Methods. Viruses expressing wild 
type and mutant B3GALNT2 were produced in 293T cells and used to infect HAP1 
B3GALNT2-deficient cells as described previously (Jae et al, 2013). 
Flow cytometry analysis
HAP1 wild type, B3GALNT2-deficient and complemented cells were incubated 
with IIH6-C4 antibody (Merck Millipore), followed by incubation with goat anti-
mouse Alexa Fluor® 568 antibody (Invitrogen). Subsequently, the fluorescence 
signal was measured at a BD Fortessa flow cytometer as described previously 
(Jae et al, 2013).
Results
Patient phenotype
Patient II-1 and patient II-3 are two affected male siblings of 14 and 8 years 
of age respectively. They have a healthy brother (Figure 1A). Patient II-1 was 
born after an uncomplicated pregnancy and birth with a normal birth weight 
of 3.655 grams (50th-75th centile). He was a very quiet baby. His psychomotor 
development was delayed. Speech development was delayed more than motor 
development. He walked independently since the age of 21 months. He started 
to speak his first words at the age of 3 years. At the age of eleven years he 
still had trouble telling simple stories and was diagnosed with dysphasia. He 
could read at beginners’ level. A formal intelligence test yielded an IQ of 55. His 
behavior was characterized by temper tantrums and features of autism spectrum 
disorder. Hearing and vision were normal. At the age of 10 years and 11 months 
he had a normal height (143 cm/20th centile) and weight (34 kg/50th centile), 
and a low normal head circumference (52 cm/5th centile). There were no facial 
dysmorphic features observed. Neurological evaluation revealed dysphasia and 
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he had symmetrical low tendon reflexes, but further no signs of pyramidal, 
extrapyramidal, cerebellar or neuromuscular problems were observed. Brain 
MRI at the age of 3 years showed mild bilateral periventricular abnormalities 
in signal intensity of the white matter. At the age of 13 years brain MRI was 
normal. The creatine kinase level was slightly elevated (187 U/L; normal <170 
U/L). A muscle biopsy including spectrin, laminin and glycosylated α-DG staining 
showed an intact muscle structure and a not significantly abnormal α-DG staining 
(Figure 1B). Genome-wide chromosomal analysis by 250K SNP array analysis and 
a metabolic screen revealed no abnormalities.
The younger brother, patient II-3, was born after an uncomplicated pregnancy 
and birth. He had a normal birth weight of 3.495 grams (50th centile). His 
psychomotor development was delayed with independent walking after the age 
of 2 years and a severe speech delay with only 5 single words at the age of 3 
years. At the age of 5 years and 4 months his speech was only intelligible to 
his parents and his articulation was poor. A formal intelligence test showed a 
total IQ of 68. He had hyperactive behaviors and need for structure, but better 
social interaction than his brother, though contact was mainly functional. He 
occasionally displayed aggressive behavior and had problems falling asleep. His 
attention span was very short. Hearing and vision were normal. At the age of 
5 years and 4 months he had a normal height (114.5 cm/50th centile), weight 
(20 kg/50th centile) and head circumference (51.4 cm/50th centile). He had 
no evident facial dysmorphic features. Upon clinical neurological evaluation 
intelligibility was poor, but his speech was not truly dysarthric. He had no signs 
of pyramidal, extrapyramidal, cerebellar or neuromuscular dysfunctioning. As 
in his brother, genome-wide chromosomal analysis by 250K SNP array analysis 
revealed no abnormalities. Therefore, both were included in whole exome 
sequencing studies assuming an autosomal recessive or X-linked inheritance 
pattern.
Genetic analysis
To identify the genetic defect underlying the phenotype of the two affected 
siblings, whole exome sequencing was performed. Potential compound 
heterozygous mutations in the B3GALNT2 gene (NM_152490.4) were identified 
(Supplementary Table 1), including a duplication of two base pairs that lead to a 
premature stop codon (c.822_823dup, p.Ile276Leufs*26) in exon 7 and a missense 
mutation (c.988C>T, p.Arg330Cys) in exon 8. Both mutations were verified by 
Sanger sequencing (Figure 1C). Segregation analysis in the family showed that 
the parents carry one of the mutations each and that the healthy brother carries 
only the missense mutation (Figure 1A). Both mutations are predicted to have 
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a considerable effect on B3GALNT2 function. The duplication of two base pairs 
predicts a premature stop codon upstream of the galactosyltransferase domain 
(Figure 1D). This could lead to a decrease of transcript carrying this mutation due 
to nonsense-mediated RNA decay or to a truncated variant of the B3GALNT2 
protein that lacks the functional galactosyltransferase domain. The missense 
mutation is located in a conserved region within the galactosyltransferase domain 
(Figure 1D) and could therefore affect the biochemical activity of B3GALNT2.
Complementation assays
To test the potential pathogenicity of the identified mutations and to compare 
their effect with previously described B3GALNT2 mutations, complementation 
experiments were performed. A previously generated B3GALNT2-deficient HAP1 
cell line (ΔB3GALNT2) was used for complementation with wild type and mutant 
variants of B3GALNT2 cDNA. To predict the effect on B3GALNT2 enzymatic 
activity, cells were stained with the IIH6 antibody, recognizing the ligand-binding 
glyco-epitope on α-DG, and subsequently cytometric analysis was performed.
B3GALNT2-deficient cells were largely devoid of IIH6 staining (Figure 2A), 
emphasizing the importance of B3GALNT2 for O-mannosylation of α-DG. 
Complementation of the B3GALTN2-deficient cells with wild type B3GALNT2 
cDNA clearly restored IIH6 staining (Figure 2B). Complementation with B3GALNT2 
cDNA containing the two base pair deletion (p.Ile276LeuFs*26) failed to restore 
IIH6 staining (Figure 2C), indicating that this mutation abolishes B3GALNT2 
activity. In contrast, complementation with B3GALNT2 cDNA containing the 
missense mutation (p.Arg330Cys) almost completely restored IIH6 staining 
(Figure 2D), indicating that this mutation might not significantly affect B3GALNT2 
activity. 
Furthermore, complementation with three previously described missense 
mutations (Stevens et al, 2013) was performed. Remarkably, complementation 
with B3GALNT2 cDNA harboring the only homozygous missense mutation 
(p.Val268Met) that was identified in that study, did restore IIH6 staining completely 
(Figure 2E). In addition, complementation with two other B3GALNT2 mutants 
(p.Gly247Glu and p.Arg292Pro), both detected compound heterozygously in one 
patient, led to partly restoration of IIH6 staining (Figure 2F-G), indicating that 
these variants are not completely dysfunctioning.
Discussion
In this report we describe a family with two mildly affected intellectual disability 
patients caused by compound heterozygous mutations in B3GALNT2, a MDDG 
syndrome causative gene. Remarkably, the patients present with severe speech 
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Figure 2: Complementation of B3GALNT2-deficient HAP1 cells. A-G) IIH6 FACS analysis of HAP1 
B3GALNT2-deficient cell lines (ΔB3GALNT2) (A) complemented with wild type (B) and different 
B3GALNT2 mutants (C-G). Percentages of IIH6 positive (upper right corner) and IIH6 negative 
(upper left corner) are given. The fluorescent signal of wild type cells incubated with only the 
secondary antibody was used to determine the percentage of IIH6-positive cells. H) Overview of 
known B3GALNT2 mutations, categorized by clinical phenotype. Effect of the underlined mutations 
was tested by the complementation assay.
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delay and behavior problems, but no signs of muscular dystrophy and ocular 
problems, a presentation not previously associated with MDDG syndromes. One 
of the siblings had signs of white matter signal intensity changes at younger age, 
but these were not seen later.
The first patients reported with B3GALNT2 mutations presented severe 
phenotypes, characterized by cobblestone lissencephaly, congenital muscular 
dystrophy and other features indicative of WWS or slightly milder MEB/FCMD-
like phenotypes (Stevens et al, 2013). Recently, a patient was reported with a 
milder phenotype consisting of psychomotor retardation, ataxia, spasticity, 
muscle weakness, white matter anomalies, a hypoplastic pons and subcortical 
cerebellar cysts (Hedberg et al, 2014) (Figure 2H). 
The severity of the mutant B3GALNT2 phenotype can only be partially explained 
by the pattern of mutations. Biallelic loss-of-function mutations were mostly 
associated with a WWS phenotype, but in one case also with an MEB/FCMD-
like phenotype (Stevens et al, 2013). Compound heterozygous missense 
mutations were associated with an MEB/FCMD-like phenotype. Remarkably, the 
combination of a missense mutation and a frameshift mutation is seen in a wide 
range of phenotypes: WWS, MEB/FCMD-like, the mild muscle-brain phenotype 
reported previously (Hedberg et al, 2014), and the mild phenotype without clear 
muscular involvement reported in this manuscript. 
We tried to find an explanation for the variable phenotypes by conducting 
complementation assays with various mutant B3GALNT2 alleles in B3GALNT2-
deficient HAP1 cells. These experiments revealed that B3GALNT2 cDNA 
containing the duplication p.Ile276LeuFs*26 could not restore IIH6-binding, 
confirming that it represents a loss-of-function allele. Compound heterozygosity 
of this mutation and another predicted loss-of-function frameshift mutation 
(p.Val243Glufs*2) is associated with WWS (Stevens et al, 2013). In the patient 
described here, the duplication is found in compound heterozygosity with 
a p.Arg330Cys substitution. This missense mutation has a minor effect on 
B3GALNT2 functioning, as this B3GALNT2 variant restored IIH6-binding almost 
to the level observed for wild type HAP1 cells (85.5% IIH6-positive cells versus 
94.9% in control). These data suggest a correlation between residual B3GALNT2 
activity and phenotype. However, a possible correlation cannot be extrapolated 
to the activity measurements for other mutations. Complementation with 
B3GALNT2 cDNAs containing either of the compound heterozygous missense 
mutations associated with a MEB-FCMD-like phenotype (p.Gly247Glu and 
p.Arg292Pro) showed a partly reduced restoration of the IIH6-binding (72.8% 
and 70.8%, respectively). In addition, complementation with the p.Val268Met 
mutation, which was found homozygously in a MEB/FCMD patient, fully restored 
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the IIH6-binding in the B3GALNT2-deficient cells (97.2% IIH6-positive cells versus 
94.9% in control). Thus, the results of the complementation study did not clarify 
the severe phenotype of these patients.
α-DG skeletal muscle staining using the IIH6 antibody does not in all cases 
correlate with the severity of the clinical phenotype, as was shown for patients 
with a defect in FKTN or FKRP	(Jimenez-Mallebrera et al, 2009). However, the 
severity of the clinical phenotype of B3GALNT2 patients seems to correlate well 
with IIH6 muscle staining. In the mildly affected patients described in this study, 
no significant reduction of IIH6 staining and an intact muscular structure were 
shown, while in MEB/FCMD-like patients a strongly reduced IIH6 staining and an 
abnormal muscular structure were observed (Stevens et al, 2013). In addition, 
a reduced IIH6 staining in combination with an intact muscle structure was 
observed for the mild muscle-brain patient (Hedberg et al, 2014).
In conclusion, we showed that mutations in B3GALNT2 can give rise to 
intellectual disability, without muscle involvement. This atypical MDDG 
syndrome phenotype could be classified as a novel variant, which is expected 
to expand due to large scale whole exome sequencing efforts in intellectual 
disability cohorts. Therewith this study broadens the spectrum of the MDDG 
syndromes, as potentially mild mutations in other MDDG syndrome genes might 
lead to non-syndromal intellectual disability as well.
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Supplementary Materials and Methods
Exome sequencing
Exome enrichment was performed using the SureSelectXT Human All Exon 50Mb 
Kit (Agilent, Santa Clara, CA, USA), targeting the coding regions of ~21,000 genes. 
Samples were multiplex and sequenced using the SOLiDTM 4 System, leading to 
6.09 Gb and 7.22 Gb of mappable sequence, respectively. Read mapping and 
variant calling was performed with SOLiD bioscope software v1.3 using hg19 as 
the human reference genome. Quality control settings included the presence 
of at least two variant reads (i.e. different start sites), as well as the variant 
being present in at least 80% of all reads for homozygous variant and >20% for 
compound heterozygous variants. Exclusion of known variants was based on 
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dbSNPv132 and an in-house database including 1142 in-house analyzed exomes. 
Remaining variants were verified by Sanger sequencing according to standard 
procedures.
Mutagenesis
Primers used for mutagenesis:
5’-GGGAGTTGCAGGTGGTTTTTTATATATACTATTCAGGAAGG and 
5’-CCTTCCTGAATAGTATATATAAAAAACCACCTGCAACTCCC for c.822_823dup, 
5’-GTGGATGTTGTCGACACTATTGTAATGTTCCTGC and 
5’-GCAGGAACATTACAATAAGTGTCGACAACATCCAC for c.988C>T, 
5’-CACAACCTTCATTCTCCCCCTCAAAGACTTATTG and 
5’-CAATAAGTCTTTGAGGGGGAGAATGAAGGTTGTG for c.875G>C, 
5’-CTCATGAATTCTTGGAAGGTATGGAGGGAGTTGCAGGTGG and 
5’-CCACCTGCAACTCCCTCCATACCTTCCAAGAATTCATGAG for c.802G>A and 
5’-GTGACAGTGAATGATGGAGAGGGAGTTCTCAGAGTCATTAC and
5’-GTAATGACTCTGAGAACTCCCTCTCCATCATTCACTGTCAC for c.740G>A.
Supplementary Tables
Supplementary Table S1: Overview results whole exome sequencing.
Chr. Genomic 
DNA
Ref. Abberation Reads Variation 
reads
Gene mRNA Protein PhyloP
1 235628968 Duplication AA 273 57 (21%) B3GALNT2 c.822_823dup p.Ile276Leufs*26 3.624
1 235621948 G A 100 30 (30%) B3GALNT2 c.988C>T p.Arg330Cys 1.708
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Abstract
Several known or putative glycosyltransferases are required for the synthesis of 
laminin-binding glycans on α-dystroglycan, including POMT1, POMT2, POMGnT1, 
LARGE, FKTN, FKRP, ISPD and GTDC2. Mutations in these glycosyltransferase 
genes result in defective α-dystroglycan glycosylation and reduced ligand 
binding by α-dystroglycan causing a clinically heterogeneous group of congenital 
muscular dystrophies, commonly referred to as dystroglycanopathies. The 
most severe clinical form, Walker-Warburg syndrome, is characterised by 
congenital muscular dystrophy and severe neurological and ophthalmological 
defects. Here, we report two homozygous missense mutations in the β-1,3-
N-acetylglucosaminyltransferase 1 (B3GNT1) gene in a family affected with 
Walker-Warburg syndrome. Functional studies confirmed the pathogenicity of 
the mutations. First, expression of wild type but not mutant B3GNT1 in human 
prostate cancer (PC3) cells led to increased levels of α-dystroglycan glycosylation. 
Second, morpholino knockdown of the zebrafish b3gnt1	 orthologue caused 
characteristic muscular defects and reduced α-dystroglycan glycosylation. These 
functional studies identify an important role for B3GNT1 in the synthesis of the 
uncharacterised laminin-binding glycan of α-dystroglycan and implicate B3GNT1 
as a novel causative gene for Walker-Warburg syndrome.
Introduction 
Dystroglycanopathies are caused by reduced glycosylation of α-dystroglycan (α-
DG) (Michele et al, 2002; Moore et al, 2002). This group of muscular dystrophy-
dystroglycanopathy syndromes include a range of clinical phenotypes. Walker-
Warburg syndrome (WWS; MIM 236670), muscle-eye-brain disease (MEB; 
MIM 253280) and Fukuyama congenital muscular dystrophy (FCMD; MIM 
253800) represent the most severe end of the clinical spectrum. These disorders 
cause muscular dystrophy and severe eye and brain abnormalities resulting 
in early infantile death (van Reeuwijk et al, 2005a). The mildest variant of the 
dystroglycanopathies is adult-onset limb-girdle muscular dystrophy (LGMD; 
MIM 607155) associated with mutations in the fukutin-related protein (FKRP) 
gene (Brockington et al, 2001).
α-DG and β-dystroglycan (β-DG) are central components of the dystrophin-
glycoprotein complex (DGC), which forms a link between the cytoskeleton and 
the basal lamina. The peripheral membrane α-DG protein is connected to the 
cytoskeleton via non-covalent binding with the transmembrane β-DG protein 
that is linked to intracellular actin. The link with the basal lamina is formed by 
the binding of α-DG to several tissue-specific extracellular matrix (ECM) proteins, 
including laminin, agrin, perlecan, neurexin and pikachurin (Campanelli et al, 
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1994; Ervasti & Campbell, 1993; Gee et al, 1994; Henry & Campbell, 1996; Peng 
et al, 1998; Sato et al, 2008; Sugita et al, 2001). α-DG is highly glycosylated 
with N-glycans, mucin type O-glycans and O-mannose type glycans (Chiba et al, 
1997; Holt et al, 2000; Sasaki et al, 1998). α-DG-ligand binding requires specific 
glycosylation of α-DG (Ervasti & Campbell, 1993) through O-linked mannosylation 
of serine or threonine residues. The proposed ligand-binding glycan occurs on a 
phosphodiester-linked O-mannose residue (Yoshida-Moriguchi et al, 2010).
Reduced α-DG–ligand binding caused by hypoglycosylation of α-DG has been 
suggested to be the underlying cause for the dystroglycanopathies (Michele et al, 
2002; Moore et al, 2002). Mutations in POMT1, POMT2, POMGNT1, LARGE, FKTN, 
FKRP,	ISPD and GTDC2,	encoding known or putative glycosyltransferases, and a 
mutation in the dystroglycan gene (DAG) itself give rise to dystroglycanopathies 
with specific O-glycosylation defects (Beltrán-Valero de Bernabé et al, 2002; 
Brockington et al, 2001; Kobayashi et al, 1998; Longman et al, 2003; Manzini 
et al, 2012; Roscioli et al, 2012; van Reeuwijk et al, 2005b; Willer et al, 2012; 
Yoshida et al, 2001). Furthermore, the phenotypes of patients with mutations in 
genes involved in producing the sugar precursor dolichol-phosphate mannose 
(DOLK, DPM3,	DPM2	and likely DPM1) are associated with dystroglycanopathies 
with combined N- and O-linked glycosylation defects (Barone et al, 2012; Lefeber 
et al, 2011; Lefeber et al, 2009). The mannose group of dolichol-phosphate 
mannose is used during the first step of the O-mannosylation of α-DG by an 
O-mannosyltransferase complex that is encoded by POMT1 and POMT2 (Manya 
et al, 2004). Protein O-linked-mannose β-1,2-N-acetylglucosaminyltransferase 1 
(POMGnT1) is involved in the second step of the O-mannosylation. This enzyme 
adds an N-acetylglucosamine residue to the first mannose (Yoshida et al, 2001). 
The exact functions of the proteins encoded by FKTN, FKRP,	ISPD	and	GTDC2 are 
still unknown. However, the protein products of these genes might play a role in 
the glycosylation of the phosphorylated O-mannose glycan (Yoshida-Moriguchi et 
al, 2010). LARGE has been shown to act as a bifunctional glycosyltransferase that 
transfers both xylose and glucuronic acid. These glycan modifications allow α-DG 
to bind ECM ligands (Inamori et al, 2012). Recently, a mutation was identified in 
the DAG1 gene, which encodes the dystroglycan precursor protein that is post-
transcriptionally cleaved into α-DG and β-DG (Ibraghimov-Beskrovnaya et al, 
1992). This mutation, identified in a patient with an LGMD phenotype, interfered 
with post-translational modifications involving LARGE (Hara et al, 2011).
Mutation analysis of all known dystroglycanopathy genes has revealed the 
underlying genetic aetiology in about 50% of individuals from our cohort of 
patients with a severe dystroglycanopathy phenotype, suggesting that more genes 
remain to be discovered. The identification of new genes is important to increase 
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insight into the nature of the unknown ligand-binding glycan. This study provides 
the first evidence that mutations in β-1,3-N-acetylglucosaminyltransferase 1 
(B3GNT1) can give rise to WWS. 
Results 
Homozygosity mapping and B3GNT1	mutation analysis
To identify causative mutations for WWS, we previously performed homozygosity 
mapping in 30 families with idiopathic WWS using Affymetrix GeneChip Human 
Mapping SNP Array (Roscioli et al, 2012). Eight families showed homozygosity 
at 11q13, containing the B3GNT1	 gene, which was associated with α-DG 
glycosylation before in a cellular model of prostate cancer (Bao et al, 2009). For 
this reason, we followed a candidate gene approach and focused on B3GNT1	
in our cohort. In one of these families (WWS-31), the homozygous region was 
delimited by SNP_A-4215126 at 11q13.1 and SNP_A-2154685 at 11q13.3 (UCSC 
hg19 database, http://genome.ucsc.edu), representing a 5.24 Mb haplotype 
that was shared among the three affected individuals but different from that 
in an unaffected sibling. In this family, we detected two homozygous missense 
mutations in the coding sequence of B3GNT1. No B3GNT1 mutations were 
detected in any of the other seven families with homozygosity at 11q13.1, 
nor in any of the 47 additional families from our dystroglycanopathy cohort. 
Both mutations are absent in 5379 control samples from the NHLBI GO Exome 
Sequencing Project (Exome Variant Server, http://evs.gs.washington.edu/EVS) 
and in 672 exomes of our in-house database.
B3GNT1 is a type II transmembrane protein and both mutations are located in 
the conserved glycosyltransferase domain (Glyco_transf_49, pfam13896; Figure 
1 and Supplementary Figure S1). The first mutation, c.1168A>G (M1), is predicted 
to lead to a substitution of asparagine by aspartic acid (p.Asn390Asp), while the 
second mutation, c.1217C>T (M2), replaces alanine by valine (p.Ala406Val). 
Screening of all available family members showed co-segregation with disease, 
with all affected members being homozygous and all unaffected individuals 
being heterozygous for both mutations (Supplementary Figure S2).
Clinical report
The index family (WWS-31) without known consanguinity is of East Indian 
descent with four siblings diagnosed with WWS and three unaffected sibs 
(Figure 1E) (clinical details are described in Materials and Methods). Three 
pregnancies were terminated and one affected son died at 2 years of age. He 
presented with hydrocephalus, Dandy-Walker malformation, retinal dysplasia, 
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severe hypotonia and seizures. His creatine kinase (CK) level was very high 
(3180 U/L). The MRI (Figure 2A-D) showed typical WWS characteristics such as 
ventricular enlargement, diffuse widening of the gyri and disorganization of the 
cortical sulci with areas of cobblestone lissencephaly along the posterior aspects 
of the occipital lobes and temporal lobes. Besides, the white matter, brain stem 
and cerebellum were clearly affected. From one of the terminated pregnancies, 
a muscle biopsy was taken. The skeletal muscle showed lack of merosin and 
α-sarcoglycan expression. In addition, α-DG was not able to bind laminin as 
assessed by laminin overlay in skeletal muscle homogenate (Figure 2E).
Figure 1: Schematic representation of B3GNT1 chromosomal position, protein structure and 
localisation of mutations. A) Ideogram of chromosome 11 showing the localisation of the SNPs 
flanking the shared homozygous region in the patients. B) Zoom-in of the 5.2 Mb homozygous 
region. C) Gene structure of B3GNT1 showing the 5’UTR, two coding exons separated by the intron 
and the 3’UTR. D) Protein structure of B3GNT1 showing the topological domains, the conserved 
glycosyltransferase domain and the position of the missense mutations M1 (p.N390D) and M2 
(p.A406V). E) Pedigree of family WWS-31. Individuals that were available for study are identified 
by their lab number. The mutation status is indicated below each individual (+=present, -=absent, 
NA=not available).
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Figure 2: A-D) MRI at 4 months of age. Sagittal T2W image (A) reveals hydrocephalus, a hypoplastic 
‘Z’-shaped brainstem (arrow) and a hypoplastic, dysplastic vermis. Coronal T1W image (B) 
demonstrates absence of the septal leaflets, vertical hippocampi and fusion of the forniceal 
columns in the midline (arrow). Axial T2W image (C) shows focal cobblestone lissencephaly of the 
occipital cortex (arrow). The subjacent white matter is abnormally increased in signal intensity. A 
shunt is present in the posterior horn of the right lateral ventricle. In addition to ventriculomegaly 
and focal cobblestone lissencephaly, coronal T2W image (D) reveals cysts (arrow) within the 
dysplastic cerebellum. E) Patient (P) and control (C) muscle homogenates were used for a laminin 
overlay assay (LO). β-dystroglycan (β-DG) staining was used as loading control.
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Overexpression of wild type and mutant B3GNT1	in human PC3 cells
To investigate the functional consequences of the mutations, we first determined 
the subcellular localisation of wild type and mutant B3GNT1. We used human 
prostate carcinoma PC3 cells with low level of endogenous α-DG glycosylation 
(Bao et al, 2009). We transfected PC3 cells with enhanced green fluorescent 
protein (EGFP)-tagged wild type and mutant B3GNT1 constructs. Wild type 
and single or double mutant fusion proteins localised to the Golgi apparatus of 
transfected cells, as determined by co-localisation with the Golgi marker Giantin 
(GOLGB1; Figure 3). These results show that the mutations do not affect B3GNT1 
subcellular localisation.
To investigate the effect of wild type and mutant forms of B3GNT1 on α-DG 
glycosylation, a flow cytometry assay was performed using the IIH6 antibody 
against glycosylated α-DG (Michele et al, 2002). The number of IIH6 positive 
cells strongly increased on transfection with wild type B3GNT1 as compared to 
transfection with empty vector. Transfection with single mutants and the double 
mutant did not cause an increase of IIH6 positive cells. Normalization of the 
results as percentage of IIH6 positive cells in relation to the empty vector control 
showed a statistically significant difference in α-DG glycosylation between wild 
type and mutant constructs (Figure 4; p=0.042). These results indicate that the 
identified mutations impair the glycosyltransferase function of B3GNT1. 
Morpholino knockdown of zebrafish b3gnt1
To evaluate the phenotypic consequences of loss of function of B3GNT1 in	vivo, 
we used zebrafish embryos as a model for the dystroglycanopathies (Roscioli et 
al, 2012). The zebrafish ortholog, B3gnt1, shows 67% similarity to the human 
B3GNT1 protein sequence, including conservation of the two amino acid residues 
mutated in the family affected by WWS: Asn390 and Ala406 (Supplementary 
Figure S1). RT-PCR analysis showed that b3gnt1 is expressed in wild type embryos 
throughout the first five days of development (Figure 5A). To knockdown b3gnt1, 
we injected zebrafish embryos with a morpholino designed to disrupt splicing of 
the only intron in the b3gnt1 gene (Figure 1C). We observed a great reduction 
in the expression of the full-length transcript and the appearance of aberrantly-
spliced transcripts by RT-PCR (Figure 5B), using cDNA extracted from 48 hours 
post fertilization (hpf) morphant embryos.
To assess the effect of loss-of-function of B3gnt1 on glycosylation of α-DG, 
we extracted cell surface proteins from 48 hpf uninjected (positive control), 
b3gnt1 morpholino-treated and dag1 morpholino-treated (negative control) 
embryos. We tested the protein extracts for the presence of laminin-binding 
glyco-epitopes by Western blot, using the IIH6 antibody (Figure 5C). Little or no 
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Figure 3: Cellular localisation of wild type and mutant B3GNT1. Wild type and mutant variants of 
EGFP-tagged B3GNT1 (green) colocalise with the Golgi marker Giantin (red). Scale bar represents 
10 µM. 
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Figure 4: Flow cytometry analysis of transfected PC3 cells. PC3 cells transfected with an empty 
vector are used as control (A). In B3GNT1 WT-transfected PC3 cells (B) the percentage of IIH6 
positive cells is significantly higher than in PC3 cells transfected with an empty vector (A, F). The 
percentages of IIH6 positive cells in B3GNT1 M1 (C), B3GNT1 M2 (D) and B3GNT1 M1M2 (E) 
transfected PC3 cells are comparable with the percentage of the PC3 cells transfected with the 
empty vector (A, summary in F), indicating that glycosylation is affected. F) Bar chart showing the 
relative amount of IIH6 positive cells, taking the empty vector control as standard. (n=3, *=p<0.05, 
one sample T-test) Error bars show the standard deviation.
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glycosylated α-DG was observed in extracts from b3gnt1 morphants compared 
to wild type. These results demonstrate that loss of function of B3gnt1 results in 
hypoglycosylation (Figure 5C) and verifies the efficacy of the morpholino.
To investigate the effect of b3gnt1 morpholino knockdown on muscle fibre 
structure and organisation, we stained 48 hpf morphant and control embryos 
with phalloidin, which labels filamentous actin (F-actin) and an antibody against 
β-DG to label myotendinous junctions (MTJs). Muscle fibre organisation and 
structure was disrupted in morphant embryos (Figure 5D), including muscle fibre 
detachment and discontinuous MTJs, with elongated muscle fibres spanning 
the myosepta. Sarcolemma integrity was evaluated by injection of Evans blue 
dye (EBD), which only penetrates the cell when the membrane is compromised 
(Figure 5E). Accumulation of EBD was observed in the muscle lesions, indicating 
muscle degeneration with a loss of sarcolemma integrity in b3gnt1 morphant 
embryos.
Taken together, these results demonstrate that the missense mutations in B3GNT1 
in this WWS family significantly impair its function in	vitro as well as in	vivo	in 
zebrafish, showing a muscle phenotype comparable with dystroglycanopathy.
Discussion
Dystroglycanopathies are caused by mutations in (putative) glycosyltransferases 
and sugar donors that result in aberrant glycosylation of α-DG. Identification 
of all genes involved is essential for understanding the pathology in this group 
of disorders with abnormal glycosylation of the α-DG glycan. In this study, we 
identified two missense mutations in B3GNT1 in a family affected with WWS and 
showed that these mutations are causative for the disease. Firstly, the mutations 
reside in the conserved glycosyltransferase domain, show complete segregation 
with the disease in the index family and are absent in control cohorts. Secondly, 
B3GNT1	overexpression in human PC3 cells results in a significant increase in 
α-DG glycosylation, whereas overexpression of singly or doubly mutated B3GNT1 
is comparable to the negative control. This demonstrates the involvement of 
B3GNT1 in α-DG glycosylation and the pathogenicity of the missense mutations. 
Thirdly, morpholino knockdown of the zebrafish ortholog b3gnt1 results in 
phenotypic features that are reminiscent of WWS, with muscle structure 
disorganization being the most prominent finding. Taken together, these results 
indicate that B3GNT1 is required for the interaction between α-DG and laminin, 
as impaired B3GNT1 function leads to diminished glycosylation and subsequent 
disruption of ligand-binding, leading to phenotypic WWS features. Previous 
genetic analyses in patients with mild-end dystroglycanopathy phenotypes have 
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not revealed B3GNT1 mutations (Godfrey et al, 2011). Furthermore, we have 
identified only one family in our cohort of WWS patients, suggesting that it is a 
rare cause of dystroglycanopathies. One hypothesis is that more severe mutations 
might cause embryonic lethality and have hitherto remained undetected.
The exact function of B3GNT1 in α-DG O-mannosylation is still unknown. 
B3GNT1	 is expressed in tissues typically affected in dystroglycanopathies, 
including skeletal muscle and brain (Sasaki et al, 1997). Previous studies in a 
prostate cancer cell line (Inamori et al, 2012) indicated a role for B3GNT1 in 
synthesis of the laminin-binding glycan. B3GNT1 was originally characterised 
as an enzyme involved in the formation of poly-N-acetyllactosamine glycans 
by adding N-acetylglucosamine residues to N-acetyllactosamines attached 
to N-glycans (Sasaki et al, 1997). It has been proposed that B3GNT1 forms a 
complex with LARGE and that terminal N-acetylglucosamine residues are targets 
for LARGE glycosyltransferase activity (Bao et al, 2009; Hu et al, 2011). One 
possibility is that B3GNT1 adds a terminal N-acetylglucosamine residue to the 
phosphodiester-linked glycan that acts as acceptor for LARGE activity. A recent 
study has shown that LARGE transfers both xylose and glucuronic acid residues 
to the unknown ligand-binding glycan (Inamori et al, 2012), perhaps using the 
N-acetylglucosamine residue transferred by B3GNT1 as initiating sugar. It is 
not yet known how these xylose and glucuronic acid structures contribute to 
ligand-binding. Together with previous studies, our data suggest that at least 
three N-acetylglucosaminyl transferases with different specificity are required 
for synthesis of the ligand-binding glycan on α-DG. POMGnT1 is responsible for 
addition of a N-acetylglucosamine residue in β1,2-linkage to the first mannose 
residue. However, the N-acetylglucosamine residue in the phosphodiester-
linked O-mannose trisaccharide was proposed in β1,4-linkage, while B3GNT1 
is supposed to add a N-acetylglucosamine residue in β1,3-linkage, likely in the 
post-phosphoryl glycan (Sasaki et al, 1997; Yoshida-Moriguchi et al, 2010). 
Altogether, the synthesis of the laminin-binding glycan on α-DG still remains 
unclear, necessitating further mechanistic studies to position uncharacterised 
proteins as FKRP, FKTN, GTDC2 and ISPD in the pathway (Roscioli et al, 2012; 
Yoshida-Moriguchi et al, 2010). 
In conclusion, we have detected two pathogenic missense mutations in B3GNT1 
that result in impaired glycosylation of α-DG, giving rise to WWS. Our genetic 
and functional data provide evidence that B3GNT1 is a novel causative gene for 
the dystroglycanopathies and recommend its inclusion in the diagnostic workup 
of patients.
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Materials and Methods 
Clinical report
The index family (WWS-31) is a non-consanguineous family of East Indian 
descent with four affected children and three unaffected siblings (Figure 1E). The 
mother had a history of gestational diabetes. The remainder of the family history 
is non-contributory for additional risk factors. The couple’s first pregnancy, when 
the parents were 25 years old, resulted in a daughter who is well.
The second pregnancy was complicated with fetal ultrasound findings, at 22 
weeks of gestation, of hydrocephalus with the lateral ventricles measuring 24 
mm each and the 3rd ventricle measuring 5 mm. The cerebellum and brainstem 
were hypoplastic. The pregnancy was terminated at 24.9 weeks gestation 
and the autopsy showed diffuse and severe leptomeningeal neuroepithelial 
heterotopia, maximal over the convexity of the cerebral hemispheres and 
ventral brainstem. There was obliteration of the subarachnoid space and diffuse 
communicating hydrocephalus. There was severe dysplasia/hypoplasia of the 
cerebellar hemisphere and vermis and ventral brainstem hypoplasia, maximal at 
the basis pontis. The karyotype was normal and female (46, XX).
The third pregnancy was complicated with cerebral ventriculomegaly involving 
the lateral and 3rd ventricles with a very thin and smooth cortex at 23 weeks 
gestation. The cerebellum was hypoplastic and the cisterna magna was enlarged. 
There was multicystic dysplastic left kidney and very few tiny cysts appeared 
in the right kidney. The karyotype was normal and male (46, XY). The couple 
was counseled and decided to terminate the pregnancy. The autopsy showed a 
male fetus with a cystic dysplastic left kidney with a thread-like ureter, testicular 
hypoplasia with decreased number and marked size variation of seminiferous 
tubules, 12 ribs on the right and 11 on the left and X-ray finding of “beaten 
silver” frontal and parietal skull bones. Neuropathological investigation showed 
lissencephaly type II with cortical dysplasia, severe wavy island architecture and 
extensive glio-neuroepithelial leptomeningeal heterotopia with obliteration of 
the subarachnoid space. There was severe communicating hydrocephalus. The 
cerebellum showed severe cortical dysplasia/hypoplasia with inferior vermian 
defect. There was hypoplasia of the pyramids at the level of the medulla and 
the inferior olives had a C shaped dysplasia. There was hydromyelia. The eyes 
showed no anterior segmental abnormalities, focal abnormalities involving the 
retinae of both eyes including disorganized neuronal layer with irregular nests 
of neurons in the nerve fiber layer, some of which appeared to break through 
the inner limiting membrane. There were no abnormalities of the extraocular 
muscles. The findings were consistent with retinal dysplasia.
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The fourth pregnancy resulted in a son who is well.
The fifth pregnancy resulted in a fetus with WWS. The fetal ultrasound at 
17.6 weeks gestation showed a slight “lemon”-shaped head with bilateral 
ventriculomegaly measuring 14 mm, a small cerebellum and agenesis of the 
corpus callosum and inferior vermis. A repeat fetal ultrasound at 21.5 weeks 
gestation showed hydrocephalus with the lateral ventricles measuring 17 mm. 
The cerebellum was slightly small and there was partial vermian dysgenesis. The 
couple was counseled and decided to terminate the pregnancy. The autopsy 
showed a female fetus with findings consistent with WWS including extensive 
glio-neuroepithelial leptomeningeal heterotopia with obliteration of the 
subarachnoid space. There was severe communicating hydrocephalus. There 
was lissencephaly, absent pyramidal tract and agenesis of the corpus callosum. 
The cerebellum showed severe cortical dysplasia/hypoplasia and aplasia of the 
vermis.
The couple’s sixth pregnancy resulted in a son, who was diagnosed prenatally 
with WWS. The couple was counseled and decided to continue the 
pregnancy. The baby was born at term via Cesarean section due to severe 
cerebral ventriculomegaly. He presented with hydrocephalus, Dandy-Walker 
malformation, retinal dysplasia, severe hypotonia and intractable seizures. His 
CK level was very high (3180 units/L) and the MRI (Figure 2) showed ventricular 
enlargement, diffuse widening of the gyri and disorganization of the cortical 
sulci with areas of cobblestone lissencephaly along the posterior aspects of 
the occipital lobes and temporal lobes. There was white matter abnormality 
in association with these findings. The brain stem was severely abnormal with 
wasting of the pons and medulla. The cerebellum was also extremely dysgenetic 
with cysts, heterotopia and disarray of cortical migration. There was absence of 
the septum pellucidum and fusion of the forniceal columns in the midline. The 
globes were apparently intact with thinning of the posterior sclera and retina, 
consistent with retinal dysplasia. He had a ventriculoperitoneal shunt inserted 
and died at 2 years of age.
The couple’s seventh pregnancy resulted in a daughter who is well.
Patient cohort
A cohort of 55 families with one or more individuals affected with WWS or MEB 
were included in this study. Informed consent was obtained from all participants. 
The study was approved by the ethical board of the Radboud University Nijmegen 
Medical Centre, CMO Regio Arnhem-Nijmegen Approval 2011/155.
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Homozygosity mapping
Genotyping analysis of genomic DNA was performed using the Affymetrix 
GeneChip Human Mapping 10K 2.0 Array or 250K NspI Array. All SNP array 
experiments were performed and analyzed according to the manufacturer’s 
instructions (Affymetrix, Santa Clara, CA, USA). Homozygosity mapping was 
performed using an in-house algorithm (J.v.R., unpublished data) for analysis of 
the genotype files generated by the Affymetrix GTC software. The number of 
contiguous homozygous SNPs required for significance in relation to the degree 
of consanguinity for each individual was calculated using an algorithm adapted 
from (Woods et al, 2006). Regions of excess homozygosity were identified in 
affected individuals and compared to haplotypes of unaffected family members 
where available. 
B3GNT1	mutation analysis
Sequencing of the two coding exons of B3GNT1 (NCBI Reference Sequence 
NM_006876.2) was performed using the ABI PRISM BigDye Terminator Cycle 
Sequencing V2.0 Ready Reaction Kit and analyzed with the ABI PRISM 3730 DNA 
analyzer (Applied Biosystems, Foster City, California, USA). Primer sequences 
and PCR conditions are available upon request.
Molecular cloning and site-directed mutagenesis
Full-length human B3GNT1 mRNA was obtained from IMAGE cDNA clone 2988041 
(Source BioScience). The wild type human coding sequences were cloned into 
the Gateway pDONR™201 vector (Invitrogen). Site-directed mutagenesis using 
the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) was carried out to 
introduce the mutations into the constructs. The presence of the mutations was 
verified by Sanger sequencing. The human c.1168A>G mutation is referred to as 
mutation 1 (M1). The c.1217C>T mutation is referred to as mutation 2 (M2). Both 
single (M1 or M2) as well as double mutant (M1M2) constructs were designed. 
Wild type and mutant sequences were subsequently cloned into pCS2+ based 
expression vectors that were used for mRNA synthesis and transfection.
Accession number
To clone full open reading frame (ORF) zebrafish b3gnt1, we carried out RT-
PCR using cDNA from 48 hpf embryos with forward and reverse primers, 
5’-TCTTTTTTTTGCTATCCAAAC-3’ and 5’-GCATTCATGAGTGTCTCCTTACA-3’. The 
full ORF zebrafish b3gnt1	 cDNA has been submitted to GenBank (Accession 
number: KC136354).
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Western blotting
For human muscle tissues, proteins were extracted from paraffin embedded 
muscle as described (Rodriguez-Rigueiro et al, 2011). Protein samples were used 
for Western blotting followed by a laminin overlay assay and β-dystroglycan 
staining as described (Lefeber et al, 2011; Michele et al, 2002). Microsome 
preparation and western blotting using zebrafish embryos were carried out as 
previously described (Roscioli et al, 2012). Primary antibody used in this study 
was glycosylated α-dystroglycan IIH6 (Millipore, 1:2000).
Cell culture and transfection
Prostate cancer cells (PC3) (a gift from Gerald Verhaegh of the Department 
of Urology, Radboud University Nijmegen Medical Centre) were cultured in 
RPMI 1690 medium (Gibco) supplemented with 10% fetal bovine serum (PAA). 
Cells were transfected using FuGENE® 6 (Roche) according to manufacturer’s 
instructions. The ratio of transfection reagents (µL) to DNA (µg) used was 6:1. 
Three days after transfection, cells were used for immunocytochemistry or flow 
cytometry analysis.
Immunocytochemistry
Transfected and untransfected cells were cultured on glass cover slips. Cells 
were briefly washed using PBS, fixed in 3,7% formaldehyde in PBS at room 
temperature for 10 min, permeabilized using 0,4% Triton X-100 in 3% BSA/PBS 
at 4 °C for 10 min, blocked with 3% BSA/PBS at room temperature for 30 min and 
subsequently incubated with Giantin antibody (Covance) diluted 1:400 in 3% 
BSA/PBS at 4 °C for 1 h. Following primary antibody incubation, cells were briefly 
washed using PBS and subsequently incubated with Alexa Fluor® 555 Donkey 
Anti-Rabbit IgG (Molecular Probes) diluted 1:500 in 3% BSA/PBS at 4 °C for 1.5 
h. Cover slips were embedded in fluorescence mounting medium (DAKO). Cells 
were analyzed using Zeiss Axio Imager Z1 fluorescence microscope (Carl Zeiss).
Flow cytometry analysis
Cells were washed using PBS and subsequently scraped in cold PBS. Cells were 
blocked using 20% goat serum in 1% BSA/PBS on ice for 20 min. Cells were 
incubated with IIH6 antibody (Millipore) 1:25 diluted in 1% BSA/PBS on ice 
overnight. Cells were washed and subsequently incubated with Alexa Fluor® 
647 Goat Anti-Mouse IgG (Molecular Probes) 1:200 diluted in 1% BSA/PBS 
on ice for 2 h. Fluorescent signal of secondary antibody was measured using 
CyAn flow cytometer (Beckman-Coulter) with 642 nm laser. A total of 75,000 
cells were analysed per experiment. Data were analyzed using Summit 4.3 
106
Chapter 6
software. The percentage of IIH6 positive cells transfected with wild type and 
mutant B3GNT1 constructs was normalized against the percentage of IIH6 
positive cells transfected with empty vectors (Figure 4F). Statistical significance 
was determined using one-sample t-test (n=3). A p value < 0.05 was considered 
statistically significant.
Morpholino and EBD injections in zebrafish
Antisense morpholino oligonucleotides (MO) were obtained from 
GeneTools. dag1 MO has been described (Parsons et al, 2002). b3gnt1 MO 
(5’-CCTATTCTCCATGTGCTCACCTGGC-3’) was designed to target the b3gnt1 exon-
intron splice site. All MOs were injected into the yolk flow at one-cell stage using 
specified dose in the figure legend. As described (Lin et al, 2011), 0.1% Evans 
blue dye (EBD, Sigma) was injected into zebrafish blood circulation at 48 hpf. MO 
or EBD injected embryos were fixed using 4% PFA for immunohistochemistry 
or analysed live under confocal and differential interference contrast (DIC) 
microscopy. 
Zebrafish immunohistochemistry
Immunostaining of fixed zebrafish embryos was performed as described 
(Roscioli et al, 2012). Alexa Fluor®-conjugated phalloidin (Molecular Probes; 
1:100 dilution) and primary antibody anti-β-Dag1 (Novocastra, 1:50) were used. 
Alexa Fluor® 488 or 594 conjugated anti-mouse IgG (Molecular Probes; 1:250 
dilution) were used as secondary antibody.
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Supplementary Figure S1: Multiple sequence alignment of B3GNT1. Darker shades of blue indicate 
higher levels of conservation. The missense mutations p.Asn390Asp and p.Ala406Val are indicated 
by solid red boxes.
Supplementary Figures
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Abstract
A unique O-mannosyl glycan on α-dystroglycan is essential for interaction with 
extracellular protein ligands in muscle and brain. A group of congenital disorders, 
called muscular-dystrophy dystroglycanopathy syndromes, is caused by defective 
formation of this glycan structure, which up to now remains unsolved. Mutations 
in the ISPD gene, with uncharacterized function in this pathway, represent 
the second most common cause of muscular dystrophy-dystroglycanopathy 
syndromes. To explore the function of human ISPD, we determined its crystal 
structure, revealing a canonical N-terminal cytidyltransferase domain linked 
to a C-terminal domain that is absent in cytidyltransferase homologues. 
Functional studies demonstrated cytosolic localization of ISPD, and CTP-
dependent cytidyltransferase activity towards the pentose-phosphate pathway 
intermediates ribulose-5-phosphate and ribose-5-phosphate and, more 
efficiently, towards ribitol-5-phosphate. Identity of the CDP-ribitol product was 
confirmed by LC-QTOF mass spectrometry and 2D NMR-spectroscopy. Enzyme 
analysis in ISPD-deficient patient cells and in a TALEN-induced ISPD-knockout 
cell line shows that ISPD acts independent from protein O-mannosyltransferase 
activity. Our combined results indicate that ISPD produces a novel human CDP-
nucleotide sugar that is essential for functional glycosylation of α-dystroglycan.
Introduction
Protein glycosylation is an essential and well-studied post-translational 
modification that requires the sequential addition of single monosaccharides 
to form a glycan structure, for which nucleotide- and dolichol-linked sugars 
serve as donors. Most nucleotide sugars are produced in the cytoplasm from 
phosphorylated monosaccharides that originate from common metabolic 
pathways such as glucose metabolism (Freeze & Elbein, 2009). Subsequently, 
nucleotide sugars are transported to the endoplasmic reticulum (ER) and Golgi 
apparatus for protein glycosylation. The pathways to generate nucleotide 
sugars are diverse and well described (Bulter & Elling, 1999). Most commonly, a 
pyrophosphorylase adds a nucleotide to a sugar phosphate, as in the synthesis 
of GDP-α-D-mannose (GDP-Man) from α-D-mannose 1-phosphate and GTP. In 
addition, epimerization reactions are known, such as the conversion of UDP-
α-D-N-acetyl galactosamine (UDP-GalNAc) into UDP-α-D-N-acetyl glucosamine 
(UDP-GlcNAc). Finally, they may be derived from other nucleotide sugars, for 
example the decarboxylation of UDP-α-D-glucuronic acid (UDP-GlcA) to form 
UDP-α-D-xylose (UDP-Xyl). For glycosylation reactions in the ER, sugar donors 
can be linked to dolichol, such as dolichol-phosphate-mannose (Dol-P-Man), 
synthesized from GDP-Man and dolichol-phosphate (Maeda & Kinoshita, 2008). 
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α-Dystroglycan (α-DG, encoded by DAG1) is a glycoprotein with a unique and not 
yet fully elucidated O-mannose linked glycan that is crucial for binding extracellular 
ligands, such as laminin in muscle (Ervasti & Campbell, 1993), and neurexin (Sugita 
et al, 2001) and slit (Wright et al, 2012) in brain. For synthesis of the functional 
glycan on α-DG, Dol-P-Man, UDP-GlcNAc and UDP-GalNAc are incorporated 
into a GalNAc-β1,3-GlcNAc-β1,4-Man-Ser/Thr trisaccharide, containing a 
6-O-phosphoryl modification on the mannose residue (Yoshida-Moriguchi et al, 
2010). This rare phosphoryl group is probably bound to an essential and not 
yet fully elucidated part of the ligand-binding epitope that contains repeating 
–3-Xyl-α1,3-GlcA-β1– units (Inamori et al, 2012), requiring the availability of 
UDP-GlcA and UDP-Xyl donors. Defective α-DG O-mannosylation leads to a group 
of human disorders, known as muscular dystrophy-dystroglycanopathy (MDDG) 
syndromes, which present with muscular dystrophy, severe brain abnormalities 
and in some cases eye abnormalities (Martin, 2005). These disorders are caused 
by defects in the DAG1 gene itself (Geis et al, 2013; Hara et al, 2011), or, in 
the majority of cases, its glycosylation enzymes (Wells, 2013). Thus far, known 
defects in the synthesis of sugar substrates for α-DG O-mannosylation have been 
limited to Dol-P-Man caused by mutations in DPM3 (Lefeber et al, 2009), DOLK 
(Lefeber et al, 2011), DPM2	(Barone et al, 2012), DPM1	(Yang et al, 2013) and 
GMPPB	(Carss et al, 2013).
Recently, mutations in the isoprenoid synthase domain-containing (ISPD) gene 
were identified in patients with deficient α-DG O-mannosylation (Roscioli 
et al, 2012; Willer et al, 2012), displaying a very heterogeneous spectrum of 
phenotypes (Supplementary Table S1). Experiments suggested an influence of 
ISPD mutations on protein O-mannosyltransferase activity (Willer et al, 2012) 
and an additive effect with MDDG syndrome genes FKTN and FKRP (Roscioli 
et al, 2012). ISPD encodes a protein with high sequence identity to the large 
glycosyltransferase superfamily-A of nucleotide sugar pyrophosphorylases and 
glycosyltransferases, which share a conserved Rossmann-like fold structure 
(Liu & Mushegian, 2003). While ISPD homologs in plants, protozoa and some 
bacteria function to synthesize 4-diphosphocytidyl-2-C-methylerythritol (CDP-
ME) from 2-C-methyl-D-erythritol 4-phosphate (MEP) and CTP (Richard et al, 
2004) as part of the non-mevalonate/MEP pathway of isoprenoid synthesis, this 
pathway is not present in humans. As such, the functional role of human ISPD 
(hISPD) remains unknown. Here, we investigated a potential role of hISPD in 
cytosolic sugar metabolism, using a combination of biochemical and structural 
biology approaches.
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Results
hISPD appends a novel domain to its conserved cytidyltransferase core
To provide molecular insight into hISPD properties, we determined the 
crystal structure of hISPD (residues 43-451), in the unliganded state, to 2.4 Å 
resolution (Table 1). hISPD features a canonical cytidyltransferase domain 
(residues 43-265) connected, via a linker helix (residues 266-281), to a domain 
of no known homology (residues 282-451) (Figure 1A). The cytidyltransferase 
domain adopts the characteristic Rossmann-like α/β-fold among nucleotide 
sugar pyrophosphorylases, featuring an extended β-arm (residues 185-203) 
for formation of a homodimer (Figure 1B-C), a solution state consistent with 
gel filtration studies (Supplementary Figure S1A). The hISPD cytidyltransferase 
domain superimposes well (Cα root mean square deviation (r.m.s.d.) 1.9-
2.7 Å, for 202-230 atomic pairs) with a series of closely related prokaryotic 
cytidyltransferases and ISPD homologs (Figure 1D and Supplementary Table S2), 
with minor structural differences in the α3-β4 loop of the core β-sheet (Figure 
1D and Supplementary Figure S2). 
Data collection and processing
Beamline Diamond I03 
Wavelength (Å) 0.9795
a,b,c (Å) 79.36, 116.8, 111.8
α=β=γ (°) 90
Space group C222
1
Resolution range (Å) 65.64-2.39 (2.50-2.39)
Observed reflections 67290 (8440)
Unique reflections 20791 (2539)
Rsym(%) 7.0 (42.9)
I/sig(I) 8.6 (2.5)
Completeness 99.3 (99.6)
Multiplicity 3.2 (3.3)
Refinement
Rcryst (%) 21.2
Rfree (%) 25.5
Wilson B factor (Å2) 41.0
R.m.s.d. bond length (Å) 0.0081
R.m.s.d. bond angle (°) 1.2452
Table 1: Data collection and refinement statistics for hISPD structure.
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Figure 1: Crystal structure of hISPD. A) Domain organization of hISPD showing the N-terminal 
cytidyltransferase domain (yellow) dimerization arm (pink), C-terminal domain (green), and inter-
domain linker helix (blue). The full-length protein (FL), produced in E.	 coli, and an N-terminal 
truncation construct (ΔN), produced in Sf9 cells, were used for enzymatic studies. B) Structure of 
the hISPD protomer, colored as in A. Dotted lines indicate disordered regions that are not modelled 
in the structure. C) Homodimer of hISPD as seen in the crystal between a protomer (chain A) 
and its dyad-related subunit (chain A’). D) Superposition of hISPD N-terminal cytidyltransferase 
domain with T.	maritima	IspD (PDB code 1vpa), S.	pneumoniae	TarI (2vsi) and E.	coli	IspD (1ini). E) 
Structural topology of hISPD C-terminal domain. F) Structural superposition of hISPD C-terminal 
domain with representative examples from short-chain dehydrogenases/reductases (e.g. enoyl 
ACP reductase, top) and response regulator proteins (CheY, bottom). * indicates the additional 
β-strand in enoyl ACP reductase not found in hISPD (top) and the additional β-strand in hISPD not 
found in CheY (bottom).
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A number of nucleotide sugar pyrophosphorylases append to their 
cytidyltransferase core a C-terminal extension which functions as an 
oligomerization module (Supplementary Figure S3) or incorporates additional 
enzyme activities (e.g. Bcs1 reductase). hISPD belongs to this subset of 
‘extended’ cytidyltransferases, but both the topology of the C-terminal domain 
(Figure 1E), as well as its angular orientation relative to the cytidyltransfersase 
core (Supplementary Figure S3C), is unprecedented. Built from a central 
6-stranded parallel β-sheet flanked by α-helices, this domain also contributes 
to the hISPD dimerization interface, and indeed dimerizes when expressed 
alone (Supplementary Figure S1B). We identified distant structural relatives of 
the hISPD C-terminal domain in two distinct α/β protein families (DALI server; 
Supplementary Table S2), including the seven-stranded NAD(P)(H)-dependent 
short-chain dehydrogenases/reductases (e.g. keto-acyl reductases, Cα r.m.s.d. 
of 2.9-3.4 Å over ~130 aa; Figure 1F, top) and five-stranded response regulator 
proteins involved in bacterial sensing systems (e.g. CheY, Cα r.m.s.d. of 2.2-2.5 Å 
over ~100 aa; Figure 1F, bottom). Despite the structural homology, there is low 
conservation at the sequence level and hISPD lacks signature sequence motifs in 
these protein families (Supplementary Figure S4).
hISPD is cytosolic and has cytidyltransferase activity
Nucleotide sugar pyrophosphorylases involved in human protein glycosylation 
are known to be cytosolic. To study the subcellular localization of hISPD, a 
HEK293 cell line stably expressing C-terminally Myc-His-tagged hISPD under a 
doxycycline inducible promoter was generated. Immunocytochemical staining 
showed a diffuse widespread staining pattern suggestive of cytosolic localization 
(Supplementary Figure S5). This was confirmed by cell fractionation studies, 
showing hISPD to be present in the cytosolic fraction after doxycycline induction 
(Figure 2A).
To determine if hISPD has cytidyltransferase activity, we established a malachite 
green assay to measure released inorganic pyrophosphate (PPi) levels. Using 
this assay, a basal level of catalytic activity for recombinant hISPD was observed 
towards MEP (Figure 2B), a known substrate of bacterial IspD (Richard et al, 2004). 
Since MEP is not known to exist in humans, we additionally screened several 
physiological pentose- and hexose-phosphates as potential ligands as well as 
choline-phosphate (choline-P) and glycerol-phosphate (glycerol-P) (Figure 2B), 
known to be present as CDP derivatives in humans (Kennedy & Weiss, 1956).
Considerable cytidyltransferase activity was observed for several pentose-5-
phosphates known to occur in the pentose phosphate pathway (PPP) (Marks, 
1956), with the highest levels of released PPi detected using ribose 5-phosphate 
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(ribose-5P) and ribulose 5-phosphate (ribulose-5P), followed by xylulose 
5-phosphate, as substrates (Figure 2B). Another pentose sugar, arabinose 
5-phosphate, as well as hexose sugars, choline-P and glycerol-P, result in PPi 
levels comparable to, or below the control. ISPD cytidyltransferase activity is 
dependent on and specific for the triphosphate CTP, while use of CDP, CMP or 
other nucleotides result in hardly detectable activity (Figure 2C). Taken together, 
hISPD has cytidyltransferase activity and can use ribulose-5P and ribose-5P as 
substrates.
hISPD is able to produce CDP-ribulose, CDP-ribose and CDP-ribitol 
The turnover of ribulose-5P and ribose-5P by hISPD in	 vitro prompted us to 
investigate if they form the corresponding products CDP-ribulose and CDP-
ribose, as well as if the related ribitol 5-phosphate (ribitol-5P) is a substrate 
for hISPD leading to CDP-ribitol. To this end, ribulose-5P, ribose-5P or ribitol-5P 
was incubated with recombinant hISPD overnight, and product formation was 
analyzed by hydrophilic interaction liquid chromatography (HILIC) HPLC. Here, a 
single product peak was observed in the ribitol-5P reaction (Figure 2D), which was 
of higher intensity than those from the ribulose-5P and ribose-5P reactions, in 
which residual CTP was still present (Figure 2E-F). This result indicates that ribitol-
5P is preferred over ribulose-5P or ribose-5P as the hISPD substrate. To check for 
potential other side reactions of hISPD the three reaction mixtures were further 
analyzed by HILIC LC-QTOF mass spectrometry and to identify all metabolites 
produced, Molecular Feature Extraction (MFE) was performed. Analysis of the 
ribulose-5P and ribose-5P reactions revealed the formation of a single molecular 
mass ([M-H]- 534.05 m/z) (Supplementary Table S3), corresponding to the 
expected products CDP-ribose and CDP-ribulose (535.29 Da, C
14
H
23
O
15
N
3
P
2
). For 
both reactions, the extracted-ion chromatogram (EIC) of m/z 534.29 showed two 
peaks at 9.7 and 10.25 minutes retention time (Supplementary Figure S6A-B), 
indicative of the presence of both CDP-ribose and CDP-ribulose by molecular 
inter-conversion. Indeed, 1H NMR analysis demonstrated the isomerization of 
ribose-5P into ribulose-5P that is independent from hISPD activity, as shown 
by the control without hISPD (Supplementary Figure S6C-F). This suggests a 
spontaneous isomerization reaction under the experimental conditions tested. 
Analysis of the ribitol-5P reaction by HILIC LC-QTOF mass spectrometry showed 
a [M-H]- molecular mass of 536.07 Da, corresponding to the mass of CDP-ribitol 
(537.31 Da, C
14
H
25
O
15
N
3
P
2
) (Supplementary Table S3).
To confirm the identity of CDP-ribitol, the reaction product was purified by HILIC 
HPLC and characterized by 1H-13C HSQC and 2D 1H COSY NMR spectroscopy. 
NMR spectra of a previously prepared CDP-ribitol sample (Pereira & Brown, 
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2004) were used as reference (Supplementary Table S4). Characteristic signals 
were observed for the ribofuranose and cytidine moieties in CDP, and for the 
ribitol moiety (Figure 3 and Supplementary Figure S7). Additionally, the signals 
at 4.14/4.21 ppm (H5’a/H5’b) and 67.4 ppm (C5’) correspond to a ribofuranose 
ring covalently-linked with ribitol via a pyrophosphate bond, consistent with 
reported HSQC spectra of CDP-D-arabinitol (Wang et al, 2012a) and CDP-D-
mannitol (Wang et al, 2012b), showing similar ppm values for H5’a/H5’b and 
C5’. Together, these NMR resonances indicate a pyrophosphate linkage between 
CDP and ribitol.
Figure 3: 1H-13C HSQC NMR spectrum of CDP-ribitol. 1H-13C HSQC NMR spectrum of HILIC HPLC-
purified CDP-ribitol with the 1H NMR spectrum on the top horizontal axis. Numbers refer to the 
carbon and proton resonances of the cytidine (C5), ribose (C1’-C5’) and ribitol (C1”-C5”) moieties.
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Since ribitol-5P appeared to be the best substrate for hISPD cytidyltransferase 
activity, producing CDP-ribitol, we questioned if ribulose-5P or ribose-5P could 
be reduced by hISPD to ribitol-5P prior to generation of CDP-ribitol. A similar 
mechanism is known for the H.	 influenzae bcs1 enzyme that contains both 
reductase and cytidyltransferase activity in the production of bacterial CDP-
ribitol. To this end, we incubated hISPD with ribulose-5P or ribose-5P in the 
presence of reductors NADPH and NADH. However, we did not observe any 
turnover as measured by absorbance at 340 nm (Supplementary Figure S8), 
indicating that hISPD is not able to catalyze this reduction under the conditions 
tested.
Hotspot of hISPD missense mutations in the cytidyltransferase core
Almost 30 disease causing truncating mutations (nonsense, frameshift and 
deletion mutations) have been reported for the ISPD gene (Supplementary Table 
S1). These aberrations terminate the protein before or within the C-terminal 
domain, the absence of which is likely the cause of the enzyme dysfunction. By 
contrast, the missense mutations reported to date for ISPD (n=12; Supplementary 
Table S1) are clustered in the N-terminal cytidyltransferase domain (Figure 4A-
B). To identify important catalytic residues for the hISPD cytidyltransferase 
activity and to investigate potential effects of these missense mutations, we 
docked the sugar substrates (ribulose-5P, ribose-5P, ribitol-5P) and nucleotide 
(CTP) onto the active site (Figure 4C), based on superposition with known 
cytidyltransferase-ligand complexes (Supplementary Figure S2B). The pentose 
sugar substrates of hISPD can fit snugly within a binding cleft lined by a number 
of polar and charged residues (Arg126, Asp156, Ser211, Gln215, Thr238 and 
Glu239), which serve to interact and stabilize the pentose hydroxyl groups. This 
pocket can also accommodate the smaller ligands that are known substrates for 
ISPD homologues (e.g. MEP, choline-P), but are expected to have less optimized 
binding interactions because of the shorter chain length. The sugar 5-phosphate 
moiety, the likely nucleophile in the cytidyltransferase reaction (Richard et al, 
2001), can be anchored by the invariant Lys263. 
Modelling of the hISPD-substrate-CTP complex allows us to postulate the 
molecular effects of the 12 missense mutations (Figure 4B) into (i) ‘catalytic’ 
substitutions that alter the shape of the active site (p.Met213Arg, p.Thr238Ile) 
or affect interactions with CTP or sugar substrates (p.Ala53Thr, p.Gly54Ala, 
p.Arg126His, p.Asp156Asn) (Figure 4D); (ii) ‘misfolding’ substitutions that 
likely disrupt protein structure and stability e.g. by introducing steric clashes 
with neighboring residues (p.Ala216Asp and p.Pro149Leu), interfering with 
the non-polar protein core (p.Tyr226His and p.Tyr226Cys), or introducing a 
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Figure 4: hISPD missense mutations localize in the N-terminal cytidyltransferase core. A) Domain 
organization of hISPD showing locations of reported missense mutations. B) Missense mutation 
sites mapped onto the hISPD monomer. For B, D and E, the mutation sites are colored in blue for 
those that could affect catalysis/substrate binding, red for those that could affect folding/stability 
and purple for the R205H mutation in the dimer arm. C) Surface representation of the hISPD active 
site colored on a scale of sequence conservation. Residues that line the binding pockets for sugar 
substrate (docked with ribulose-5P, Ru5P) and nucleotide (docked with CTP) are shown as sticks. 
* indicates residues reported to be mutated in patients. D) View of the hISPD active site showing 
missense mutation sites (red and blue lines) and other residues (E239, S211, Q215, K263) that 
are part of the sugar-binding cleft as described in the text (black lines). E) View of hISPD missense 
mutation sites with the dimeric subunit shown (surface representation). Residue 205 in the dimer 
arm, site of the R205H mutation, is highlighted in purple.
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conformationally-constrained proline to the core β-sheet (p.Ala122Pro) (Figure 
4D); and (iii) ‘oligomerisation’ substitution, represented solely by the p.Arg205His 
mutation that localizes in the dimer arm (Figure 4E) and may affect homodimer 
formation. 
hISPD acts independently from POMT activity
hISPD has previously been implicated in the regulation of the protein O-mannosyl 
transferase POMT1-POMT2 complex, where POMT activity (Willer et al, 2012), 
i.e. transfer of the first mannose residue of the O-mannose glycan to Ser/Thr 
residues of α-DG, was measured as described previously (Manya et al, 2004). 
In that study, POMT activity in ISPD-deficient patient fibroblasts (30 – 150 
pmol/g/h) was comparable with that in POMT1-deficient patient fibroblasts 
(~100 pmol/g/h). Here we performed a similar POMT assay, following the 
incorporation of labelled Dol-P-Man to GST-tagged α-DG. In two ISPD-deficient 
patient cell lines, we found considerable POMT activity (245.3 and 332.0 pmol/
g/h) comparable with to a control cell line (190.2 pmol/g/h). In addition, POMT 
activity obtained for a POMT2-deficient cell line (11.6 pmol/g/h) (Figure 5A) was 
similarly negative to reported values of < 9 pmol/g/h for POMT1- and POMT2-
deficient patient cell lines (Manya et al, 2008). To confirm these observations, we 
assayed POMT activity in the haploid HAP1 cell line after inducing a frameshift 
mutation into ISPD by transcription activator-like effector nucleases (TALENs). 
While two independent HAP1 clones, each carrying a frameshift mutation in the 
catalytic domain of hISPD (Figure 5B), were deficient for IIH6 and laminin binding 
on western blots (Figure 5C), both clones retained POMT activity similar to wild 
type HAP1 cells (Figure 5A and Supplementary Figure S9), indicating that hISPD 
acts independently from POMT activity in α-DG O-mannosylation. 
Discussion
Although mutations in ISPD are the second most common cause of MDDG 
syndrome (Roscioli et al, 2012; Willer et al, 2012), until now the function of the 
hISPD protein in α-DG O-mannosylation is unknown. This study determines the 
three-dimensional structure of hISPD, identifies its cytidyltransferase activity 
towards pentose phosphate sugars, and proposes a role of hISPD in a novel 
metabolic pathway for nucleotide sugar synthesis.
Involvement of hISPD in α-dystroglycan O-mannosylation
Our investigations into hISPD led to the findings that it is a cytoplasmic 
cytidyltransferase which uses CTP as its preferred nucleotide. While hISPD 
demonstrated no activity against any hexose sugar tested, it is active with 
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pentoses, especially ribulose-5P and ribose-5P which are part of the PPP. 
Interestingly, the most efficient substrate we found was ribitol-5P. We therefore 
investigated the potential of hISPD to catalyze the reduction of ribulose-5P 
or ribose-5P to ribitol-5P, analogous to cytidyltransferases in the bacteria H.	
influenza,	 S.	 pneumonia and S.	 aureus, which couple their cytidyltranserase 
activity with NAD(P)H-dependent reductase activity either in a single enzyme 
(bcs1) or in two different enzymes (tarI and tarJ) (Baur et al, 2009; Follens et al, 
1999; Pereira & Brown, 2004). The lack of NAD(P)H consumption in our study 
suggests that this is not the case, in line with the absence of a dinucleotide binding 
motif in the hISPD C-terminal domain despite its weak structural homology 
with members of the short chain dehydrogenases/reductases. As a possible 
explanation, an alternative reductase could act on one or both substrates prior 
to or after cytidyltransfer, allowing production of CDP-ribitol. 
Until now, CDP-ribitol has not been shown to be present in humans. In the 
synthesis of pneumococcal and H.	 influenzae polysaccharides, CDP-ribitol is 
Figure 5: POMT activity in ISPD-knockout cells and fibroblasts. A) POMT activity in ISPD- and 
POMT2-deficient patient fibroblasts and HAP1 ISPD-knockout cells. n=2, error bars show standard 
deviation. B) ISPD locus and genomic DNA sequence of HAP1 cells carrying a TALEN-induced 
mutation in exon 2 of ISPD that leads to a premature stopcodon. TALEN-recognition sites are 
highlighted in red and blue. C) Laminin overlay (LO) assay and IIH6 staining of HAP1 ISPD-knockout 
cells. β-dystroglycan (β-DG) immunostaining was used as a control to asses protein loading.
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used as a precursor for the integration of ribitol-P (Baur et al, 2009). By analogy, 
in humans CDP-ribitol may be incorporated as ribitol or ribitol-phosphate in the 
laminin-binding epitope of α-DG at an attachment point yet to be elucidated. 
This will require the transfer of CDP-ribitol to the Golgi apparatus via a nucleotide 
sugar transporter. The CMP-sialic acid transporter SLC35A1 was recently 
identified in a genome-wide screen to be essential for α-DG O-mannosylation 
(Jae et al, 2013), although sialic acid itself is not part of the laminin-binding 
epitope (Combs & Ervasti, 2005). This opens the possibility of transfer of another 
nucleotide sugar, such as CDP-ribitol. It will be of interest to investigate whether 
the MDDG syndrome-associated Golgi proteins FKTN and FKRP, belonging to the 
LicD type of glycosyltransferases with uncharacterized substrates, are involved 
in the incorporation of ribitol in α-DG. In the bacterium Prevotella	tannerae, a 
protein (ZP_05736246) containing both an IspD and a LicD domain is present 
and a previous study in zebrafish showed a cooperative interaction between ispd 
and fktn, and between ispd and fkrp (Roscioli et al, 2012). 
In the bacterial non-mevalonate/MEP pathway for isoprenoid synthesis, 
CDP-ME, the product of bacterial IspD cytidyltransferase activity, is further 
phosphorylated for subsequent conversion into isopentenyl- and dimethylallyl-
pyrophosphates for the synthesis of dolichol. In humans, the mevalonate 
pathway for isoprenoid synthesis is important for O-mannosylation, as deficient 
dolichol production leads to deficient O-mannosylation in a tissue specific 
manner (Cantagrel et al, 2010; Lefeber et al, 2011). It is unlikely that the hISPD 
products are subsequently used for isoprenoid synthesis, as no other genes 
downstream of IspD in the bacterial non-mevalonate pathway are conserved 
in humans. We investigated a proposed scenario (Willer et al, 2012) by which 
hISPD could influence α-DG O-mannosylation via modulation of POMT1/POMT2 
activity. However, our results, both with patient fibroblasts and the well-defined 
HAP1 knockout system, revealed this was not the case.
Homology with crystal structures of other cytidyltransferases
The N-terminal domain of hISPD shows strong sequence and structural 
homology with known cytidyltransferases, corresponding to its activity towards 
pentose phosphates, and pointing to an evolutionarily conserved mechanism 
of protein-substrate interaction as well as cytidyl transfer. Recent efforts were 
made to develop small molecule inhibitors that target microbial or parasitic 
ISPDs as potential anti-bacterial, anti-malarial or herbicidal treatment (Witschel 
et al, 2011), with the rationale that these enzymes, part of the non-mevalonate/
MEP pathway of isoprenoid synthesis, are absent in humans. The discovery of 
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disease mutations and cytidyltransferase activity for hISPD, coupled with its high 
homology across the phyla, however, raises the question of its validity as a drug 
discovery target.
It remains to be determined whether the C-terminal domain of hISPD is 
endowed with an as yet undetected enzymatic activity, or merely functions in 
enhancing the stability, activity and integrity of the N-terminal cytidyltransferase 
domain. Consistent with the latter, we observed that a construct encompassing 
the hISPD cytidyltransferase domain alone is poorly soluble both in E.	coli	and 
Sf9 insect cells. While pathogenic missense mutations are localized only to the 
N-terminal cytidyltransfersase domain, many of which disrupt the active site 
integrity, the C-terminal domain, by contrast, harbors a number of truncating 
aberrations (e.g. premature termination, frameshift or deletion mutations) that 
lead to reduced cytidyltransferase activity and disease, further suggesting the 
potential importance of the C-terminal domain towards hISPD function. The 
limited number of patients identified with ISPD mutations, most of which are 
compound heterozygous, has thus far hindered a determination of a genotype-
phenotype relationship, however, a few inferences can be made. Homozygosity 
for p.Gly54Ala in one patient lead to a mild phenotype, while homozygosity for 
p.Asp156Asn in another case gave rise to a severe phenotype. It is possible, then, 
that Gly54 has a less important role in substrate binding, or that the specific 
p.Asp156Asn substitution has a more severe effect on the catalytic domain 
than p.Gly54Ala. Additionally, the most common mutation identified thus far, 
c.1114_1116del (p.Val372del) found in 5 patients, results in a missing residue 
in the C-terminal domain but a mild phenotype. Unlike larger deletions or 
truncations in the C-terminus (e.g. p.Glu396*; deletion of exon 9 and 10) which 
cause a more severe phenotype when homozygous, this mutation may result in 
only minor destabilization of the C-terminal domain, allowing it to partially fulfill 
its function.
Although the majority of genes required for α-DG O-mannosylation seems to 
have been uncovered, a complete picture of the O-mannose glycan structure 
and its underlying synthetic pathways still eludes us. Here, we add a new piece 
to the puzzle by showing that hISPD, in contrast to most MDDG syndrome gene 
products in the ER and Golgi, acts in the cytosol to produce a novel CDP-nucleotide 
sugar that is important and specific for proper α-DG O-mannosylation. Future 
identification of additional enzymes involved in sugar metabolism may help to 
establish the exact position of hISPD in the O-mannosylation pathway.
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Materials and Methods
Expression and purification of recombinant hISPD in Sf9 cells
To express sufficient quantity of recombinant protein for crystallization, a DNA 
fragment encoding an N-terminal truncation (hISPD
ΔN,
 residues 43-451) of hISPD 
was subcloned into a pFB-Lic-Bse vector (GenBank accession number EF199842), 
in frame with an N-terminal His
6
-tag and a TEV protease cleavage site. Protein 
was expressed in Sf9 insect cells and purified to homogeneity by affinity and size 
exclusion chromatography, followed by His-tag removal. 
Expression and purification of recombinant hISPD in E.	coli
To express recombinant hISPD for the enzymatic assay, DNA fragments 
containing full-length (residues 1-451) or C-terminal domain alone (residues 
283-451) were sub-cloned into the pNIC28-Bsa4 vector (GenBank accession 
EF198106) incorporating an N-terminal TEV-cleavable His
6
-tag. The plasmids 
were transformed into E.	coli BL21(DE3)-R3-pRARE2, grown in 12 L TB medium 
with induction by 0.1 mM IPTG overnight at 18 °C and purified as described for 
the Sf9 cells-expressed protein. 
Crystallographic studies of hISPD
Crystals of hISPD
ΔN
 were grown by vapor diffusion at 20 °C from sitting drops 
of 75 nl protein (15 mg/ml, hISPD
ΔN
, purified from Sf9 cells) and 75 nl reservoir 
solution containing 25% (v/v) PEG3350 and 0.1 M Bis-Tris pH 6.5. Crystals were 
mounted in the presence of 25% (v/v) ethylene glycol and flash-cooled in liquid 
nitrogen. Diffraction data were collected at the Diamond Light Source beamline 
I03, and processed using MOSFLM and SCALA (Collaborative Computational 
Project, 1994). The structure was solved by molecular replacement with PHENIX 
(Adams et al, 2010), using PDB code 3Q80 as the starting model. Iterative cycles 
of restrained refinement and manual model building were performed using 
COOT (Emsley & Cowtan, 2004) and REFMAC5 (Murshudov et al, 1997). Residues 
55-60, 319-334 and 345-347 are disordered in the electron density map, and 
not modeled in the final model. Crystallographic statistics are shown in Table 1. 
Structure analysis and generation of Figures 3 and 4 were performed in ICM-Pro 
(Molsoft, San Diego).
Generation of a HEK293 hISPD overexpressing cell line
Full-lentgh ISPD mRNA (Gen Bank NM_001101426) was obtained from a Myc-
DDK-tagged hISPD ORF clone (OriGene) and the coding sequence was cloned in a 
pcDNATM5/FRT/TO based expression vector containing a C-terminal-Myc-His tag 
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using the Gateway system (Invitrogen). Generation of a stable T-REx™ Flp-In™ 
HEK293 cell line and overexpression of hISPD was performed using the hISPD-
mycHis tagged construct according to manufacturer’s instructions (Invitrogen). 
Cells from a confluent 175 cm2 flask were used for cell fractionation as described 
(Holden & Horton, 2009). 
Immunoblotting and laminin overlay
SDS-PAGE was performed using 5% or 8% polyacrylamide gels and subsequently 
proteins were transferred to a nitrocellulose membrane by western blotting. 
Membranes were incubated with primary and secondary antibodies as detailed 
in Supplementary Materials and Methods. A laminin overlay was performed as 
described (Lefeber et al, 2009; Michele et al, 2002). 
hISPD enzyme reactions
The hISPD enzyme assay and subsequent malachite green assay were performed 
as described (Baur et al, 2009; Bernal et al, 2005), with minor adaptations. 
Larger scale enzyme reactions were performed for HILIC HPLC and LC-QTOF mass 
spectrometry and NMR analysis. Detailed protocol is described in Supplementary 
Materials and Methods. 
HILIC HPLC analysis
A HILIC column (TOSOH BioScience 13071, TSK gel Amide-80, 4.6mmID x 25.0 cm 
L 8AM283HKO288) was used on a Shimadzu Nexera UHPLC system. UV detection 
was performed at 269 nm. Detailed protocol is described in Supplementary 
Materials and Methods.
NMR analysis
NMR spectra were recorded using a Bruker 500 MHz Avance I or a Varian 
Unity 800 MHz NMR spectrometer at 298K. For calibration of 1D 1H spectra, 
the chemical shift of trimethylsilyl propionic acid (TSP) was set at 0.00 ppm. For 
calibration of 1H-13C HSQC and 2D 1H COSY NMR spectra, the chemical shift was 
calibrated using the water resonance at 4.7 ppm. NMR spectra were analyzed 
using Bruker (1D) and Varian (2D) software. 
Generation of ISPD-knockout cell lines using TALEN technology
HAP1 cells (Carette et al, 2011) were cultured in Iscove’s modified Dulbecco’s 
medium (IMDM, Gibco) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin/L-glutamine (Gibco) at 37 °C under 5% CO
2
 atmosphere. 
HAP1 ISPD-knockout cells were generated using TALEN technology as described 
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(Sanjana et al, 2012). Used target sequences: 5’TGGCAGAAGATCAGATCAAC-3’ 
and 5’GAAGTAGTGATTATCCATGA-3’. Sanger sequencing was performed to verify 
the TALEN plasmid induced mutations. 
POMT enzyme activity
Fibroblasts of two ISPD-deficient patients (ISPD1: c.832A>T, p.K278* and ISPD2: 
c.614G>A, p.R205H), control fibroblasts and fibroblasts of a POMT2-deficient 
patient (c.220del, p.D734fs) and HAP1 control and HAP1 ISPD-knockout cell lines 
(#1 and #2) were pelleted (4 x 107 fibroblasts and 9 x 107 HAP1 cells) for assaying 
POMT activity as described previously (Manya et al, 2004; Yoshida et al, 2001) 
and in protocol provided in Supplementary Materials and Methods. 
Accesion number
Atomic coordinates and structure factors have been deposited with the PDB 
under the accession code 4CVH.
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Supplementary Materials and Methods
Size exclusion chromatography
Analytical gel filtration was performed on a HiPrep 16/20 Superdex 200 column 
(GE Healthcare) pre-equilibrated with buffer containing 25 mM HEPES pH 7.5, 
500 mM NaCl and 5% glycerol. The column was calibrated using of bovine 
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thyroglobulin (670 kDa), bovine γ -globulin (158 kDa), chicken ovalbumin (44 
kDa), horse myoglobin (17 kDa) and Vitamin B12 (1.35 kDa) as MW standards.
Cell culture
T-REx™ Flp-In™ human embryonic kidney 293 cells (HEK293, Invitrogen) were 
cultured in Dulbecco’s modified Eagle medium (DMEM, Lonza) supplemented 
with 10% fetal bovine serum (PAA), 1% penicillin/streptomycin (Gibco), 300 µg/
ml Zeocin (Invitrogen) and 5 µg/ml Blasticidin S (InvivoGen) at 37 °C under 5% 
CO
2
 atmosphere. 
Fibroblasts were cultured in Medium 199 (Gibco) supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin at 37 °C under 5% CO
2
 atmosphere.
Antibodies used for western blotting
Primary antibodies used for western blotting: anti-Myc (mouse monoclonal 
IgG
1
 antibody, 1:5000, Invitrogen), HSP90 (rabbit monoclonal IgG antibody, 
1:1000, Pierce), Calnexin (rabbit polyclonal antibody, 1:1000, Novus Biologicals), 
ATP5H (mouse monoclonal IgG
2b 
antibody, 1:1000, Mitosciences), IIH6 (mouse 
monoclonal IgG antibody, 1:1000, Millipore) and β-DG (mouse monoclonal 
antibody IgG
2A
, 1:250, Novacastra). Secondary antibodies: horse radish 
peroxidase (HRP) conjugated polyclonal goat anti-mouse IgG (1:5000, Santa 
Cruz) or HRP conjugated polyclonal goat anti-rabbit IgG (1:5000, Pierce). 
Immunocytochemistry
Cells were cultured on cover slips and induced to hISPD overexpression. Cells 
were fixated using 3.7% paraformaldehyde and permeabilized using 0.4% Triton 
X-100. Primary antibodies used: anti-Myc (mouse monoclonal IgG
1
 antibody, 
1:200, Invitrogen) and anti-HSP90 (rabbit monoclonal IgG antibody, 1:50, Pierce). 
Secondary antibody incubation was performed using Alexa Fluor® 488 goat anti-
mouse IgG (1:500, Molecular Probes) and Alexa Fluor® 568 goat anti-rabbit IgG 
(1:500, Molecular Probes). Cover slips were analyzed using a Zeiss Axio Imager 
fluorescence microscope (Carl Zeiss). 
Chemicals and substrates used for the hISPD enzyme assay
Chemicals: D-ribose 5-phosphate, D-ribulose 5-phosphate, D-xylulose 5-phosphate, 
D-arabinose 5-phosphate, D-ribose 1-phosphate, Ribose, D-Glucose 6-phosphate, 
D-Glucose 1-phosphate, Rac-Glycerol 1-phosphate, phosphorylcholine, cytidine 
5’triphosphate (CTP), cytidine 5’diphosphate (CDP), cytidine 5’monophosphate 
(CMP), adenosine 5’triphosphate (ATP), guanosine 5’triphosphate (GTP), 
uridine 5’triphosphate (UTP), inorganic pyrophosphatase from S.	 cerevisiae, 
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β-nicotinamide adenine dinucleotide 2’-phosphate (NADPH), β-nicotinamide 
adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD) and riboflavin 
5’-monophosphate (FMN) were purchased from Sigma Aldrich. 2-C-Methyl-
D-erythritol 4-phosphate (MEP) was purchased from Echelon Bioscience.
Ribitol 5-phosphate was produced as previously described (Baddiley et al, 1956), 
with some adaptations. In short, 180 mg ribose 5-phosphate was dissolved in 4 
ml MilliQ (164 mM) and a sodium borohydride solution (23 mg in 2 ml water, 
304 mM) was added. After 10 min incubation on ice, 8 h at room temperature 
and 15 h at 4 °C, 0.5 ml additional sodium borohydride solution (304 mM) was 
added and after 4 h incubation at room temperature, the reaction was stopped 
by addition of 0.3 ml acetic acid. 4 ml of a 10% ammonia solution was added to 
neutralize the pH. 14 ml water was added and the solution was passed through 
a Dowex® 1X8 (chloride form, Serva) 30 ml column. The column was washed 
once with water, followed by elution of ribitol 5-phosphate with 30 ml 1 M 
ammonium acetate solution. An excess (7.5 ml) of Dowex® 50W X8 (H+-form, 
Fluka
 
) was added to the eluate to remove cations. The eluate was lyophilized. 
The dried product was dissolved in 3 ml water and 10 ml 1 N barium hydroxide 
solution was added. Salts were precipitated by addition of 1 ml ethanol and 
removed by centrifugation. 10 ml ethanol was added to 10 ml supernatant to 
precipitate the barium ribitol 5-phosphate. The precipitate was obtained by 
centrifugation, dissolved in 20 ml water and lyophilized to remove traces of 
ethanol. For quantification, the H3 signal in the 1H NMR spectrum was compared 
to the internal standard trimethylsilyl propanoic acid (TSP) at 0.00 ppm.
NMR (δ in ppm (1H)): 3.64 (H1a), 3.80 (H1b), 3.88 (H2), 3.75 (H3), 3.85 (H4), 3.92 
(H5).
hISPD enzyme reaction monitored by malachite green assay
For the substrate screen, 625 µM substrate was incubated with 40 µM nucleotide 
sugar, 1 mM MgCl
2
, 1 mM DTT, 445 mU/ml inorganic pyrophosphatase and ~10 
µg/ml full-length hISPD (residues 1-451, produced in E.	coli) in 0.1 M Tris-HCl 
pH 7.5 overnight at 37 °C. Subsequently, inorganic phosphate concentrations 
were determined using a malachite green assay. An aliquot of 30 µl sample 
was mixed with 90 µl water and 30 µl malachite green reagents (3% (w/v) 
ammonium molybdate, 0.2% (v/v) Tween-20 and 0.12 mg/ml malachite green 
in 3 M H
2
SO
4
). 125 µL of this mixture was transferred to a 384-wells plate and 
after 10 min incubation at room temperature absorbance was measured at 630 
nm using a Victor2 1420 Multilabel counter (Wallac). Absorbance of the reaction 
mixture was used to calculate the amount of released inorganic phosphate, after 
subtraction of the measured absorbance in the absence of hISPD protein. The 
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resulting absorbance differences were compared with a calibration curve of 
inorganic phosphate.
hISPD enzyme reaction monitored by HILIC HPLC and LC-QTOF mass 
spectrometry analysis
hISPD enzyme reactions were performed using 625 µM substrate, 300 µM CTP, 
1 mM MgCl
2
, 1 mM DTT and ~12 µg/ml hISPD
ΔN 
(residues 43-451, produced in 
Sf9 cells) in 4 mM Tris-HCl pH 7.5 overnight at 37 °C. Reactions were stopped by 
separating the protein from the reaction mixture using an Amicon-Ultra 10K filter 
(Millipore). Subsequently, the reactions were lyophilized. For HPLC analysis, per 
100 µl reaction volume 12.5 µl water was added. 12.5 µl sample was mixed with 
12.5 µl acetonitrile and 18 µl was injected. For mass spectrometry analysis, per 
100 µl reaction volume 25 µl water was added. 12.5 µl sample was mixed with 
12.5 µl acetonitrile and 18 µl was injected. Reactions without hISPD, without 
phosphorylated sugar or without both hISPD and phosphorylated sugar were 
used as controls.
A HILIC column (TOSOH BioScience 13071, TSK gel Amide-80, 4.6mmID x 25.0 cm 
L 8AM283HKO288) was used on a Shimadzu Nexera UHPLC system. UV detection 
was performed at 269 nm. Buffer A consisted of 10 mM ammonium acetate 
(set at pH 6.0 with formic acid) in 90% acetonitrile, 5% water and 5% methanol. 
Buffer B consisted of 10 mM ammonium acetate (pH 6.0) in 5% acetronitrile, 
90% water and 5% methanol. The following gradient was used: 0-5 min: 20-35% 
buffer B, 5-20 min: 35-45% buffer B, 20-22 min: 45-60% buffer B, 22-25 min: 60-
20% buffer B, 25-30 min: 20% buffer B, at a flow rate of 1 ml/min and a column 
temperature of 30 °C. UV detection was performed at 269 nm.
For LC-QTOF mass spectrometry analysis, an Agilent 1290 Infinity LC system was 
coupled to a 6540 Q-TOF mass spectrometer. HPLC was performed using the 
above described column, buffers, gradient and flow rate. The column was kept at 
room temperature. Data acquisition was set to negative ionization mode with a 
mass range of m/z 100-1700 and a collection rate of 1.34 spectra/s. The nitrogen 
drying gas was set at a flow rate of 12 L/min and the temperature at 350 °C. An 
internal calibration solution was introduced by a constant flow (100 µl/min) via 
a dual nebulizer electrospray source, containing the internal reference masses 
(119.03632 and 980.016375) in negative ion mode (ESI-TOF Tuning Mix G1969-
85 000, Agilent Technologies, Santa Clara, CA). The Molecular Feature Extraction 
algorithm (Agilent Mass Hunter Qualitative Analysis software version B.04.00) 
was used to detect all compounds with a peak height above 1000. Compounds 
specifically present in reactions with hISPD and phosphosugar in a volume 
percentage above 1% were listed.
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NMR analysis
Analysis of enzyme reaction mixtures: hISPD enzyme reactions were performed 
using 625 µM substrate, 300 µM CTP, 1 mM MgCl
2
, 1 mM DTT and ~12 µg/ml 
hISPD
ΔN
 (residues 43-451, produced in Sf9 cells) in 4 mM Tris-HCl pH 7.5 for 6 h 
at 37 °C. Reactions were stopped by separating the protein from the reaction 
mixture using an Amicon-Ultra 10K filter (Millipore), which was pre-washed with 
water. Subsequently, the reaction mixtures were lyophilized. An equivalent of 
500 µl reaction mixture was dissolved in 600 µl 10% D
2
O and 90% H
2
O.
Analysis of CDP-ribitol: To purify the reaction product ribitol 5-phosphate reaction 
mixture, large-scale enzyme incubation was performed. A 3 ml reaction mixture 
using 300 µM ribitol-5P as substrate, was incubated overnight and stopped as 
described. Subsequently, 20 µL FastAP thermosensitive alkaline phosphatase 
(20 U, Thermo Scientific) was added and the mixture was incubated for 1 h at 
37 °C. The reaction was stopped as described for the hISPD enzyme reaction 
and lyophilized. The product was purified by HPLC (6 runs, 100 µL fractions 
containing the peak at 10.5 min). Fractions were neutralized by addition of 
sodium phosphate buffer (pH 7.2) to a final phosphate concentration of 67 mM 
and pooled. Samples were concentrated using a Savant Speedvac concentrator 
and dissolved in 10% D
2
O and 90% H
2
O for NMR spectroscopy. 
NADPH and NADH reduction
hISPD enzyme reactions were performed using 208 µM substrate, 100 µM CTP, 
333 µM MgCl
2
, 333 µM DTT, 100 µM NADPH or NADH, 0.66 µM FAD or FMN 
and ~36 µg/ml hISPD
ΔN 
(residues 43-451, produced in Sf9 cells) in 0.1 M Tris-HCl 
pH 7.5. Reactions were mixed and transferred to a 384-wells plate. Reactions 
were incubated at 37 °C in a Victor2 1420 Multilabel counter (Wallac) and 
absorbance was measured at 340 nm during the reaction every 15 min. Control 
incubations were performed without hISPD for each condition. The absorbance 
of all incubations at t=0 was set at 100% and at later time points expressed as 
percentage of the absorbance at t=0. Data are presented as the percentage of 
control reactions minus the respective incubations with hISPD. Average of two 
independent experiments is shown.
Enzyme activity of POMT, POMGnT1 and GnT-I
The cell pellets were homogenized in 1.5 ml of 10 mM Tris-HCl, pH 7.4 containing 
1 mM EDTA, 250 mM sucrose, 1 mM DTT and a protease inhibitor cocktail (3 µg/
ml pepstatin A, 1 µg/ml leupeptin, 1 mM benzamidine-HCl, and 1 mM PMSF). 
After centrifugation at 900 g for 10 min, the supernatant was subjected to ultra 
centrifugation at 100,000 g for 1 h. The precipitate was used as the microsomal 
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membrane fraction. Protein concentrations were determined by the BCA assay 
(Pierce). 
The POMT activity was performed as described previously (Manya et al, 2004). 
Briefly, the reaction mixture contained 20 mM Tris-HCl (pH 8.0), 200 nM of 
[3H]-mannosylphosphoryldolichol (Dol-P-Man, 125,000 dpm/pmol) (American 
Radiolabeled Chemical, Inc., St. Louis, MO), 2 mM 2-m ercaptoethanol, 10 mM 
EDTA, 0.5% n-octyl-β-D-thioglucoside, 10 µg GST-α-DG and enzyme source (80 
µg of microsomal membrane fraction) in 20 µl total volume. After 1 h incubation 
at 22 °C, the reaction was stopped by adding 150 µl PBS containing 1% Triton 
X-100, and the reaction mixture was centrifuged at 10,000 g for 10 min. The 
supernatant was removed, mixed with 400 µl of PBS containing 1% Triton X-100 
and 10 µl of Glutathione-Sepharose 4B beads (GE Healthcare Bio-Sciences Corp., 
NJ, USA), rotated at 4 °C for 1 h, and washed 3 times with 20 mM Tris-HCl (pH 
7.4) containing 0.5% Triton X-100. The radioactivity absorbed to the beads was 
measured using a liquid scintillation counter.
As a control, POMGnT1 activity was measured as described (Yoshida et al, 2001). 
The reaction buffer containing 140 mM MES buffer (pH 7.0), 1 mM UDP-[3H]
GlcNAc (225,000 dpm/nmol) (PerkinElmer, Inc., Waltham, MA), 1 mM mannosyl 
nanopeptide (Ac-Ala-Ala-Pro-Thr(Man)-Pro-Val-Ala-Ala-Pro-NH
2
), 10 mM MnCl
2
, 
2% Triton X-100, 5 mM AMP, 200 mM GlcNAc, 10% glycerol and enzyme source 
(100 µg of microsomal membrane fraction) in 20 µl total volume was incubated at 
37 °C for 4 h. After boiling for 3 min, the mixture was analyzed by reversed phase 
HPLC with a Wakopak 5C18-200 column (4.6 x 250 mm, Wako Pure Chemical 
Industries, Ltd., Osaka, Japan). Solvent A was 0.1% trifluoroacetic acid in distilled 
water and solvent B was 0.1% trifluoroacetic acid in acetonitrile. The peptide was 
eluted at a flow rate of 1 ml/min using a linear gradient of 1-25% solvent B. The 
peptide separation was monitored continuously at 214 nm, and the radioactivity 
of each fraction was measured using a liquid scintillation counter. 
As a control, GnT-I activity (Yoshida et al, 2001) was performed in a total volume 
of 20 µl reaction mixture containing 100 mM MES buffer, 10 µM pyridylaminated 
Man
5
GlcNAc
2
 (M5-PA, Takara Bio Inc., Otsu, Japan), 2 mM UDP-GlcNAc, 5 mM 
AMP, 0.5% Triton X-100, 0.2% BSA, 20 mM MnCl
2
 and enzyme source (100 µg 
of microsomal membrane fraction) at 37 °C for 2 h. The samples were then 
analyzed by reversed phase HPLC with a COSMOSIL 5C18-AR-II column (4.6 x 
250 mm, Nacalai Tesque, Kyoto, Japan). The solvent used was a 100 mM, pH 
6.0, ammonium acetate buffer containing 0.15% 1-butanol, and the substrate 
and the product were isocratically separated. Fluorescence was detected with 
a fluorescence detector (RF-10AXL, Shimadzu Corp.) at excitation and emission 
wavelengths of 320 nm and 400 nm, respectively.
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Supplementary Figure S1: Dimerization of hISPD. A-B) Size exclusion chromatography of the 
crystallized hISPD construct (hISPD
ΔN
, residues 43-451, produced in Sf9 cells) (A) and C-terminal 
hISPD (residues 283-451, produced in E.	coli) (B). The eluted peaks of full-length (49.9 kDa per 
monomer) and C-terminal (19.4 kDa per monomer) proteins correspond to molecular weights 
of 123 kDa and 40.0 kDa respectively, consistent with both constructs being a dimer in solution. 
Arrows denote the elution volumes for the calibrated molecular weight standards.
Supplementary Figures
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Supplementary Figure S2: Structure based sequence alignment of hISPD with three structural 
homologues of the cytidyltransferase domain. A) The four aligned sequences include hISPD 
(Uniprot ID A4D126), S.	 pneumoniae	 TarI (2VSI, A5MSS9), E.	 coli	 YgbP (1INI, Q46893), and T. 
maritime	 TM1393 protein (1VPA, Q9X1B3). Residue numbering for hISPD is shown above the 
aligned sequences. Residues linked with patient missense mutations are marked with X above 
the aligned sequences. Polar residues in the putative pentose sugar binding pocket, as described 
in the main text, are marked with black triangle below the aligned sequences. B) The structures 
used for the above sequence alignment are shown in overlayed presentation (right) and on their 
own (left).
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Supplementary Figure S3: The different C-terminal modules of ISPD proteins. A-C) Monomeric 
(top) and dimeric (bottom) structures of three ISPD proteins, from T.	maritama (A), C.	jejuni (B) 
and human (C), shown in the same orientation with respect to the cytidyltransferase domain of 
one protomer (colored). This highlights the diverse topology and orientation of the appended 
C-terminal modules and the resultant dimer.
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Supplementary Figure S4: Limited structural homology of hISPD C-terminal domain to the short-
chain family of dehydrogenases/reductases. Protein structures are viewed in the same relative 
orientation, to highlight the presence of an additional β-strand (numbered ‘2.5’) and the Gly-rich 
motif involved in NAD(P) binding (red), which are not observed in the hISPD C-terminal domain.
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Supplementary Figure S5: hISPD localizes to the cytoplasm. Myc-tagged hISPD (green) 
overexpressed in HEK293 cells colocalizes with HSP90 (red). Scale bar represents 5 µm.
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Supplementary Figure S6: HILIC QTOF-LC mass spectrometry and 1H NMR spectroscopy of hISPD 
enzyme reaction mixtures. A-B) EIC of m/z 534.29 of hISPD
ΔN
 (residues 43-451, produced in Sf9 
cells) enzyme reactions using ribulose 5-phosphate (A) or ribose 5-phosphate (B) as substrate. 
C-E) 1H NMR analysis of the hISPD
ΔN
 (residues 43-451, produced in Sf9 cells) enzyme mixtures 
with ribose-5P as substrate to study isomerization to ribulose-5P (C). Control incubations were 
performed without CTP (D) and without enzyme (E). R5P: ribose-5P; P: product (CDP-ribose + 
CDP-ribulose). F) 1H NMR analysis of commercial ribulose-5P, showing the characteristic H1 and 
H3 signals of ribulose-5P.
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Supplementary Figure S7: 2D 1H COSY NMR spectrum of CDP-ribitol. Part of a 2D 1H COSY 
NMR spectrum of HILIC HPLC-purified CDP-ribitol, used to assign the signals of the ribitol- and 
ribofuranose moieties.
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Supplementary Figure S8: NADPH/NADH consumption of hISPD. A-F) Absorbance at 340 nm to 
measure NADPH and NADH consumption in the presence of hISPD
ΔN
 (residues 43-451, produced 
in Sf9 cells) (A-B) or in combination with potential cofactors FAD (C-D) or FMN (E-F). Absorbance at 
different time points was defined as percentage of the initial absorbance at t=0 for each individual 
reaction. To correct for unspecific absorbance decrease, the absorbance percentage of control 
reactions lacking hISPD minus the absorbance percentage of complete reaction mixtures is shown. 
Average of two independent experiments is shown.
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Supplementary Figure S9: Relative POMT activity. Relative POMT activity, expressed as ratio of 
POMGnT1 and GnT-I activity, in ISPD- and POMT2-deficient patient fibroblasts and HAP1 ISPD-
knockout cells.
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Zygosity Nucleotide change Protein change Affected exon(s) Phenotype Reference
Heterozygous
Heterozygous
c.2T>G
c.377G>A
p.Met1_Arg59del
p.Arg126His
1
2
LGMD-CBR (Cirak et al, 2013)
Heterozygous
Heterozygous
c.53dupT
c.377G>A
p.Ser19Glufs*97
p.Arg126His
1
2
WWS (Roscioli et al, 2012)
Heterozygous
Heterozygous
c.53dupT
c.677A>G
p.Ser19Glufs*97
p.Tyr226Cys
1
3
LGMD MR (Cirak et al, 2013)
Heterozygous
Heterozygous
c.157G>A
c.1183A>T
p.Ala53Thr
p.Arg395*
1
9
LGMD no MR (Cirak et al, 2013)
Homozygous c.161G>C p.Gly54Ala 1 LGMD no MR (Tasca et al, 2013)
Heterozygous 
Heterozygous
c.256A>T
c.713C>T
p.Arg86*
p.Thr238Ile
1
4
WWS/MEB (Vuillaumier-Barrot et 
al, 2012)
Heterozygous
Heterozygous
c.257+2T>G
c.773C>A
Splice defect
p.Ser258*
1
4
WWS/MEB (Vuillaumier-Barrot et 
al, 2012)
Heterozygous
Heterozygous
c.364G>C
c.802C>T
p.Ala122Pro
p.Arg268*
2
5
MEB (Roscioli et al, 2012)
Heterozygous
Heterozygous
c.446C>T
c.643C>T
p.Pro149Leu
p.Gln215*
2
3
CMD no MR (Cirak et al, 2013)
Homozygous c.466G>A p.Asp156Asn 2 WWS/MEB (Vuillaumier-Barrot et 
al, 2012)
Homozygous c.550C>T p.Arg184* 3 WWS (Willer et al, 2012)
Heterozygous c.614G>A
Deletion
p.Arg205His
Deletion
3
9 and 10
WWS (Czeschik et al, 2013)
Heterozygous
Heterozygous
c.638T>G
Deletion
p.Met213Arg
Deletion
3
3 to 6
WWS/MEB (Vuillaumier-Barrot et 
al, 2012)
Heterozygous
Heterozygous
c.643C>T
Deletion
p.Gln215*
Deletion
3
9 to10
WWS (Willer et al, 2012)
Homozygous c.647C>A p.Ala216Asp 3 WWS/MEB (Roscioli et al, 2012)
Heterozygous
Heterozygous
c.676T>C
Deletion
p.Tyr226His
Deletion
3
4 to 6
WWS/MEB (Vuillaumier-Barrot et 
al, 2012)
Heterozygous
Heterozygous
c.676T>C
Deletion
p.Tyr226His
Deletion
3
4 to 6
WWS/MEB (Vuillaumier-Barrot et 
al, 2012)
Homozygous Deletion Deletion In-frame del 
exon 3
WWS (Willer et al, 2012)
Homozygous Deletion Deletion 3 to 5 WWS (Roscioli et al, 2012)
Heterozygous
Heterozygous
c.789+2T>G
c.277_279del ATT
Splice defect
p.Ile93del
IVS4
Del exon 4
WWS (Willer et al, 2012)
Homozygous c.832A>T p.Lys278* 5 WWS (Roscioli et al, 2012)
Homozygous c.832A>T p.Lys278* 5 MEB (Roscioli et al, 2012)
Homozygous c.836-?_1119+?dup p.Val374Argfs*8 6 to 8 duplication LGMD-CBR (Cirak et al, 2013)
Homozygous Deletion Deletion 6 to 8 WWS (Roscioli et al, 2012)
Homozygous c.1114_1116delGTT p.Val372del 8 LGMD noMR (Cirak et al, 2013)
Homozygous c.1114_1116delGTT p.Val372del 8 LGMD noMR (Cirak et al, 2013)
Homozygous c.1114_1116delGTT p.Val372del 8 LGMD noMR (Cirak et al, 2013)
Homozygous c.1114_1116delGTT p.Val372del 8 LGMD no MR (Tasca et al, 2013)
Heterozygous
Heterozygous
c.1114_1116delGTT
c.1183A>T
p.Val372del
p.Arg395*
8
9
CMD/LGMD 
no MR
(Cirak et al, 2013)
Homozygous c.1120-1G>T Splice defect Del exon 9 WWS (Willer et al, 2012)
Homozygous c.1186G>T p.Glu396* 9 WWS (Roscioli et al, 2012)
Homozygous Deletion Deletion 9 and 10 WWS (Roscioli et al, 2012)
Homozygous c.1354T>A p.*452Arg 10 WWS (Willer et al, 2012)
Supplementary Tables 
Supplementary Table S1: Overview of published ISPD mutations.
Missense mutations are underlined. The predicted effect of these mutations is indicated in Figure 
4. WWS: Walker-Warburg syndrome, MEB: Muscle-Eye-Brain disease, LGMD: Limb-girdle muscular 
dystrophy, CBR: cerebellar involvement, MR: mental retardation.
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A) Structure similarity of hISPD N-terminal domain, identified using DALI
PDB Z-score R.m.s.d. Lali Nres %id Protein
1vpa 28.0 1.9 213 221 29 T.	maritima IspD
2vsi 27.4 2.0 217 223 27 S.	pneumoniae TarI
3f1c 26.7 2.6 223 229 28 L.	monocytogenes	IspD
3q80 26.6 1.8 211 218 29 M.	tuberculosis IspD
2xwn 26.4 2.1 218 227 28 M.	smegmatis IspD
1ini 25.8 2.2 214 225 23 E.	coli	IspD
2px7 25.0 2.2 199 202 28 T.	thermophilus IspD
1vgw 24.9 2.1 208 214 21 N.	gonorrhoeae IspD
2yc3 24.2 2.7 211 219 26 A.	thaliana IspD
B) Structure similarity of hISPD C-terminal domain, identified using DALI
PDB Z-score R.m.s.d. Lali Nres %id Protein
4alm 12.1 2.9 132 224 8 FabI S.	aureus
3f9i 11.7 3.3 137 220 12 FabG R.	prowazekii
1i01 11.6 3.3 132 228 14 E.	coli
4bo9 11.5 3.3 137 235 12 FabG P.	aeruginosa
1uzm 11.5 3.2 132 210 11 MabA M.	tuberculosis
3grp 11.4 3.2 131 209 15 B.	henseliae
3m1l 11.3 3.0 128 362 13 M.	tuberculosis
3tpc 11.3 3.4 132 225 11 SMA1452 S.	Meliloti
1zmo 11.0 3.1 137 243 17 Halohydrin dehalogenase
2o23 11.0 3.2 132 248 10 Human HADH2
C) Structure similarity of hISPD C-terminal domain, identified using PDBeFOLD
PDB Z-score R.m.s.d. Lali Nres %id Protein
3f6p 7.5 2.18 98 120 13 Unphosphorylated receiver domain of yycf
3gl9 6.9 2.32 98 120 15 Histidine kinase-response regulator complex 
2gkg 7.3 2.24 97 122 13 Receiver domain from M.	xanthus social motility protein frzs
3oo0 6 2.31 100 128 10 Structure of apo chey a113p
2ftk 7 2.44 98 119 13 Beryllofluoride spo0f complex with spo0b
4tmy 6.1 2.41 96 118 5 Chey from T.	maritima (mg-iv)
1dbw 6.7 2.43 99 125 11 Crystal structure of fixj-n
2tmy 5.9 2.36 95 118 4 Chey from T.	maritima (apo-ii)
3tmy 6.1 2.39 95 118 4 Chey from T.	maritima (mn-iii)
1jbe 5.6 2.64 102 126 12 Structure of apo-chey 
Supplementary Table S2: hISPD structure similarity searches.
Top 10 hits from structure similarity searches using the hISPD N-domain, performed with DALI 
(http://ekhidna.biocenter.helsinki.fi/dali_server/) (A); and C-domain, performed with DALI (B) 
and PDBeFOLD (C) (http://www.ebi.ac.uk/msd-srv/ssm/cgi-bin/ssmserver). R.m.s.d.: root-mean-
square deviation (in Å), Lali: length of the aligned region, Nres: number of residues in the hit 
protein, %id: percentage sequence identity. 
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Abstract
Binding of cellular α-dystroglycan to its extracellular matrix ligands is fully 
dependent on a unique O-mannose-linked glycan. Disrupted O-mannosylation 
is the hallmark of the muscular dystrophy-dystroglycanopathy syndromes. 
SLC35A1, encoding the transporter of CMP-sialic acid, was recently identified 
as muscular dystrophy-dystroglycanopathy syndrome candidate gene. This is 
surprising, since sialic acid itself is dispensable for α-dystroglycan-ligand binding. 
In a novel SLC35A1-deficient cell model, we demonstrated a lack of α-dystroglycan 
O-mannosylation, ligand binding and incorporation of sialic acids. Removal of 
sialic acids from HAP1 wild type cells after incorporation or preventing sialylation 
during synthesis did not affect α-dystroglycan O-mannosylation or ligand binding 
but did affect sialylation. Lentiviral-mediated complementation with the only 
known disease mutation p.Q101H failed to restore deficient O-mannosylation in 
SLC35A1-knockout cells and partly restored sialylation.
These data indicate a role for SLC35A1 in α-dystroglycan O-mannosylation that 
is distinct from sialic acid metabolism. In addition, human SLC35A1 deficiency 
can be considered as a combined disorder of α-dystroglycan O-mannosylation 
and sialylation, a novel variant of the muscular dystrophy-dystroglycanopathy 
syndromes.
Introduction
α-Dystroglycan (α-DG) is a heavily glycosylated extracellular protein and binds 
several extracellular matrix ligands, including laminin (Ervasti & Campbell, 1993), 
agrin (Campanelli et al, 1994; Gee et al, 1994), perlecan (Peng et al, 1998), 
neurexin (Sugita et al, 2001), pikachurin (Sato et al, 2008) and slit (Wright et al, 
2012). α-DG has a peripheral non-covalent binding with transmembrane protein 
β-dystroglycan (β-DG), that is bound to dystrophin and F-actin (Ibraghimov-
Beskrovnaya et al, 1992; Ervasti & Campbell, 1993). This complex, also known as the 
dystrophin-glycoprotein complex (DGC), connects the extracellular matrix to the 
cytoskeleton. α-DG-ligand binding requires a specific O-mannose-linked glycan. 
Two types of O-mannose glycans are described, a tetrasaccharide: Neu5Acα2-
3Galβ1-4GlcNAcβ1-2Man-Ser/Thr (Chiba et al, 1997) and a trisaccharide: 
GalNAcβ1-3GlcNAcβ1-4Man-Ser/Thr (Yoshida-Moriguchi et al, 2010). The 
mannose residue of the trisaccharide contains a 6-O-linked phosphate group 
(Yoshida-Moriguchi et al, 2010) that is probably bound to an as far not completely 
known, but crucial part of the laminin-binding glycan epitope, containing 
xylose and glucuronic acid residues (Willer et al, 2014; Praissman et al, 2014). 
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Defective O-mannosylation results in reduced ligand binding and causes 
muscular dystrophy-dystroglycanopathy (MDDG) syndromes, a group of severe 
congenital disorders characterized by muscular dystrophy and brain and eye 
abnormalities (Muntoni et al, 2007). The O-mannose ligand-binding structures 
are also used by Lassa virus for entry into host cells (Cao et al, 1998). A recent 
genome-wide screen for genes involved in Lassa virus entry (Jae et al, 2013) 
revealed a large set of genes involved in α-DG O-mannosylation that were 
subsequently associated with disease mutations in various MDDG syndromes. An 
exception was the CMP-sialic acid transporter SLC35A1, which has not yet been 
associated with the MDDG syndromes. Instead, a patient with a homozygous 
p.Q101H mutation in SLC35A1 was recently diagnosed as a congenital disorder 
of glycosylation (CDG) type II (Mohamed et al, 2013) with reduced sialylation of 
protein-linked N-glycans and mucin type O-glycans. Clinical symptoms included 
proteinuria, macrothrombocytopenia and neurological disease with intellectual 
disability and epilepsy. In this report, we studied the influence of sialic acid on 
the synthesis of the laminin-binding O-mannose epitope of α-DG and we studied 
the effect of the p.Q101H disease mutation on sialic acid metabolism and α-DG 
O-mannosylation.
Results
SCL35A1 acts independently from sialic acid in functional α-DG O-mannosylation
To analyze the role of SLC35A1 in the O-mannosylation of α-DG, we used two 
independent SLC35A1-knockout HAP1 cell lines that were generated using TALEN 
technology (Jae et al, 2013). These SLC35A1-deficient HAP1 cells are suitable 
for direct analysis of defective O-mannosylation, in contrast to Lec2 SLC35A1-
deficient Chinese hamster ovary (CHO) cells, that require LARGE overexpression 
for detection of α-DG-laminin binding (Patnaik & Stanley, 2005). Thus, these 
cells provide an ideal model system for monitoring the simultaneous effect on 
sialylation and O-mannosylation. 
First, we characterized the sialylation status of the HAP1 SLC35A1-knockout cells. 
Maackia amurensis lectin II (MALII), recognizing α-2,3-linked sialic acid residues, 
was able to bind to HAP1 wild type cells, whereas binding was abolished for both 
HAP1 knockout cell lines. Similarly, sialidase-treated wild type HAP1 cells were 
unable to bind to MALII (Figure 1A). Moreover, Arachis hypogaea (peanut) lectin 
(PNA), recognizing the non-sialylated Galβ1-3GalNAc epitope of core 1 mucin 
O-glycans, showed a lack of binding in the wild type cells, but in both knockout 
cell lines and in the sialidase-treated wild type cells, a clear PNA staining was 
observed, confirming the loss of terminal sialic acids (Figure 1A).
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To analyze the effect of sialic acid loss on α-DG-ligand binding, expression of 
the functional O-mannose glycan was analyzed by a laminin overlay assay and 
by immunoblotting using the IIH6 antibody that recognizes the laminin-binding 
epitope, and the DAG1 antibody, that recognizes the α-DG and β-DG core 
proteins. After sialidase treatment, laminin overlay and IIH6 immunostaining 
showed an even stronger signal as compared to wild type cells, indicating that the 
integrity of the ligand-binding epitope was not affected by the lack of sialic acid 
moieties (Figure 1B). Remarkably, for both SLC35A1-knockout cell lines no signal 
was obtained. Analysis using the DAG1 antibody against the α-DG and β-DG non-
glycosylated core proteins showed a small shift in molecular weight of α-DG after 
sialidase treatment, but a considerably lower molecular weight in both knockout 
cell lines. These results confirm earlier observations that sialic acid is not directly 
required for laminin binding (Patnaik & Stanley, 2005; Combs & Ervasti, 2005).
Figure 1: Knockout of SLC35A1 results in reduced sialylation, absent laminin binding and a 
considerably reduced molecular weight of α-DG. A-B) Assessment of sialylation levels by MALII 
and PNA staining (A) and analysis of α-DG O-mannosylation using a laminin overlay (LO), and IIH6, 
DAG1 and β-DG immunostaining (B) of sialidase-treated wild type cells, SLC35A1-knockout cells 
and wild type cells incubated with P-3F
ax
-Neu5Ac to inhibit the sialylation. Control reactions were 
performed without sialidase or without incubation with P-3F
ax
-Neu5Ac.
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We hypothesized that sialic acid could play a role during synthesis of the 
O-mannose glycan in the Golgi apparatus, by acting as a scaffold for docking 
of α-DG related glycosyltransferases. To study this, we cultured HAP1 cells in 
the presence of the synthetic fluorinated sialic acid analogue (peracetylated 
3Fax-Neu5Ac), known to inhibit sialic acid incorporation by Golgi resident 
sialyltransferases (Rillahan et al, 2012; Büll et al, 2013). Inhibition of sialylation 
in wild type HAP1 cells revealed identical results as for sialidase-treated cells; 
lower binding of MALII and increased binding of PNA with no effect on α-DG-
laminin binding (Figure 1).
Collectively, these results show that SLC35A1 is essential for synthesis of the 
functional O-mannose glycan on α-DG, by a mechanism that is independent 
from sialylation.
Disease causing p.Q101H mutation in SLC35A1 reduces α-DG ligan binding
To analyze the effect of the previously described SLC35A1 missense mutation 
on α-DG O-mannosylation, we complemented a HAP1 SLC35A1-knockout cell 
line with wild type and mutant (p.Q101H) V5-tagged SLC35A1 constructs using 
lentiviral transduction. Comparable SLC35A1 expression levels were confirmed 
by anti-V5 immunoblotting (Figure 2A), and both constructs localized to the 
Golgi (data not shown) as previously shown in CHO cells (Mohamed et al, 2013).
The sialylation levels of the different cell lines were investigated using lectin 
staining and metabolic labeling. Complementation with wild type SLC35A1 fully 
restored the amount of MALII positive cells, while mutant SLC35A1 showed only 
partial restoration (Figure 2B-C). In parallel, complementation with wild type 
SLC35A1 strongly reduced the amount of PNA positive cells, whereas mutant 
SLC35A1 complementation resulted only in a slight reduction (Figure 2B-C). 
Metabolic labeling was performed using a novel sialic acid analog, Ac5SiaNPoc, 
that specifically labels protein- and lipid-linked sialic acids. Cells were incubated 
with peracetylated Ac5SiaNPoc (Büll, et al., in preparation) and reacted with a 
biotinylated-labeled azide, followed by streptavidin-phycoerythrin for analysis by 
flow cytometry. The incorporation of Ac5SiaNPoc was completely absent in the 
knockout cell lines (Figure 2D). In knockout cells complemented with a wild type 
SLC35A1 construct, Ac5SiaNPoc incorporation was completely restored, whereas 
complementation with mutant SLC35A1 restored Ac5SiaNPoc incorporation for 
only ~20% (Figure 2C). These results confirm the effect of the p.Q101H mutation 
in SLC35A1 on glycan sialylation as previously shown by mass spectrometry of 
patient serum N-glycans (Mohamed et al, 2013).
Next, expression of the laminin-binding O-mannose glycan was analyzed. In 
SLC35A1-deficient cells complemented with the wild type construct, both 
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laminin binding and IIH6 immunoreactivity were restored, but the signal was 
less intense than for wild type cells. Possibly less α-DG is present in the sample of 
the wild type complemented cells, as also the α-DG core antibody showed a less 
intense signal. In the mutant complemented cell line, the α-DG core signal was 
comparable with that of the knockout cell line and both laminin and IIH6 binding 
Figure 2: Complementation of knockout cells using mutant (p.Q101H) SLC35A1 partly restores 
sialylation levels, but results in a nearly absent laminin binding. A) Immunostaining of microsomal 
fractions using anti-V5 antibody to asses expression levels of wild type and mutant SLC35A1. 
Calnexin antibody was used to assess equal protein loading. B-D) Analysis of sialylation levels of 
wild type, knockout and complemented cell lines using MALII and PNA labeling measured by flow 
cytometry (B) and on western blot (C), and using metabolic incorporation of Ac
5
SiaNPoc (D). Error 
bars show standard deviation. E) Analysis of α-DG O-mannosylation in wild type, knockout and 
complemented cells lines using a laminin overlay (LO), and IIH6, DAG1 and β-DG immunostaining 
on western blot. Braces indicate specific bands, asterisks indicate aspecific bands.
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were nearly absent (Figure 2E). These data show that the p.Q101H mutation in 
SLC35A1 affects not only the transport of CMP-sialic acid, thereby reducing sialic 
acid levels on glycoproteins, but also the synthesis of the O-mannosyl glycan on 
α-DG.
Discussion
SLC35A1 is known as a nucleotide sugar transporter that has been considered to 
be highly selective for CMP-sialic acid (Eckhardt et al, 1996; Tiralongo et al, 2006). 
Although sialic acid is not directly involved in α-DG-laminin binding, as has been 
shown by sialidase treatment of fully glycosylated α-DG from rabbit skeletal 
muscle (Combs & Ervasti, 2005), surprisingly a recent Lassa virus screen revealed 
SLC35A1 as essential gene for functional O-mannosylation of α-DG (Jae et al, 
2013). Here, we show that SLC35A1 is required for functional O-mannosylation 
of α-DG, while sialic acid is neither directly nor indirectly needed for the binding 
of α-DG to laminin. 
Previously, Lec2 SLC35A1-deficient CHO cells did not show a defective 
O-mannosylation in a model where LARGE was overexpressed (Patnaik & 
Stanley, 2005). However, it is known that LARGE overexpression bypasses several 
O-mannosylation defects (Barresi et al, 2004), and possibly an impairment 
of SLC35A1 activity on proper synthesis of O-mannose glycans on α-DG may 
therefore go unnoticed. Here, we employed HAP1 cells for studying sialylation 
and α-DG O-mannosylation without the need of LARGE overexpression (Patnaik 
& Stanley) to reach sufficient expression levels of functional O-mannosylated 
α-DG. Knockout of SLC35A1 in HAP1 cells clearly showed a defect in sialylation 
and O-mannosylation, while neither sialidase treatment nor inhibition of the 
sialylation resulted in defective α-DG-laminin binding. Complementation of 
knockout cells with mutant (p.Q101H) SLC35A1 restored sialylation levels 
partly, in agreement with our previous research showing 50% residual activity 
in transport of CMP-sialic acid (Mohamed et al, 2013). In addition, laminin 
binding could not be repaired, indicating that α-DG-laminin binding is disturbed 
in patients with SLC35A1-CDG. 
In analogy with the interaction between LARGE and the N-terminal α-DG domain 
that is required for glycosylation of distant residues (Kanagawa et al, 2004), 
sialic acids on specific a-DG domains could hypothetically provide a scaffold 
for binding of other glycosyltransferases. However, this seems unlikely, since 
incubation with the sialylation inhibitor did not affect α-DG-laminin binding. 
The considerable difference between the molecular weight of α-DG in sialidase-
treated or sialylation-inhibited cells and in SLC35A1-knockout cells, indicates that 
the knockout cells not only lack sialic acids on the O-mannose glycan. Possibly, 
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SLC35A1 could transport, additional to CMP-sialic acid, another nucleotide 
sugar, that might be incorporated in the O-mannose glycan and might be crucial 
for binding of α-DG to laminin (Figure 3).
Previously, other nucleotide transporters have been shown to transport multiple 
nucleotide sugars. SLC35B4 is a UDP-xylose and UDP-GlcNAc transporter 
(Ashikov et al, 2005) and HFRC1 transports UDP-glucose and UDP-GlcNAc (Suda 
et al, 2004). A recent report suggests that for CMP-sialic acid transport by 
SLC35A1, CMP-recognition is more important than recognition of the sialic acid 
substrate (Maggioni et al, 2013). However, to our knowledge CMP-sialic acid is 
the only known substrate for the mammalian SLC35A1 transporter (Tiralongo et 
al, 2006). Remarkably, some SLC35A1 homologs from plants are shown to have 
CMP-sialic acid transport activity in Lec2 cells, but as sialic acids are absent in 
plants, these transporters are suggested to have physiological CMP-Kdo (2-keto-
3-deoxymanno-octulosonic acid) transporter activity (Takashima et al, 2009; 
Bakker et al, 2008). Kdo is not present in mammals, which could indicate that 
Figure 3: Schematic overview of SLC35A1 activity towards CMP-sialic acid and possibly towards 
another nucleotide sugar.
Sia = Sialic acid, Man = Mannose, GlcNAc = N-acetylglucosamine, Gal = Galactose, GalNAc = 
N-acetylgalactosamine, Xyl = Xylose, GlcA = Glucuronic acid.
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SLC35A1 has potential activity towards another, yet to be identified cytidine 
nucleotide sugar, that might be required for functional α-DG O-mannosylation.
At the time we identified the SLC35A1 missense mutation in a patient from 
our CDG cohort (Mohamed et al, 2013), we did not foresee a role for SLC35A1 
in the O-mannosylation pathway. With the current knowledge, a reappraisal 
of the dominant neurological phenotype is warranted to incorporate the 
combined biochemical deficiencies in sialylation and O-mannosylation. The 
reported macrothrombocytopenia and proteinuria are uncommon in MDDG 
syndromes and therefore likely correlated with deficient sialylation. The 
neurological phenotype of intellectual disability and epilepsy is known in the 
MDDG syndromes as well as in CDG. Therefore, these symptoms can not easily 
be linked to a single pathway and maybe the effect on multiple pathways in 
brain development and function result in the dominant neurological phenotype 
in this patient. The SLC35A1 missense mutation in this adult patient is relatively 
mild and might therefore not cause specific O-mannosylation characteristics, 
such as muscular dystrophy. Recently, genetic defects in combined pathways for 
N-glycosylation and O-mannosylation have been described resulting in human 
disorders with mixed clinical phenotypes. Thus far, these have been limited to 
defects in the synthesis of dolichol-phosphate-mannose required for the initial 
step in O-mannosylation, including defects in DOLK (Lefeber et al, 2011), DPM1 
(Yang et al,2013), DPM2 (Barone et al, 2012) and DPM3 (Lefeber et al, 2009). 
This study shows that mutations in SLC35A1 can be added to this growing group 
of combined CDG and MDDG syndromes.
In conclusion, we showed that SLC35A1 has a crucial role in the O-mannosylation 
pathway without involvement of sialic acid. SLC35A1 defects can be added to 
the growing group of diseases that show overlap between MDDG syndromes 
and N-linked CDG. These novel findings are important for elucidation of the 
O-mannosylation pathway and the identification of the ligand-binding epitope 
on α-DG.
Materials and Methods
Cell culture
HAP1 cells (Carette et al, 2011) were cultured in Iscove’s modified Dulbecco’s 
medium (IMDM, Gibco) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin/L-glutamine (Gibco) at 37 °C under 5% CO
2
 atmosphere. 
SLC35A1-knockout cells (Jae et al, 2013) were a kind gift from T.R. Brummelkamp 
(Netherlands Cancer Institute, Amsterdam, the Netherlands).
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Inhibition of sialic acid transfer
P-3F
ax
-Neu5Ac was synthesized as described before (Rillahan et al, 2012). To 
inhibit sialylation, cells were cultured three days in the presence or absence 
(control) of 100 µM of P-3F
ax
-Neu5Ac.
Metabolic labeling of sialoglycans
To assess incorporation of propargyloxycabonyl sialic acids into cell surface 
sialoglycans, HAP1 cells were cultured three days in the presence or absence 
(control) of 100 µM Ac
5
SiaNPoc (Büll et al, in preparation), washed in 1x PBS and 
incubated with 100 µl CuAAC reaction buffer (1x PBS containing 250 µM CuSO4, 
250 µM L-histidine, 500 µM sodium ascorbate and 100 µM azide-PEG3-biotin) 
for 30 min at room temperature. Cells were washed in FACS buffer (1x PBS 
containing 1% FBS and 0.02% sodium azide) and biotinylated glycoconjugates 
were conjugated for 10 min at 4 °C with 2 µg/ml streptavidin-phycoerythrin (BD 
Pharmingen). Mean fluorescence intensities were measured using a CyAn ADP 
flow cytometer (BD Biosciences, San Jose, CA) and quantified utilizing FlowJo 
software (Tree Star Inc., Ashland, OR). Azide-PEG3-biotin, sodium L-ascorbate, 
L-histidine and copper (II) sulfate pentahydrate were purchased from Sigma-
Aldrich (St. Louis, MO).
Complementation of SLC35A1-knockout HAP1 cells
Full-length wild type and mutant (p.Q101H) SLC35A1 mRNAs were obtained 
from pYEScupFLAG K SLC35A1 vectors (Mohamed et al, 2013) by PCR. The coding 
sequence was cloned in a pLenti6.2/V5-DEST expression vector containing a 
C-terminal V5-tag, using the Gateway system (Invitrogen). Constructs were 
verified by sequence analysis. HEK293FT cells were transfected with pLP1,	pLP2,	
pVSV/G and either the SLC35A1 wild type or mutant vector to produce virus 
particles according to manufacturer’s protocol (Life Technologies). Viruses were 
harvested after 72 h. HAP1 KO cells #1 were transduced by incubation with either 
the SLC35A1 wild type or mutant viruses in the presence of 6 µg/ml polybrene. 
After 24 h incubation, virus was removed and medium was refreshed. Next day, 
30 µg/ml blasticidin was added to select virus-transduced cells.
Sample preparation for western blotting
Cells were harvested by scraping in buffer containing 0.35 M sucrose, 30 
mM Tris and 3 mM EDTA and enriched using Triticum	 vulgaris (wheat) lectin 
(WGA)-beads as described previously (Lefeber et al, 2011; Michele et al, 2002). 
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Subsequent sialidase treatment was performed overnight using 10 mU/µg 
α(23,6,8,9) neuraminidase from Arthrobacter	Ureafaciens (Sigma Aldrich) at 
room temperature. A control reaction was performed without sialidase. 
Enrichment of microsomal proteins was performed as described previously 
(Holden & Horton, 2009). In short, HAP1 cells from a confluent 175 cm2 flask 
were harvested by trypsinization. The cell pellet was washed once using PBS 
and subsequently solubilized in 300 µl digitonin buffer containing 25 µg/ml 
digitonin for 10 min. Centrifugation was performed for 10 min at 2000 g at 4 
°C, supernatant, containing the cytosolic proteins, was removed. The remaining 
pellet was solubilized in 300 µl 1% Triton-X100 buffer. After centrifugation for 
5 min at 7000 g at 4 °C the supernatant was collected and used for western 
blotting.
Western blotting
WGA-enriched samples were run on a 7.5% homogeneous gel on a PhastSystem 
gel electrophoresis system (GE Healthcare) following standard protocols and 
blotted on nitrocellulose (0.2 µm Protran Whatman) by diffusion blotting (60 - 
90 min at 60 °C). 
Microsome fractions were run on 10% polyacrylamide gel, either with 4 M Urea 
(anti-V5) or without (Calnexin). After SDS-PAGE, proteins were transferred to a 
nitrocellulose membrane by Western blotting (Biorad Mini PROTEAN®3).
Lectins and antibodies used: peroxidase-labeled PNA (Sigma Aldrich, 0.2 µg/
ml), biotin-labeled MALII (Vector Labs, 10 µg/ml), peroxidase-labeled avidin 
(Sigma Aldrich, 0.4 µg/ml), anti-V5 (Life Technologies, 1:5000 dilution), Calnexin 
(Novus Biologicals, NB100_1965, 1:1000 dilution), IIH6 (Millipore, IIH6C4, 
1:2500 dilution), DAG1 (Genetex, GTX105038, 1:333 dilution), β-DG (Novacastra 
Laboratories, 1:250 dilution). A laminin overlay assay was performed as described 
previously (Michele et al, 2002; Lefeber et al, 2011).
Lectin flow cytometry analysis
Cells were washed using PBS and subsequently harvested by scraping in cold 
PBS. Cells were washed twice using blocking buffer (1% fetal bovine serum, 1 
mM CaCl
2
 and 1 mM MgCl
2
 in PBS). Cells were either incubated with 20 µg/ml 
tetramethylrhodamine (TRITC)-labeled PNA (Sigma Aldrich) for 90 min or with 20 
µg/ml biotin-labeled MALII (Vector labs) for 45 min. After MALII incubation, cells 
were washed three times using 1% FBS in PBS and subsequently incubated with 
10 µg/ml fluorescein isothiocyanate (FITC)-labeled streptavidin (Sigma Aldrich) 
for 10 min. Before measuring, all cells were washed three times using 1% FBS-
PBS. The fluorescent signal was measured at a CyAn flow cytometer (Beckman-
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Coulter). A total of 40,000 cells were analyzed using Summit 4.3 software. 
Cells incubated with blocking solution or Streptavidin-FITC only were used to 
determine the background signal. Average of two independent experiments is 
shown.
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O-mannose glycans on α-dystroglycan (α-DG) are required for binding with 
extracellular matrix ligands and therewith play a crucial role in linking the 
cytoskeleton with the extracellular matrix. Defective α-DG-ligand binding causes 
severe muscular dystrophy-dystroglycanopathy (MDDG) syndromes, which are 
characterized by severe muscular dystrophy and brain and eye abnormalities. 
This study aimed to come to a better understanding of the ligand-binding 
O-mannose glycan. Both a genetic approach to identify novel gene defects 
and a biochemical approach to functionally characterize proteins involved in 
the O-mannosylation pathway, were used. This has led to the identification 
of B3GNT1 as a novel disease gene and broadened the clinical spectrum of 
MDDG syndromes by describing patients with novel mutations in DAG1,	 ISPD 
and B3GALNT2. In addition, this study contributed to the elucidation of the 
O-mannosylation pathway by showing that ISPD produces a novel nucleotide 
sugar that potentially could be transported by the SLC35A1 transporter.
Clinics and genetics of the MDDG syndromes
MDDG syndromes have a broad clinical phenotype, ranging from severe Walker-
Warburg syndrome (WWS) to mild limb-girdle muscular dystrophy (LGMD). 
About ten years ago, the first six MDDG syndrome causative genes, including 
POMT1, POMT2, POMGNT1, FKTN,	 FKRP	and LARGE, were identified. At that 
time, in only about 50% of the patients a genetic defect could be found (van 
Reeuwijk et al, 2005). In my research, B3GNT1 was identified as a novel MDDG 
syndrome causative gene (Chapter 6). Besides, our group succeeded in the 
identification of other MDDG syndrome disease genes as well, including ISPD 
(Roscioli et al, 2012), POMK (SGK196) (Jae et al, 2013), GMPPB (Carss et al, 
2013), DOLK (Lefeber et al, 2011) and DPM2 (Barone et al, 2012). In addition, I 
described novel mutations in DAG1	(Chapter 3), ISPD (Chapter 4) and B3GALNT2 
(Chapter 5). By the use of novel genetic tools such as whole exome sequencing, 
the number of known MDDG syndrome causative genes increased fast and 
nowadays in about 70% of the patients the underlying genetic defect can be 
identified.
Defects in most of the identified genes can give rise to a wide spectrum of 
phenotypes, ranging from very severe early-lethal ones to those that manifest 
only in (late) adult life (Table 1). This would suggest that a specific mutation, 
rather than the mutated gene, is important for the clinical outcome. However, 
as was shown for the first six identified MDDG syndrome causative genes 
previously (van Reeuwijk et al, 2005) and is observed for the novel disease genes 
as well, prediction of the clinical phenotype on base of mutation severity is 
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difficult. In Chapter 3 I show that a severe DAG1 mutation indeed led to a severe 
phenotype, while previously identified less severe mutations were shown to give 
rise to muscle-eye-brain disease (MEB) and mild LGMD (Hara et al, 2011; Geis 
et al, 2013). However, mutations in other genes, such as B3GALNT2 are more 
difficult to correlate with the clinical presentation (Chapter 5). A previous study 
described severely affected B3GALNT2 patients of which most harbor severe 
stop mutations, while in a few relatively mild missense mutations were identified 
(Stevens et al, 2013). Although the mutations I identified were predicted to lead 
to a comparable clinical phenotype, the patients presented only with a very mild 
brain phenotype without muscular dystrophy, a unique presentation within the 
MDDG syndromes. Using a complementation assay I showed that the difference 
in clinical phenotype and mutation severity could only be partly clarified. Only 
two cases of B3GNT1 gene defects are known. Remarkably, the two homozygous 
missense mutations that I identified (Chapter 6) seemed to be less severe than 
the truncating mutation that was identified in another study (Shaheen et al, 
2013), while both defects result in severe WWS. Mutations in ISPD are the second 
most common cause of MDDG syndrome (Roscioli et al, 2012). In Chapter 7 I 
show that I could partly clarify the genotype-phenotype correlation of several 
ISPD defects by making use of the identification of the functional domain and 
catalytic residues of the human ISPD protein. Furthermore, homozygous and 
compound heterozygous GMPPB missense mutations were detected in a broad 
range of patients. As expected, the only identified truncating mutation was found 
in the most severely affected MEB/Fukuyama congenital muscular dystrophy 
(FCMD) patient (Carss et al, 2013). Remarkably, a homozygous POMK (SGK196) 
truncating mutation was shown to cause congenital muscular dystrophy (CMD) 
with cerebellar involvement (von Renesse et al, 2014) or mild LGDM (Di Costanzo 
et al, 2014), while a patient with a compound heterozygous missense mutation 
presented with severe WWS (Jae et al, 2013). 
In addition to the classical broad clinical phenotype, some patients present 
with atypical characteristics. Independent from the clinical severity, muscular 
dystrophy is a common clinical feature in all patients, but some exceptions are 
known. The patients with a B3GALNT2 mutation described in Chapter 5 were 
the first MDDG syndrome patients presenting with only a mild brain phenotype, 
but without muscular dystrophy. On the other hand, I detected atypical and 
unexplained calcifications in the brain of severely affected WWS patients with a 
single base pair deletion in DAG1 (Chapter 3). Other uncommon phenotypes are 
described as well. For example, a patient with a POMGNT1 mutation presenting 
with muscular weakness, but without muscular dystrophy was described 
(Raducu et al, 2014). Besides, three siblings from a family with mutations in FKRP 
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Table 1: Updated overview gene mutations and phenotypes according to OMIM classification. 
CBR: with cerebellar involvement. MR: with mental retardation. *= not yet in OMIM database. The 
genes most frequently mutated in different MDDG syndrome types are highlighted in dark grey.
 Type A B C
WWS MEB/
FCMD
CMD
CBR
CMD
MR
CMD LGMD
CBR
LGMD
MR
LGMD Isolated 
brain
CDG CDG/
DCM
POMT1 1 X X X X X X X
236670 613155 609308
POMT2 2 X X X X X X
613150 613156 613158
POMGNT1 3 X X X X
253280 613151 613157
FKTN 4 X X X X
253800 613152 611588
FKRP 5 X X X X X
613153 606612 607155
LARGE 6 X X X
613154 608840
ISPD 7 X X X X X X
614643 * 616052
POMGNT2 
(GTDC2)
8 X
614830
DAG1 9 X X X
* 613818
TMEM5 10 X X
615041
B3GALNT2 11 X X X
615181 *
POMK
(SGK196)
12 X X X X
615249 * 616094
B3GNT1 13 X
615287
GMPPB 14 X X X X X
615350 615351 615352
DPM1 X
608799
DPM2  X
 615042
DPM3 X X
612937
DOLK X
610768
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showed isolated dilated cardiomyopathy (DCM) (Muller et al, 2005). Besides 
the heart phenotype in these FKRP-deficient patients, cardiac involvement is 
also described in a minority of the MDDG syndrome patients with mutations in 
POMT1, POMT2, FKTN, FKRP and GMPPB (Pane et al, 2012; Finsterer et al, 2010; 
Carss et al, 2013).
Using novel genetic tools such as whole exome sequencing, it becomes easier 
to diagnose MDDG syndrome patients with an atypical phenotype. For example, 
the B3GALNT2 patients described in this thesis were initially diagnosed with 
mild intellectual disability and were therefore not tested for mutations in well 
known MDDG syndrome genes. However, using whole exome sequencing it 
became clear that these patients have a mutation in a MDDG syndrome disease 
gene. As nowadays whole exome sequencing becomes available as a diagnostic 
tool (Biesecker et al, 2014), it is expected that more atypical MDDG syndrome 
patients will be identified in the future.
MDDG syndromes overlap with N-linked glycosylation disorders
In addition to the classical MDDG syndromes, a small group of disorders 
characterized by a combination of O-mannosylation and N-linked glycosylation 
defects was identified. Defects in the pathway for synthesizing dolichol-
phosphate-mannose (Dol-P-Man), a precursor for both O-mannosylation 
and N-linked glycosylation, are the underlying cause of these disorders. The 
last step in the Dol-P-Man producing pathway is the addition of mannose 
from GDP-mannose (GDP-Man) to dolichol-phosphate (Dol-P) by the DPM 
synthase complex. Severe mutations in DPM1 and DPM2, encoding two out 
of three subunits of the DPM complex, result in a similar phenotype. This 
phenotype is characterized by muscular dystrophy in combination with typical 
congenital disorders of glycosylation (CDG) characteristics caused by a defective 
N-glycosylation, such as seizures and developmental delay (Yang et al, 2013; 
Barone et al, 2012). Mild mutations in DPM3, encoding the third subunit of the 
DPM synthase complex, lead to mild muscular dystrophy and, unlike mutations 
in DPM1 and DPM2, to DCM (Lefeber et al, 2009). Remarkably, mutations in 
DOLK, acting one step upstream of the DPM complex by producing Dol-P via 
phosphorylation of dolichol, resulted in an isolated DCM phenotype (Lefeber 
et al, 2011). This specific isolated phenotype could potentially be clarified by 
tissue-specific differences in the Dol-P-Man synthesizing pathway. Notably, 
mutations in SRD5A3, encoding the dolichol producing polyprenol reductase do 
not result in an O-mannosylation phenotype (Cantagrel et al, 2010). In addition, 
MPDU1 mutations cause lowered levels of Dol-P-Man in patients, but do not 
cause O-mannosylation symptoms (Schenk et al, 2001; Kranz et al, 2001). The 
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production of dolichol is suggested to occur via different routes (Cantagrel et al, 
2010), which might be tissue specific. Possibly alternative pathways also exist 
for later steps in the Dol-P-Man pathway, which could clarify the variable clinical 
phenotype of patients with a defect in the Dol-P-Man producing pathway. 
Remarkably, mutations in GMPPB, encoding a protein that produces GDP-Man, 
a substrate of the DPM synthase complex, result in a typical MDDG syndrome 
phenotype and at both the clinical and biochemical level no signs of a defective 
N-linked glycosylation could be obtained (Carss et al, 2013). GMPPA is a homolog 
of GMPPB which might regulate GMPPB activity. Mutations in GMPPA were 
shown to result in increased levels of GDP-mannose, though neither an N-linked 
nor an O-mannosylation defect was shown in the patients, which presented with 
achalasia, alacrima and neurological defects (Koehler et al, 2013). In addition, 
defects in other proteins involved in producing GDP-Man, including MPI and 
PMM2, cause GDP-mannose deficiency and result in CDG type I, without 
symptoms of an O-mannosylation defect (Niehues et al, 1998; Matthijs et al, 
1997).
Mutations in SLC35A1 give rise to a phenotype that might result from the combined 
defects in sialic aid metabolism (CDG-like features) and O-mannosylation (MDDG-
like features) (Chapter 7). SLC35A1 was previously shown to transport CMP-sialic 
acid required for proper N-linked glycosylation (Eckhardt et al, 1996; Tiralongo 
et al, 2006). In addition to this function, I hypothesize that SLC35A1 transports a 
specific nucleotide sugar required for α-DG O-mannosylation (Chapter 7). Indeed, 
I showed that a defective O-mannosylation clarifies some clinical characteristics 
of a previously identified SLC35A1-deficient patient that was initially diagnosed 
with a N-linked glycosylation disorder (Mohamed et al, 2013). 
α-DG O-mannosylation
The proteins encoded by MDDG syndrome causative genes are expected to 
play a role in the synthesis of the ligand-binding O-mannose glycan on α-DG. 
The catalytic activity of several of these proteins has already been identified, 
but the O-mannosylation pathway is still not completely understood (Figure 
1). DOLK, DPM1, DPM2, DPM3 and GMPPB are known to produce precursor 
Dol-P-Man. This substrate is used by POMT1 and POMT2, that form a complex 
and transfer the first mannose residue to α-DG (Manya et al, 2004). The ligand-
binding glycan is further modified by subsequently POMGnT2 and B3GALNT2 
to form the trisaccharide GalNAcβ1-3GlcNAcβ1-4Man-Ser/Thr. As a next step, 
the trisaccharide is 6-O-phosphorylated at the first mannose residue by POMK 
(Yoshida-Moriguchi et al, 2013). This phosphate group is hypothesized to be 
attached to an important part of the ligand-binding glycan, which is not yet 
188
Chapter 9
Fi
gu
re
 1
: E
nz
ym
es
 in
 t
he
 O
-m
an
no
sy
la
ti
on
 p
at
hw
ay
 s
yn
th
es
iz
in
g 
th
e 
lig
an
d-
bi
nd
in
g 
gl
yc
an
 o
n 
α
-D
G
.
189
General discussion
9
identified (Yoshida-Moriguchi et al, 2010). LARGE produces repeating xylose-
glucuronic acid repeats (Inamori et al, 2012) and B3GNT1 is a β-1,3-N-acetyl 
glucosamine transferase (Sasaki et al, 1997). Likely these sugar residues are 
part of the unknown ligand-binding structure, but their exact positions remain 
to be identified. FKRP, FKTN and TMEM5 contain predicted glycosyltransferase 
domains and localize to the Golgi apparatus (Esapa et al, 2002; Vuillaumier-
Barrot et al, 2012). Therefore, these proteins are hypothesized to function as 
glycosyltransferases as well, but their exact activities remain to be elucidated. 
In Chapter 7 I describe the identification of a novel nucleotide sugar that is 
produced by ISPD. I predict that this sugar might be part of the ligand-binding 
glycan. In Chapter 8 I show that the Golgi-localized transporter SLC35A1 might 
transport, besides CMP-sialic acid, another still unknown nucleotide sugar 
required for α-DG O-mannosylation. Potentially this could be the CDP-nucleotide 
sugar that is produced by ISPD. Both FKRP and FKTN contain a LicD domain, 
that is homologous to a LicD domain from a bacterial protein (ZP_05736246 
from P.	tannerae), harboring an IspD domain as well. Therefore, it is tempting to 
speculate that FKRP and FKTN have transferase activity towards the nucleotide 
sugar produced by ISPD.
Besides the proposed ligand-binding trisaccharide, a tetrasaccharide: Neu5Acα2-
3Galβ1-4GlcNAcβ1-2Man-Ser/Thr was originally proposed to be required for 
α-DG-ligand binding (Chiba et al, 1997). According to the current hypothesis 
this tetrasaccharide is not directly involved in ligand-binding. However, as 
POMGnT1 specifically transfers the β1,2-linked N-acetyl glucosamine to the first 
mannose of the tetrasaccharide and because mutations in POMGNT1 give rise 
to severe variants of MDDG syndrome (Yoshida et al, 2001), this tetrasaccharide 
might have an important role. Possibly this glycan structure is required for 
proper synthesis of the ligand-binding glycan in an indirect way. For example, 
glycosyltransferases involved in the ligand-binding structure might require 
binding to this tetrasaccharide to be active, similar to the molecular interaction 
between α-DG and LARGE (Kanagawa et al, 2004). 
Remaining gene defects
In 30% of the patients a genetic defect still remains to be identified, suggesting 
that additional MDDG syndrome causative genes can be identified in the future. 
As described in Chapter 2, most of the recently detected MDDG syndrome 
causative gene defects were identified using whole exome sequencing. However, 
due to technical limitations such as incomplete coverage and imperfect read 
mapping, whole exome sequencing can usually not identify a genetic defect in 
all patients, as was also shown for type I congenital disorders of glycosylation 
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(CDG) (Timal et al, 2012). This suggests that a low percentage of the potential 
MDDG syndrome causative genes can be missed. Another genome-wide 
approach to detect novel disease candidate genes was performed using a 
haploid HAP1 cell line (Jae et al, 2013). As described in Chapter 2, HAP1 cells 
were randomly mutagenized and cells defective for IIH6 antibody-binding were 
selected. Deep-sequencing of this cell population revealed mutations in almost 
all known candidate genes. However, a few known MDDG syndrome disease 
genes were missed in this genetic screen, including DOLK, DPM2 and GMPPB. 
Interestingly, all these genes are involved in production of the precursor Dol-P-
Man. Possibly in HAP1 cells alternative pathways for Dol-P-Man production are 
available, that prevent identification of these three and potential other MDDG 
syndrome genes. Although α-DG from HAP1 cells is able to bind laminin, some 
hypothetical tissue-specific O-mannosylation differences compared to muscle or 
brain tissue might avoid identification of all MDDG syndrome causative genes. 
Besides, technical limitations of exome sequencing could prevent elucidation 
of all disease causing genes. In conclusion, more genetic analyses are needed 
to complete the identification of all MDDG syndrome disease genes. As whole 
exome sequencing methods are still being improved, novel gene defects could 
potentially be identified by this technique in the future. Furthermore, elucidation 
of the ligand-binding glycan structure and the underlying O-mannosylation 
pathway could help to detect novel candidate genes. 
Further elucidation of the O-mannosylation pathway
The O-mannosylation pathway still remains an interesting puzzle and future 
research is needed to identify this pathway completely. As a first step, my 
hypothesis concerning the production of a novel nucleotide sugar by ISPD and 
the transport of this specific O-mannosylation precursor by SLC35A1 (Chapter 7 
and 8) has to be confirmed. My results showed that human ISPD has the highest 
cytidyltransferase activity towards ribitol 5-phosphate, a compound not known 
to be present in the human cytosol. In addition, ISPD activity towards ribulose 
5-phosphate and ribose 5-phosphate was shown. Future research is required 
to identify the in	 vivo ISPD enzyme activity. To test whether SLC35A1 indeed 
is able to transport CDP-ribitol, CDP-ribulose and/or CDP-ribose, a transporter 
assay using a radio-active nucleotide sugar could be performed, similar to the 
previously described CMP-sialic acid transporter assay (Mohamed et al, 2013). 
Nowadays genetic tools to make knockout cell lines such as transcription 
activator-like effector nucleases (TALEN) (Sanjana et al, 2012) and clustered 
regulary interspaced short palindromic repeats (CRISPR) (Pennisi, 2013) are 
easily accessible and could give more insight in the specific roles of the proteins 
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involved in the O-mannosylation pathway. Individual knockout of each MDDG 
syndrome causative gene in a cell line that overexpresses O-mannosylated 
α-DG could be a useful model. Subsequent purification of α-DG followed by 
mass spectrometry analysis could be used to identify the individual protein 
activities towards the O-mannose glycan structure. Recent mass spectrometry 
studies provided new insights into the glycosylation of α-DG, but these studies 
were not able to identify the unknown part of the ligand-binding structure 
attached to the phosphate group. However, with the continuous development 
of glycomic analysis, future research is expected to lead to the identification of 
the O-mannose glycan structure (Live et al, 2013).
Therapy development
No therapies for MDDG syndromes are available yet. Rescue of the severe 
structural brain abnormalities observed in the most severely affected patients 
might be impossible as these arise during early brain development. However, 
interventions can be envisaged to ameliorate specific phenotype features or to 
slow down disease progression at postnatal stages. In particular, the late-onset 
muscular phenotype in LGMD patients may be amenable to interventions. Gene 
therapy aiming to rescue the phenotype of LGMD patients has been tested in 
mouse models. In FKTN-deficient mice specific restoration of FKTN expression in 
myofibers rescued the muscular dystrophy phenotype (Kanagawa et al, 2013). 
In addition, systemic FKRP expression in a FKRP-mutant mouse at either the 
neonatal age or at nine months of age, was shown to restore functional α-DG 
glycosylation and improved the skeletal and cardiac muscle function (Xu et al, 
2013; Qiao et al, 2014).
Other strategies focus on restoration of α-DG O-mannosylation by LARGE 
overexpression (Barresi et al, 2004). In several experiments using mouse deficient 
for LARGE, FKTN or POMGNT1, LARGE gene transfer is shown to rescue the 
muscular dystrophy phenotype (Kanagawa et al, 2009; Yu et al, 2013). Therefore 
LARGE overexpression could not only be beneficial for patients with mutations 
in LARGE, but also for patients with mutations in other genes. The underlying 
mechanism of restoration of α-DG-ligand binding by LARGE overexpression still 
remains unknown and future research is needed to identify this phenomenon. In 
addition, elucidation of the ligand-binding glycan structure would be helpful for 
future therapy development, stressing the great relevance for further research 
to elucidate the O-mannosylation pathway.
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Summary
Muscular dystrophy-dystroglycanopathy (MDDG) syndromes are characterized 
by a broad clinical spectrum. Typical clinical features of the most severe variant, 
Walker-Warburg syndrome (WWS), include congenital muscular dystrophy, 
ophthalmologic aberrations and structural brain abnormalities, such as type II 
cobblestone lissencephaly, hydrocephalus and cerebellar abnormalities. The 
least severe variant is limb-girdle muscular dystrophy (LGMD), which typically 
manifests at a later age. MDDG syndromes are caused by a defective link between 
the extracellular matrix and the cell membrane. The extracellular α-dystroglycan 
(α-DG) protein, via β-dystroglycan (β-DG) anchored to the cell membrane, 
requires typical O-mannose glycans to bind extracellular matrix ligands. Two 
types of O-mannose glycans on α-DG are described, a tetrasaccharide, probably 
not directly involved in ligand binding and the likely ligand-binding trisaccharide 
of which the first mannose residue is 6-O-phosphorylated. This phosphate 
group probably binds an important part of the ligand-binding structure 
that is not yet completely resolved. Known MDDG syndrome genes encode 
proteins that have a (putative) role in the O-mannosylation pathway by either 
synthesizing or transporting specific O-mannosylation precursors or by acting as 
glycosyltransferase in the endoplasmic reticulum (ER) or Golgi apparatus (Chapter 
2). Prior to the research project described in this thesis only in about 50% of the 
MDDG syndrome patients a genetic defect could be identified. My research aim 
was to find novel genetic defects and to contribute to the elucidation of the 
O-mannosylation pathway.
In Part	 I:	 Novel	 gene	 defects	 in	 muscular	 dystrophy-dystroglycanopathy	
syndrome	patients, novel genetic defects in different MDDG syndrome patients 
are described. In Chapter 3 severely affected WWS patients with atypical brain 
calcifications are described. I identified a novel homozygous single base pair 
deletion in DAG1, encoding α-DG and β-DG. This deletion leads to a premature 
stop codon in the N-terminal part of α-DG, which according to my biochemical 
experiments results in a complete absence of α-DG and β-DG expression. This 
research showed the first primary MDDG syndrome patients without α-DG 
and β-DG expression and with that proved that absence of these proteins is 
not embryonic lethal. In Chapter 4, novel ISPD mutations are shown to be the 
underlying cause in four typical WWS patients. Two cousins harboring a missense 
mutation in exon 3, a patient with a splice site mutation and a patient with a 84-
kb deletion harboring exon 6 to 9 are described. In Chapter 5, two patients with 
a mild, apparently nonsyndromic intellectual disability phenotype caused by 
compound heterozygous missense mutations in B3GALNT2 are described. The 
absence of muscular pathology is striking as this is the hallmark of all MDDG 
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syndrome gene mutations described so far. I compared the mutations of these 
patients with those found in severely affected MDDG syndrome patients using 
complementation assays, which provided no support for a clear genotype-
phenotype correlation. The mechanistic explanation for the lack of genotype-
phenotype associations, which is also seen for other MDDG syndrome genes is 
currently enigmatic (Chapter 9). Besides novel mutations in known disease genes, 
I identified a novel MDDG syndrome causative gene (Chapter 6). I combined 
homozygosity mapping with a candidate gene approach and identified two 
homozygous missense mutations in B3GNT1 in three typical WWS patients from 
one family. I confirmed that B3GNT1 is indeed a WWS causative gene by showing 
that overexpression of wild type B3GNT1 in prostate cancer cells increased IIH6-
binding, while overexpression of the mutant did not. Further support of the 
causality of B3GNT1 mutations in WWS was obtained by knockdown of zebrafish 
b3gnt1 using morpholinos. These experiments showed various histological 
defects of zebrafish musculature as well as a reduced binding of α-DG to laminin.
In Part	 II:	 Dissecting	 the	 O-mannosylation	 pathway, biochemical work to 
elucidate the function of ISPD (Chapter 7) and SLC35A1 (Chapter 8) in the 
O-mannosylation pathway is described. A crystal structure of human ISPD was 
established, revealing a tertiary structure of the cytidyltransferase domain 
similar to the structure of bacterial IspD. In comparison to bacterial IspD, human 
ISPD contains an additional non-homologous C-terminal domain that may have 
another enzymatic activity or which is required for ISPD protein stabilization and 
citydyltransferase function. Via an enzymatic screen, cytidyltransferase activity 
was confirmed towards ribulose 5-phosphate, ribose 5-phosphate and, more 
efficiently, ribitol 5-phosphate. Using analytical methods, formation of CDP-
nucleotide sugars was confirmed. In Chapter 8, I describe that SLC35A1 has a 
crucial role in the O-mannosylation pathway, but not via its well-described CMP-
sialic acid transport function. I show that a mutation in SLC35A1 provides a novel 
link between N-glycosylation and O-mannosylation disorders. I hypothesize 
that SLC35A1 is able to transport another nucleotide sugar as well and possibly 
transports the nucleotide sugar that is produced by ISPD. 
In conclusion, this research project identified several novel genetic defects 
in different MDDG syndrome patients and with that broadened the clinical 
spectrum of the MDDG syndromes. I described B3GNT1 as a novel disease 
gene and I contributed to the elucidation of the O-mannosylation pathway by 
showing that human ISPD produces a novel nucleotide sugar required for α-DG 
O-mannosylation that could possibly be transported to the Golgi apparatus by 
SLC35A1.
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Samenvatting
Spierdystrofie-dystroglycanopathie (muscular dystrophy-dystroglycanopathy, 
MDDG)-syndromen hebben een breed klinisch spectrum. Typische kenmerken 
van de meest ernstige variant, Walker-Warburg-syndroom (WWS), zijn 
aangeboren spierdystrofie, oogafwijkingen en hersenafwijkingen, zoals type 
II cobblestone lissencefalie, hydrocefalus en afwijkingen van het cerebellum. 
Limb-girdle spierdystrofie is de mildste variant. Deze aandoening komt op latere 
leeftijd tot uiting, meestal zonder afwijkingen van het cerebellum en slechts in 
een enkel geval met mentale retardatie. MDDG-syndromen worden veroorzaakt 
door een afwijkende glycosylering van dystroglycaan, en soms door fouten in het 
dystroglycaan-eiwit zelf, waardoor de koppeling tussen de extracellulaire matrix 
en celmembraan verstoord is. Het extracellulaire α-dystroglycaan (α-DG)-eiwit 
wordt via β-dystroglycaan (β-DG) verbonden met de celmembraan en heeft een 
unieke O-mannose glycaan nodig om liganden in de extracellulaire matrix te 
kunnen binden. Er zijn twee typen O-mannose glycanen op α-DG beschreven: 
een tetrasacharide, die waarschijnlijk niet direct betrokken is bij de binding 
van liganden, en een trisacharide waarvan het eerste mannose residu een 
6-O-gebonden fosfaatgroep bevat. Deze fosfaatgroep bindt waarschijnlijk een 
belangrijk gedeelte van de nog niet compleet geïdentificeerde ligand-bindende 
structuur. Bekende ziekteveroorzakende genen coderen voor eiwitten die een 
rol spelen in de O-mannosyleringsroute via synthese of transport van specifieke 
substraten , of actief zijn als glycosyltransferase in het endoplasmatisch 
reticulum (ER) of in het Golgi-apparaat (Hoofdstuk 2). Bij aanvang van het 
onderzoeksproject dat in dit proefschrift is beschreven, kon bij ongeveer 50% 
van de MDDG-syndroompatiënten een genetisch defect worden vastgesteld. 
Het doel was om nieuwe genetische defecten te vinden en bij te dragen aan het 
ophelderen van de O-mannosyleringsroute. 
In Deel	 I:	 Nieuwe	 gendefecten	 in	 spierdystrofie-dystroglycanopathie-
syndroompatiënten, zijn nieuwe genetische defecten in verschillende MDDG-
syndroompatiënten beschreven. In Hoofdstuk 3 worden ernstig aangedane 
WWS-patiënten met atypische calcificaties beschreven. Ik heb een nieuwe 
homozygote deletie van één basepaar geïdentificeerd in DAG1, dat codeert voor 
α-DG en β-DG. Deze deletie leidt tot een vroegtijdig stopcodon in het N-terminale 
gedeelte van α-DG en resulteert, zoals aangetoond met mijn biochemische 
experimenten, in een complete afwezigheid van α-DG en β-DG. Dit onderzoek 
heeft de eerste primaire MDDG-patiënten gevonden, waarbij geen expressie van 
α-DG en β-DG werd aangetoond, waarmee ik bewees dat volledige afwezigheid 
van deze eiwitten niet fataal is tijdens de embryonale fase. In Hoofdstuk 4 zijn in 
vier typische WWS-patiënten nieuwe homozygote ISPD-mutaties aangetoond als 
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onderliggende ziekteoorzaak. Dit betrof twee nichtjes met een missense mutatie 
in exon 3, een patiënt met een splice site mutatie en een patiënt met een 84-kb 
deletie bevattende exon 6 tot exon 9. In Hoofdstuk 5 worden twee patiënten met 
milde mentale retardatie, veroorzaakt door mutaties in B3GALNT2, beschreven. 
Het is opvallend dat deze patiënten geen spierafwijkingen vertonen, omdat dit 
een belangrijk kenmerk is van MDDG syndromen. Door middel van functionele 
complementatie-experimenten heb ik de mutaties van deze patiënten 
vergeleken met mutaties die zijn gevonden in MDDG-syndroom patiënten met 
een ernstig fenotype. Ik heb laten zien dat de genotype-fenotype correlatie niet 
altijd eenduidig is, zoals eerder al voor andere genen van het MDDG-syndroom 
is laten zien (Hoofdstuk 9). Naast nieuwe mutaties in bekende genen heb ik ook 
een nieuw MDDG-syndroom veroorzakend gen geïdentificeerd (Hoofdstuk 6). 
Ik heb homozygosity mapping gecombineerd met een kandidaatgen-aanpak en 
zo in drie typische WWS-patiënten van één familie twee homozygote missense 
mutaties in B3GNT1 gevonden. Ik heb laten zien dat beide mutaties de activiteit 
van het B3GNT1 eiwit ernstig verstoren en dat de combinatie van de twee 
mutaties tot een volledig verlies van activiteit leidt. Dit laatste werd bevestigd 
in een cellulair overexpressie experiment, waarin overexpressie van B3GNT1 in 
prostaatkankercellen de IIH6-binding verhoogde, terwijl overexpressie van de 
dubbelmutant dat niet deed. Daarnaast leidde knockdown van b3gnt1 in zebravis 
tot spierafwijkingen en een verminderde binding tussen α-DG en laminine.
In Deel	 II:	 Opheldering	 van	 de	 O-mannosyleringsroute, zijn biochemische 
experimenten beschreven met als doel de opheldering van de functie van 
ISPD (Hoofdstuk 7) en SLC35A1 (Hoofdstuk 8). Van het humane ISPD is een 
kristalstructuur gemaakt, waaruit bleek dat de tertiaire structuur van het 
cytidyltransferase-domein sterke gelijkenis vertoont met de structuur van IspD 
uit bacteriën. Daarnaast heeft humaan ISPD een niet-homoloog C-terminaal 
domein dat mogelijk een andere enzymactiviteit heeft, nodig is voor de 
stabilisatie van het ISPD eiwit, of voor optimale citydyltransferase activiteit. Door 
middel van een enzymatische screening bevestigde ik cytidyltransferaseactiviteit 
voor omzetting van ribulose 5-fosfaat, ribose 5-fosfaat en ribitol 5-fosfaat. 
De vorming van de betreffende CDP-suikers werd bevestigd met analytische 
methoden. In Hoofdstuk 8 wordt beschreven dat SLC35A1 een cruciale rol speelt 
in de O-mannosyleringsroute, maar niet via zijn welbekende CMP-siaalzuur 
transportactiviteit. Ik laat zien dat een mutatie in SLC35A1 een nieuwe link 
vormt tussen N-glycosylerings- en O-mannosyleringsziekten. Mijn hypothese is 
dat SLC35A1 in staat is om ook een ander nucleotidesuiker te transporteren, 
mogelijk de nucleotidesuiker die gemaakt wordt door ISPD.
Samenvattend heeft dit onderzoek een aantal nieuwe gendefecten laten zien in 
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verschillende MDDG-syndroompatiënten en daarmee het klinisch spectrum van 
de MDDG-syndromen uitgebreid. Ik heb B3GNT1 beschreven als nieuw ziektegen 
en bijgedragen aan de opheldering van de O-mannosyleringsroute door te laten 
zien dat humaan ISPD een nieuwe nucleotidesuiker kan produceren dat vereist is 
voor de O-mannosylering van α-DG en mogelijk door SLC35A1 getransporteerd 
kan worden naar het Golgi-apparaat.
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Het is af. Na vier jaar onderzoek ligt hier het resultaat. In dit laatste hoofdstuk 
van mijn proefschrift wil ik graag iedereen bedanken die op de één of andere 
manier heeft bijgedragen aan mijn onderzoek. Een aantal mensen wil ik in het 
bijzonder bedanken.
Als eerste mijn promotor en co-promotor. Beste Hans, bedankt voor jouw 
begeleiding tijdens mijn promotietraject. Ondanks je volle agenda kon je vaak 
toch even tijd maken wanneer dat nodig was. Ik heb veel gehad aan jouw input 
in het project en jouw feedback en suggesties op mijn experimenten en teksten.
Beste Dirk, graag wil je bedanken voor jouw dagelijkse begeleiding. Ik heb veel 
geleerd van jouw ideeën, feedback en tips en het was prettig dat ik altijd even 
binnen kon lopen voor overleg. Ik vond het erg leuk om te zien hoe het met jouw 
enthousiasme en gedrevenheid voor het glycosyleringsonderzoek is gelukt om 
een mooi aantal subsidies binnen te halen, waardoor de groep in de loop van de 
jaren steeds groter is geworden.
En dan mijn collega-onderzoekers uit de glycosgroep. Monique, jij bent er vanaf 
het begin van mijn project bij geweest en we konden het altijd goed vinden 
samen. Bedankt voor de fijne samenwerking en natuurlijk ook voor alle gezellige 
lunches. Leuk dat je mijn paranimf wil zijn! Sharita, onze projecten zijn bijna 
tegelijkertijd begonnen en de afgelopen vier jaar zaten we dan ook in hetzelfde 
schuitje. Ik vond het fijn dat we onze ervaringen (en soms frustraties) altijd 
met elkaar konden delen. Bedankt voor de leuke samenwerking en veel succes 
met de laatste loodjes! Ik vind het leuk dat ook jij mijn paranimf wil zijn! Ook 
de andere onderzoekers uit de groep wil ik bedanken, het was leuk om met 
jullie samen te werken. Angel, many thanks for your help with the biochemical 
SLC35A1 and ISPD projects, it was nice to work with you. Walinka, veel succes 
met het vervolg van het ISPD-project en jouw promotieproject. Jos, Amin en 
Anke ook veel succes met jullie promoties!
Natuurlijk wil ik ook de glycos- en lyso-analisten bedanken voor de fijne en 
gezellige samenwerking en leuke lunches. Ik heb op het lab veel van jullie geleerd. 
Karin, bedankt voor je hulp met de ISPD enzymassay, patiëntenmonsters en nog 
veel meer! Mede door jouw inzet kon ik na elke verhuizing weer snel aan de slag 
op een nieuwe plek. Gerry, ook jij bedankt voor al je hulp op het lab! Ik heb veel 
geleerd van jouw ruime ervaring en ik vond het leuk om de western blot assays 
die ik ontwikkeld heb aan jou over te dragen. Fokje, het werken met de HPLC 
was helemaal nieuw voor mij, maar jij hebt het me goed geleerd, dank daarvoor! 
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Ine en Astrid, bedankt voor jullie hulp op het lab en alle bestellingen die jullie 
voor mij gedaan hebben!
Ook wil ik een aantal collega’s van Genetica noemen. Ellen, bedankt voor de 
fijne samenwerking de afgelopen jaren en je hulp bij de genetische kant van mijn 
project. Karen en Tony, in de beginjaren van mijn project waren jullie de andere 
onderzoekers uit de WWS-groep. Bedankt voor voor jullie input in het project en 
de leuke samenwerking.
Door de jaren heen heb ik verschillende studenten begeleid, die mij hebben 
geholpen met het ontwikkelen en uitvoeren van verschillende experimenten. 
Annalena, Tatjana, Julia en Max, bedankt voor jullie inzet.
Na vier jaar promotieonderzoek, voorafgegaan door een jaar stage, ben ik in 
totaal vijf jaar werkzaam geweest bij LGEM, inmiddels TML. Ik heb het hier altijd 
erg naar mijn zin gehad en wil iedereen dan ook bedanken voor de prettige 
samenwerking en leuke sfeer op het lab.
Naast mijn collega’s zijn er ook nog een aantal andere mensen die ik wil noemen. 
Als eerste alle (inmiddels oud-)hazen uit de sprintgroep. De gezellige trainingen, 
wedstrijden, etentjes en andere uitjes waren altijd goed voor mijn ontspanning. 
Het soms bijzondere lage niveau (en gelukkig heb ik het nu niet over de kwaliteit 
van de training) tijdens de trainingen zorgde ervoor dat ik het werk snel even 
kon vergeten.
Daarnaast wil ik Petra & Joris, Koos & Elleke, Jasper & Aimée, Jurjen & Sabrina en 
Renee & Marcel noemen. We zien elkaar dan wel niet meer zo vaak als vroeger 
en in plaats van allemaal aan dezelfde busroute, wonen we nu verspreid door 
Nederland, maar de gezellige etentjes, uitjes en verjaardagsfeestjes hebben 
zeker bijgedragen aan mijn ontspanning. Petra, veel succes met de afronding 
van jouw promotie, dat gaat zeker ook goedkomen!
Ook alle etentjes, uitjes, feestjes en BBQ’s met mijn familie waren een leuke 
afwisseling van het werk. Bedankt ook voor jullie interesse in mijn onderzoek. 
Marianne, ik weet nog dat je mijn eerste publicatie hebt opgezocht en samen 
met Oma hebt bekeken. Ondanks dat jullie er weinig van begrepen vonden jullie 
het leuk om te zien dat mijn naam er boven stond. En Hans, bedankt voor je hulp 
bij het ontwerpen van de omslag, het is erg mooi geworden!
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Stella en Ton, ook jullie wil ik bedanken voor de leuke etentjes en bezoekjes. Ook 
al was het voor jullie lastig om te begrijpen waar ik doordeweeks nou precies zo 
druk mee bezig was, jullie interesse in mijn onderzoek deed me altijd goed.
Dan is het nu tijd voor mijn naaste familieleden. Ivon & Tim en Kris, met jullie is 
het altijd kei gezellig en ik vind het leuk dat we nog tijd hebben om regelmatig 
iets samen te doen. Shoppen en musicals bezoeken met Ivon, samen naar 
atletiekwedstrijden en natuurlijk naar de Spelen in Londen met Kris, het heeft er 
de afgelopen vier jaar allemaal aan bijgedragen dat ik lekker kon ontspannen van 
mijn werk. Ivon, over een paar jaar heb jij vast ook een heel mooi proefschrift 
geschreven!
En dan ons pap en ons mam. Jullie hebben ons altijd aangemoedigd om te gaan 
doen wat we leuk vinden. Dat heb ik gedaan en hier ligt het resultaat! Al is wat ik 
“uitgevonden heb” voor jullie grotendeels abracadabra, jullie hebben mij altijd 
gesteund en daarmee een belangrijke rol gespeeld bij mijn promotie. Het was 
altijd gezellig en lekker ontspannen om in het weekend langs te komen in Uje en 
natuurlijk hebben ook alle etentjes, uitjes, wandelingen met de hondjes en nog 
veel meer ervoor gezorgd dat ik het werk even uit mijn hoofd kon zetten. Kei 
bedankt daarvoor!
Dan is nu het allerlaatste woord van dit boekje aan jou, Michel. Van begin tot 
eind heb je me altijd overal mee geholpen. Als ik het even niet meer zag zitten of 
een keer te lang was door gegaan, hielp jij me er weer bovenop. En als ik weer 
eens zei dat ik er “zo” aankwam omdat ik nog “effe” iets af moest maken op het 
lab, was je altijd geduldig en had dan al heerlijk gekookt als ik eindelijk thuis 
kwam. Ook voor jou was het een drukke tijd. Bedankt voor alles lieverd, je bent 
een kanjer, ik hou van jou!
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